10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2018

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to              

Commission file numbers: 001-34465 and 001-31441

SELECT MEDICAL HOLDINGS CORPORATION

SELECT MEDICAL CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware Delaware	20-1764048 23-2872718
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of Principal Executive Offices and Zip code)

(717) 972-1100

(Registrants’ telephone number, including area code)

Indicate by check mark whether the Registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.   Yes ý  No o

Indicate by check mark whether the Registrants have submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrants were required to submit such files).   Yes ý  No o

Indicate by check mark whether the Registrant, Select Medical Holdings Corporation, is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x	Accelerated filer o
Non-accelerated filer o	Smaller reporting company o
	Emerging Growth Company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Indicate by check mark whether the Registrant, Select Medical Corporation, is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o	Accelerated filer o
Non-accelerated filer x	Smaller reporting company o
	Emerging Growth Company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Indicate by check mark whether the Registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No ý

As of October 31, 2018, Select Medical Holdings Corporation had outstanding 135,331,864 shares of common stock.

This Form 10-Q is a combined quarterly report being filed separately by two Registrants: Select Medical Holdings Corporation and Select Medical Corporation. Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select’s subsidiaries. Any reference to “Concentra” refers to Concentra Inc., the indirect operating subsidiary of Concentra Group Holdings Parent, LLC (“Concentra Group Holdings Parent”), and its subsidiaries. References to the “Company,” “we,” “us,” and “our” refer collectively to Holdings, Select, and Concentra Group Holdings Parent and its subsidiaries.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	Condensed consolidated balance sheets	3
	Condensed consolidated statements of operations	4
	Condensed consolidated statements of changes in equity and income	6
	Condensed consolidated statements of cash flows	7
	Notes to condensed consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	33
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	59
ITEM 4.	CONTROLS AND PROCEDURES	59
PART II	OTHER INFORMATION	60
ITEM 1.	LEGAL PROCEEDINGS	60
ITEM 1A.	RISK FACTORS	62
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	63
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	63
ITEM 4.	MINE SAFETY DISCLOSURES	63
ITEM 5.	OTHER INFORMATION	63
ITEM 6.	EXHIBITS	64
SIGNATURES

PART I: FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	Select Medical Holdings Corporation				Select Medical Corporation
	December 31, 2017		September 30, 2018		December 31, 2017			September 30, 2018
ASSETS
Current Assets:
Cash and cash equivalents	$	122,549	$	160,413	$	122,549		$	160,413
Accounts receivable	691,732		746,816		691,732			746,816
Prepaid income taxes	31,387		19,852		31,387			19,852
Other current assets	75,158		96,214		75,158			96,214
Total Current Assets	920,826		1,023,295		920,826			1,023,295
Property and equipment, net	912,591		965,390		912,591			965,390
Goodwill	2,782,812		3,311,459		2,782,812			3,311,459
Identifiable intangible assets, net	326,519		444,847		326,519			444,847
Other assets	184,418		235,190		184,418			235,190
Total Assets	$	5,127,166	$	5,980,181	$	5,127,166		$	5,980,181
LIABILITIES AND EQUITY
Current Liabilities:
Overdrafts	$	29,463	$	23,291	$	29,463		$	23,291
Current portion of long-term debt and notes payable	22,187		24,175		22,187			24,175
Accounts payable	128,194		137,540		128,194			137,540
Accrued payroll	160,562		176,221		160,562			176,221
Accrued vacation	92,875		106,026		92,875			106,026
Accrued interest	19,885		23,648		19,885			23,648
Accrued other	143,166		188,079		143,166			188,079
Income taxes payable	9,071		6,129		9,071			6,129
Total Current Liabilities	605,403		685,109		605,403			685,109
Long-term debt, net of current portion	2,677,715		3,305,533		2,677,715			3,305,533
Non-current deferred tax liability	124,917		148,227		124,917			148,227
Other non-current liabilities	145,709		174,170		145,709			174,170
Total Liabilities	3,553,744		4,313,039		3,553,744			4,313,039
Commitments and contingencies (Note 10)
Redeemable non-controlling interests	640,818		779,574		640,818			779,574
Stockholders’ Equity:
Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 134,114,715 and 135,140,269 shares issued and outstanding at 2017 and 2018, respectively	134		135		—			—
Common stock of Select, $0.01 par value, 100 shares issued and outstanding	—		—		0			0
Capital in excess of par	463,499		477,822		947,370			964,683
Retained earnings (accumulated deficit)	359,735		296,635		(124,002		)	(190,091		)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	823,368		774,592		823,368			774,592
Non-controlling interests	109,236		112,976		109,236			112,976
Total Equity	932,604		887,568		932,604			887,568
Total Liabilities and Equity	$	5,127,166	$	5,980,181	$	5,127,166		$	5,980,181

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Three Months Ended September 30,						For the Three Months Ended September 30,
	2017			2018			2017			2018
Net operating revenues	$	1,077,014		$	1,267,401		$	1,077,014		$	1,267,401
Costs and expenses:
Cost of services	939,079			1,087,062			939,079			1,087,062
General and administrative	27,065			29,975			27,065			29,975
Depreciation and amortization	38,772			50,527			38,772			50,527
Total costs and expenses	1,004,916			1,167,564			1,004,916			1,167,564
Income from operations	72,098			99,837			72,098			99,837
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	4,431			5,432			4,431			5,432
Non-operating gain	—			2,139			—			2,139
Interest expense	(37,688		)	(50,669		)	(37,688		)	(50,669		)
Income before income taxes	38,841			56,739			38,841			56,739
Income tax expense	14,017			14,060			14,017			14,060
Net income	24,824			42,679			24,824			42,679
Less: Net income attributable to non-controlling interests	6,362			9,762			6,362			9,762
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	18,462		$	32,917		$	18,462		$	32,917
Income per common share:
Basic	$	0.14		$	0.24
Diluted	$	0.14		$	0.24
Weighted average shares outstanding:
Basic	129,142			130,387
Diluted	129,322			130,447

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2017			2018			2017			2018
Net operating revenues	$	3,270,996		$	3,816,575		$	3,270,996		$	3,816,575
Costs and expenses:
Cost of services	2,788,411			3,247,606			2,788,411			3,247,606
General and administrative	83,415			90,951			83,415			90,951
Depreciation and amortization	119,644			149,022			119,644			149,022
Total costs and expenses	2,991,470			3,487,579			2,991,470			3,487,579
Income from operations	279,526			328,996			279,526			328,996
Other income and expense:
Loss on early retirement of debt	(19,719		)	(10,255		)	(19,719		)	(10,255		)
Equity in earnings of unconsolidated subsidiaries	15,618			14,914			15,618			14,914
Non-operating gain (loss)	(49		)	9,016			(49		)	9,016
Interest expense	(116,196		)	(147,991		)	(116,196		)	(147,991		)
Income before income taxes	159,180			194,680			159,180			194,680
Income tax expense	59,593			47,460			59,593			47,460
Net income	99,587			147,220			99,587			147,220
Less: Net income attributable to non-controlling interests	23,200			34,053			23,200			34,053
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	76,387		$	113,167		$	76,387		$	113,167
Income per common share:
Basic	$	0.57		$	0.84
Diluted	$	0.57		$	0.84
Weighted average shares outstanding:
Basic	128,745			129,972
Diluted	128,916			130,066

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Condensed Consolidated Statements of Changes in Equity and Income

(unaudited)

(in thousands)

				Select Medical Holdings Corporation Stockholders
	Redeemable Non-controlling Interests			Common Stock Issued		Common Stock Par Value		Capital in Excess of Par			Retained Earnings			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2017	$	640,818		134,115		$	134	$	463,499		$	359,735		$	823,368		$	109,236		$	932,604
Net income attributable to Select Medical Holdings Corporation											113,167			113,167						113,167
Net income attributable to non-controlling interests	25,896													—			8,157			8,157
Issuance of restricted stock				1,222		1		(1		)				—						—
Forfeitures of unvested restricted stock				(88	)	0		0						—						—
Vesting of restricted stock								15,059						15,059						15,059
Repurchase of common shares				(285	)	0		(2,989		)	(2,651		)	(5,640		)				(5,640		)
Exercise of stock options				176		0		1,633						1,633						1,633
Issuance and exchange of non-controlling interests	163,659							1,553			74,341			75,894			1,921			77,815
Distributions to and purchases of non-controlling interests	(215,847		)					(932		)	(83,617		)	(84,549		)	(7,471		)	(92,020		)
Redemption adjustment on non-controlling interests	164,065										(164,065		)	(164,065		)				(164,065		)
Other	983										(275		)	(275		)	1,133			858
Balance at September 30, 2018	$	779,574		135,140		$	135	$	477,822		$	296,635		$	774,592		$	112,976		$	887,568

				Select Medical Corporation Stockholders
	Redeemable Non-controlling Interests			Common Stock Issued	Common Stock Par Value		Capital in Excess of Par			Accumulated Deficit			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2017	$	640,818		0	$	0	$	947,370		$	(124,002	)	$	823,368		$	109,236		$	932,604
Net income attributable to Select Medical Corporation										113,167			113,167						113,167
Net income attributable to non-controlling interests	25,896												—			8,157			8,157
Additional investment by Holdings							1,633						1,633						1,633
Dividends declared and paid to Holdings										(5,640		)	(5,640		)				(5,640		)
Contribution related to restricted stock award issuances by Holdings							15,059						15,059						15,059
Issuance and exchange of non-controlling interests	163,659						1,553			74,341			75,894			1,921			77,815
Distributions to and purchases of non-controlling interests	(215,847		)				(932		)	(83,617		)	(84,549		)	(7,471		)	(92,020		)
Redemption adjustment on non-controlling interests	164,065									(164,065		)	(164,065		)				(164,065		)
Other	983									(275		)	(275		)	1,133			858
Balance at September 30, 2018	$	779,574		0	$	0	$	964,683		$	(190,091	)	$	774,592		$	112,976		$	887,568

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2017			2018			2017			2018
Operating activities
Net income	$	99,587		$	147,220		$	99,587		$	147,220
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	14,542			10,734			14,542			10,734
Depreciation and amortization	119,644			149,022			119,644			149,022
Provision for bad debts	914			(373		)	914			(373		)
Equity in earnings of unconsolidated subsidiaries	(15,618		)	(14,914		)	(15,618		)	(14,914		)
Loss on extinguishment of debt	6,527			484			6,527			484
Gain on sale of assets and businesses	(9,499		)	(9,129		)	(9,499		)	(9,129		)
Stock compensation expense	14,227			17,175			14,227			17,175
Amortization of debt discount, premium and issuance costs	8,546			9,845			8,546			9,845
Deferred income taxes	(6,126		)	(2,092		)	(6,126		)	(2,092		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(143,308		)	23,495			(143,308		)	23,495
Other current assets	(2,677		)	(10,274		)	(2,677		)	(10,274		)
Other assets	1,407			4,828			1,407			4,828
Accounts payable	3,913			(3,507		)	3,913			(3,507		)
Accrued expenses	18,752			49,391			18,752			49,391
Income taxes	19,141			9,072			19,141			9,072
Net cash provided by operating activities	129,972			380,977			129,972			380,977
Investing activities
Business combinations, net of cash acquired	(19,371		)	(519,258		)	(19,371		)	(519,258		)
Purchases of property and equipment	(173,800		)	(121,039		)	(173,800		)	(121,039		)
Investment in businesses	(11,374		)	(12,936		)	(11,374		)	(12,936		)
Proceeds from sale of assets and businesses	34,555			6,691			34,555			6,691
Net cash used in investing activities	(169,990		)	(646,542		)	(169,990		)	(646,542		)
Financing activities
Borrowings on revolving facilities	805,000			420,000			805,000			420,000
Payments on revolving facilities	(705,000		)	(585,000		)	(705,000		)	(585,000		)
Proceeds from term loans	1,139,487			779,904			1,139,487			779,904
Payments on term loans	(1,176,567		)	(8,625		)	(1,176,567		)	(8,625		)
Revolving facility debt issuance costs	(4,392		)	(1,333		)	(4,392		)	(1,333		)
Borrowings of other debt	27,571			30,134			27,571			30,134
Principal payments on other debt	(15,112		)	(17,971		)	(15,112		)	(17,971		)
Repurchase of common stock	(3,603		)	(5,640		)	—			—
Dividends paid to Holdings	—			—			(3,603		)	(5,640		)
Proceeds from exercise of stock options	1,634			1,633			—			—
Equity investment by Holdings	—			—			1,634			1,633
Decrease in overdrafts	(20,439		)	(6,172		)	(20,439		)	(6,172		)
Proceeds from issuance of non-controlling interests	8,986			2,926			8,986			2,926
Distributions to non-controlling interests	(9,276		)	(306,427		)	(9,276		)	(306,427		)
Net cash provided by financing activities	48,289			303,429			48,289			303,429
Net increase in cash and cash equivalents	8,271			37,864			8,271			37,864
Cash and cash equivalents at beginning of period	99,029			122,549			99,029			122,549
Cash and cash equivalents at end of period	$	107,300		$	160,413		$	107,300		$	160,413
Supplemental Information
Cash paid for interest	$	101,341		$	134,378		$	101,341		$	134,378
Cash paid for taxes	46,553			40,460			46,553			40,460
Non-cash equity exchange for acquisition of U.S. HealthWorks	—			238,000			—			238,000

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.              Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings and Select and its subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of September 30, 2018, and for the three and nine month periods ended September 30, 2017 and 2018, have been prepared pursuant to the rules and regulations of the Securities Exchange Commission (the “SEC”) for interim reporting and accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and nine months ended September 30, 2018, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 22, 2018.

2.              Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Lease Accounting

Beginning in February 2016, the Financial Accounting Standards Board (the “FASB”) issued several Accounting Standards Updates (“ASU”) which established Topic 842, Leases (the “standard”). This standard includes a lessee accounting model that recognizes two types of leases: finance and operating. This standard requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in the standard will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. There are two transition approaches available under the standard: a modified retrospective approach for leases that exist, or are entered into, after the beginning of the earliest comparative period in the financial statements or a cumulative-effect approach with an adjustment to the opening balance of retained earnings in the period of adoption.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

8

The Company will implement the new standard beginning January 1, 2019, using the cumulative-effect approach, without adjusting the comparative periods. The Company has completed its inventory of leases and has begun to implement a new technology platform to account for leases under the new standard.  The Company has substantially completed validating its lease data to ensure it is complete and accurate. The Company’s remaining implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

Cloud Computing Arrangements

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the impacts that adoption of this ASU will have on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

Revenue from Contracts with Customers

Beginning in May 2014, the FASB issued several ASUs which established Topic 606, Revenue from Contracts with Customers (the “revenue recognition standard”). This revenue recognition standard supersedes existing revenue recognition requirements and seeks to eliminate most industry-specific guidance under current GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company adopted the new revenue recognition standard on January 1, 2018, using the full retrospective transition method. Adoption of the revenue recognition standard impacted the Company’s reported results as follows:

	Three Months Ended September 30, 2017
	As Reported		As Adjusted(1)		Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	1,097,166	$	1,077,014	$	(20,152	)
Bad debt expense	20,321		169		(20,152		)

	Nine Months Ended September 30, 2017
	As Reported			As Adjusted(1)			Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	3,329,202		$	3,270,996		$	(58,206	)
Bad debt expense	59,120			914			(58,206		)
Condensed Consolidated Statements of Cash Flows
Provision for bad debts	$	59,120		$	914		$	(58,206	)
Changes in accounts receivable	(201,514		)	(143,308		)	58,206

 _____________________________________________________________

(1) Bad debt expense is now included in cost of services on the condensed consolidated statements of operations.

	December 31, 2017
	As Reported		As Adjusted		Adoption Impact
	(in thousands)
Condensed Consolidated Balance Sheets
Accounts receivable	$	767,276	$	691,732	$	(75,544	)
Allowance for doubtful accounts	75,544		—		(75,544		)
Accounts receivable	$	691,732	$	691,732	$	—

The Company has presented the applicable disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers in Note 7.

9

Income Taxes

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), and Intra-Entity Transfers of Assets Other Than Inventory. Previous GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra‑entity transfer of an asset other than inventory when the transfer occurs. The Company adopted the guidance effective January 1, 2018. Adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.

3.  Acquisitions

U.S. HealthWorks Acquisition

On February 1, 2018, Concentra Inc. (“Concentra”) acquired all of the issued and outstanding shares of stock of U.S. HealthWorks, Inc. (“U.S. HealthWorks”), an occupational medicine and urgent care service provider, pursuant to the terms of an Equity Purchase and Contribution Agreement (the “Purchase Agreement”) dated as of October 22, 2017, by and among Concentra, U.S. HealthWorks, Concentra Group Holdings, LLC (“Concentra Group Holdings”), Concentra Group Holdings Parent, LLC (“Concentra Group Holdings Parent”) and Dignity Health Holding Corporation (“DHHC”). For the nine months ended September 30, 2018, the Company recognized $2.9 million of U.S. HealthWorks acquisition costs which are included in general and administrative expense.

In connection with the closing of the transaction, Concentra Group Holdings made distributions to its equity holders and redeemed certain of its outstanding equity interests from existing minority equity holders. Subsequently, Concentra Group Holdings and a wholly owned subsidiary of Concentra Group Holdings Parent merged, with Concentra Group Holdings surviving the merger and becoming a wholly owned subsidiary of Concentra Group Holdings Parent. As a result of the merger, the equity interests of Concentra Group Holdings outstanding after the redemption described above were exchanged for membership interests in Concentra Group Holdings Parent.

Concentra acquired U.S. HealthWorks for $753.0 million. The Purchase Agreement provides for certain post-closing adjustments for cash, indebtedness, transaction expenses, and working capital. DHHC, a subsidiary of Dignity Health, was issued a 20% equity interest in Concentra Group Holdings Parent, which was valued at $238.0 million. The remainder of the purchase price was paid in cash. Select retained a majority voting interest in Concentra Group Holdings Parent following the closing of the transaction.

For the U.S. HealthWorks acquisition, the Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values in accordance with the provisions of Accounting Standards Codification Topic 805, Business Combinations. The Company is in the process of completing its assessment of the acquisition-date fair values of the assets acquired and the liabilities assumed and determining the estimated useful lives of long-lived assets and finite-lived intangible assets; therefore, the values set forth below are subject to adjustment during the measurement period. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price allocation activities by December 31, 2018.

The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):

Identifiable tangible assets	$	184,163
Identifiable intangible assets	140,406
Goodwill	533,124
Total assets	857,693
Total liabilities	104,693
Consideration given	$	753,000

10

The preliminary fair value assigned to identifiable intangible assets was determined through the use of the income and cost approaches. Both valuation methods rely on management judgment including expected future cash flows, customer attrition rates, contributory effects of other assets utilized in the business, peer group cost of capital and royalty rates, and other factors. Useful lives for identifiable intangible assets were determined based upon the remaining useful economic lives of the identifiable intangible assets that are expected to contribute directly or indirectly to future cash flows. The valuations of tangible assets were derived using a combination of the market and cost approaches. Significant judgments used in valuing tangible assets include estimated reproduction or replacement cost, useful lives of assets, and estimated selling prices.

	Fair Value		Weighted Average Amortization Period
	(in thousands)		(in years)
Customer relationships	$	135,000	15.0 years
Trademarks	5,000		1.0 year
Favorable leasehold interests	406		2.9 years
Identifiable intangible assets	$	140,406

The customer relationships and trademarks are being amortized on a straight-line basis over their expected useful lives. Favorable leasehold interests are being amortized over their remaining lease terms at the time of acquisition.

A preliminary estimate for goodwill of $533.1 million has been recognized for the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from U.S. HealthWorks’ future earnings potential and its assembled workforce. Goodwill has been assigned to the Concentra reporting unit and is not deductible for tax purposes. However, prior to its acquisition by the Company, U.S. HealthWorks completed certain acquisitions that resulted in tax deductible goodwill with an estimated value of $83.1 million, which the Company will deduct through 2032.

For the three months ended September 30, 2018, U.S. HealthWorks had net operating revenues of $133.3 million which is reflected in the Company’s consolidated statements of operations. For the period February 1, 2018 through September 30, 2018, U.S. HealthWorks had net operating revenues of $362.7 million which is reflected in the Company’s consolidated statements of operations for the nine months ended September 30, 2018. Due to the integrated nature of our operations, it is not practicable to separately identify earnings of U.S. HealthWorks on a stand-alone basis.

Pro Forma Results

The following pro forma unaudited results of operations have been prepared assuming the acquisition of U.S. HealthWorks occurred on January 1, 2017. These results are not necessarily indicative of results of future operations nor of the results that would have occurred had the acquisition been consummated on the aforementioned date.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Net revenue	$	1,215,869	$	1,267,401	$	3,687,574	$	3,864,155
Net income	21,929		45,721		85,317		153,144
Net income attributable to the Company	17,011		34,441		69,237		116,135
Income per common share:
Basic	$	0.13	$	0.26	$	0.52	$	0.86
Diluted	$	0.13	$	0.26	$	0.52	$	0.86

 The pro forma financial information is based on the preliminary allocation of the purchase price of the U.S. HealthWorks acquisition and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period. The net income tax impact was calculated at a statutory rate, as if U.S. HealthWorks had been a subsidiary of the Company as of January 1, 2017.

For the nine months ended September 30, 2017, pro forma results were adjusted to include the U.S. HealthWorks acquisition costs recognized by the Company during 2017 and 2018, which were approximately $5.7 million. For the nine months ended September 30, 2018, pro forma results were adjusted to exclude approximately $2.9 million of U.S. HealthWorks acquisition costs which were recognized by the Company during the period.

11

4.          Intangible Assets

Goodwill

The following table shows changes in the carrying amounts of goodwill by reporting unit for the nine months ended September 30, 2018:

	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation			Concentra			Total
	(in thousands)
Balance as of December 31, 2017	$	1,045,220	$	415,528	$	647,522		$	674,542		$	2,782,812
Acquired	—		1,118		2,465			536,945			540,528
Measurement period adjustment	—		—		—			(2,472		)	(2,472		)
Sold	—		—		(9,409		)	—			(9,409		)
Balance as of September 30, 2018	$	1,045,220	$	416,646	$	640,578		$	1,209,015		$	3,311,459

_______________________________________________________________________________

(1) The critical illness recovery hospital reporting unit was previously referred to as the long term acute care reporting unit. The rehabilitation hospital reporting unit was previously referred to as the inpatient rehabilitation reporting unit.

Identifiable Intangible Assets

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company’s identifiable intangible assets:

	December 31, 2017							September 30, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived intangible assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	19,155		—			19,155		19,118		—			19,118
Accreditations	1,895		—			1,895		1,857		—			1,857
Finite-lived intangible assets:
Trademarks	—		—			—		5,000		(3,333		)	1,667
Customer relationships	143,953		(38,281		)	105,672		279,967		(55,760		)	224,207
Favorable leasehold interests	13,295		(4,319		)	8,976		13,553		(5,653		)	7,900
Non-compete agreements	28,023		(3,900		)	24,123		28,953		(5,553		)	23,400
Total identifiable intangible assets	$	373,019	$	(46,500	)	$	326,519	$	515,146	$	(70,299	)	$	444,847

 The Company’s accreditations and indefinite-lived trademarks have renewal terms and the costs to renew these intangible assets are expensed as incurred. At September 30, 2018, the accreditations and indefinite-lived trademarks have a weighted average time until next renewal of 1.5 years and 8.4 years, respectively.

The Company’s finite-lived customer relationships, non-compete agreements, and trademarks amortize over their estimated useful lives. Amortization expense was $4.4 million and $7.9 million for the three months ended September 30, 2017 and 2018, respectively. Amortization expense was $13.1 million and $22.1 million for the nine months ended September 30, 2017 and 2018, respectively. The Company’s leasehold interests have finite lives and are amortized to rent expense over the remaining term of their respective leases to reflect a market rent per period based upon the market conditions present at the acquisition date.

Estimated amortization expense for the Company’s finite-lived customer relationships, non-compete agreements, and trademarks for the remaining period of 2018 and each of the four succeeding years is as follows:

	2018		2019		2020		2021		2022
	(in thousands)
Amortization expense	$	7,811	$	26,490	$	25,864	$	25,648	$	25,443

12

5.  Long-Term Debt and Notes Payable

For purposes of this indebtedness footnote, references to Select exclude Concentra because the Concentra credit facilities are non-recourse to Holdings and Select.

As of September 30, 2018, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	607		$	(5,122	)	$	705,485	$	718,875
Credit facilities:
Revolving facility	65,000		—			—			65,000		59,800
Term loans	1,132,750		(11,000		)	(11,058		)	1,110,692		1,139,830
Other	49,004		—			(508		)	48,496		48,496
Total Select debt	1,956,754		(10,393		)	(16,688		)	1,929,673		1,967,001
Concentra:
Credit facilities:
Term loans	1,414,175		(3,078		)	(20,417		)	1,390,680		1,427,181
Other	9,355		—			—			9,355		9,355
Total Concentra debt	1,423,530		(3,078		)	(20,417		)	1,400,035		1,436,536
Total debt	$	3,380,284	$	(13,471	)	$	(37,105	)	$	3,329,708	$	3,403,537

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2018		2019		2020		2021		2022		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	710,000	$	—	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		65,000		—		65,000
Term loans	2,875		11,500		11,500		11,500		11,500		1,083,875		1,132,750
Other	3,992		5,391		24,285		221		—		15,115		49,004
Total Select debt	6,867		16,891		35,785		721,721		76,500		1,098,990		1,956,754
Concentra:
Credit facilities:
Term loans	—		—		5,719		12,365		1,156,091		240,000		1,414,175
Other	1,341		3,625		346		346		324		3,373		9,355
Total Concentra debt	1,341		3,625		6,065		12,711		1,156,415		243,373		1,423,530
Total debt	$	8,208	$	20,516	$	41,850	$	734,432	$	1,232,915	$	1,342,363	$	3,380,284

13

As of December 31, 2017, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	778		$	(6,553	)	$	704,225	$	727,750
Credit facilities:
Revolving facility	230,000		—			—			230,000		211,600
Term loans	1,141,375		(12,445		)	(12,500		)	1,116,430		1,154,215
Other	36,877		—			(533		)	36,344		36,344
Total Select debt	2,118,252		(11,667		)	(19,586		)	2,086,999		2,129,909
Concentra:
Credit facilities:
Term loans	619,175		(2,257		)	(10,668		)	606,250		625,173
Other	6,653		—			—			6,653		6,653
Total Concentra debt	625,828		(2,257		)	(10,668		)	612,903		631,826
Total debt	$	2,744,080	$	(13,924	)	$	(30,254	)	$	2,699,902	$	2,761,735

 Select Credit Facilities

On March 22, 2018, Select entered into Amendment No. 1 to the senior secured credit agreement (the “Select credit agreement”) dated March 6, 2017. The Select credit agreement originally provided for $1.6 billion in senior secured credit facilities comprised of $1.15 billion in term loans (the “Select term loans”) and a $450.0 million revolving credit facility (the “Select revolving facility” and together with the Select term loans, the “Select credit facilities”), including a $75.0 million sublimit for the issuance of standby letters of credit.

Amendment No. 1 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement and subject to an Adjusted LIBO floor of 1.00%) plus 3.50% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate (as defined in the Select credit agreement and subject to an Alternate Base Rate floor of 2.00%) plus 2.50% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio (as defined in the Select credit agreement); (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 3.00% to 3.25% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate plus a percentage ranging from 2.00% to 2.25% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio; (iii) extended the maturity date for the Select term loans from March 6, 2024 to March 6, 2025; and (iv) made certain other technical amendments to the Select credit agreement as set forth therein.

Concentra Credit Facilities

Concentra First Lien Credit Agreement

On February 1, 2018, Concentra entered into an amendment to its first lien credit agreement (the “Concentra first lien credit agreement”) dated June 1, 2015, by and among Concentra, as the borrower, Concentra Holdings, Inc., a subsidiary of Concentra Group Holdings Parent, JPMorgan Chase Bank, N.A., as the administrative agent and the collateral agent, and the other lenders party thereto. Concentra used borrowings under the Concentra first lien credit agreement and the Concentra second lien credit agreement, as described below, together with cash on hand, to pay the cash purchase price for all of the issued and outstanding stock of U.S. HealthWorks to DHHC and to finance the redemption and reorganization transactions executed under the Purchase Agreement (as described in Note 3), as well as to pay fees and expenses associated with the financing.

Concentra amended the Concentra first lien credit agreement to, among other things, provide for (i) an additional $555.0 million in tranche B term loans that, along with the existing tranche B term loans under the Concentra first lien credit agreement, have a maturity date of June 1, 2022 (collectively, the “Concentra first lien term loan”) and (ii) an additional $25.0 million to the $50.0 million, five-year revolving credit facility under the terms of the existing Concentra first lien credit agreement. The tranche B term loans bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus 2.75% (subject to an Adjusted LIBO Rate floor of 1.00%) for Eurodollar Borrowings (as defined in the Concentra first lien credit agreement), or Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus 1.75% (subject to an Alternate Base Rate floor of 2.00%) for ABR Borrowings (as defined in the Concentra first lien credit agreement). All other material terms and conditions applicable to the original tranche B term loan commitments are applicable to the additional tranche B term loans created under the Concentra first lien credit agreement.

14

Concentra Second Lien Credit Agreement

On February 1, 2018, Concentra entered into a second lien credit agreement (the “Concentra second lien credit agreement” and, together with the Concentra first lien credit agreement, the “Concentra credit facilities”) with Concentra Holdings, Inc., Wells Fargo Bank, National Association, as the administrative agent and the collateral agent, and the other lenders party thereto.

The Concentra second lien credit agreement provided for $240.0 million in term loans (the “Concentra second lien term loan” and, together with the Concentra first lien term loan, the “Concentra term loans”) with a maturity date of June 1, 2023. Borrowings under the Concentra second lien credit agreement bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra second lien credit agreement) plus 6.50% (subject to an Adjusted LIBO Rate floor of 1.00%), or Alternate Base Rate (as defined in the Concentra second lien credit agreement) plus 5.50% (subject to an Alternate Base Rate floor of 2.00%).

In the event that, on or prior to February 1, 2019, Concentra prepays any of the Concentra second lien term loan to refinance such term loans, Concentra shall pay a premium of 2.00% of the aggregate principal amount of the Concentra second lien term loan prepaid. If Concentra prepays any of the Concentra second lien term loan to refinance such term loans on or prior to February 1, 2020, Concentra shall pay a premium of 1.00% of the aggregate principal amount of the Concentra second lien term loan prepaid.

Concentra will be required to prepay borrowings under the Concentra second lien term loan with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (iii) 50% of excess cash flow (as defined in the Concentra second lien credit agreement) if Concentra’s leverage ratio is greater than 4.25 to 1.00 and 25% of excess cash flow if Concentra’s leverage ratio is less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00, in each case, reduced by the aggregate amount of term loans and certain debt optionally prepaid during the applicable fiscal year and the aggregate amount of senior revolving commitments reduced permanently during the applicable fiscal year (other than in connection with a refinancing). Concentra will not be required to prepay borrowings with excess cash flow if Concentra’s leverage ratio is less than or equal to 3.75 to 1.00.

The Concentra second lien credit agreement also contains a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Concentra second lien credit agreement contains events of default for non-payment of principal and interest when due (subject to a grace period for interest), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

The borrowings under the Concentra second lien term loan are guaranteed, on a second lien basis, by Concentra Holdings, Inc., Concentra, and certain domestic subsidiaries of Concentra and will be guaranteed by Concentra’s future domestic subsidiaries (other than Excluded Subsidiaries and Consolidated Practices, each as defined in the Concentra second lien credit agreement). The borrowings under the Concentra second lien term loan are secured by substantially all of Concentra’s and its domestic subsidiaries’ existing and future property and assets and by a pledge of Concentra’s capital stock, the capital stock of certain of Concentra’s domestic subsidiaries and up to 65% of the voting capital stock and 100% of the non-voting capital stock of Concentra’s foreign subsidiaries, if any.

Loss on Early Retirement of Debt

The amendments to the Select credit facilities and Concentra credit facilities resulted in losses on early retirement of debt totaling $10.3 million for the nine months ended September 30, 2018. The losses on early retirement of debt consisted of $0.5 million of debt extinguishment losses and $9.8 million of debt modification losses during the nine months ended September 30, 2018.

Fair Value

The Company considers the inputs in the valuation process to be Level 2 in the fair value hierarchy for Select’s 6.375% senior notes and for its credit facilities. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly, which includes quoted prices for identical assets or liabilities in markets that are not active.

The fair values of the Select credit facilities and the Concentra credit facilities were based on quoted market prices for this debt in the syndicated loan market. The fair value of Select’s 6.375% senior notes was based on quoted market prices. The carrying amount of other debt, principally short-term notes payable, approximates fair value.

15

6.  Segment Information

The Company identifies its operating segments according to how the chief operating decision maker evaluates financial performance and allocates resources. During the year ended December 31, 2017, the Company changed its internal segment reporting structure which is reflective of how the Company now manages its business operations, reviews operating performance, and allocates resources. The Company’s reportable segments include the critical illness recovery hospital segment (previously referred to as the long term acute care segment), rehabilitation hospital segment (previously referred to as the inpatient rehabilitation segment), outpatient rehabilitation segment, and Concentra segment. Prior year results for the three and nine months ended September 30, 2017, presented herein have been recast to conform to the current presentation. The Company previously disclosed financial information for the following reportable segments: specialty hospitals, outpatient rehabilitation, and Concentra.

Other activities include the Company’s corporate shared services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, acquisition costs associated with U.S. HealthWorks, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
	(in thousands)
Net operating revenues:(1)
Critical illness recovery hospital(2)	$	416,934		$	420,108		$	1,301,251		$	1,327,236
Rehabilitation hospital(2)	157,499			176,885			453,702			525,428
Outpatient rehabilitation	246,644			265,927			751,999			790,491
Concentra	255,881			404,481			763,357			1,173,420
Other	56			—			687			—
Total Company	$	1,077,014		$	1,267,401		$	3,270,996		$	3,816,575
Adjusted EBITDA:
Critical illness recovery hospital(2)	$	46,873		$	53,292		$	194,253		$	186,989
Rehabilitation hospital(2)	22,581			25,343			62,038			80,314
Outpatient rehabilitation	29,298			34,531			102,575			107,003
Concentra	40,003			68,754			125,656			199,119
Other	(22,928		)	(25,292		)	(71,125		)	(75,337		)
Total Company	$	115,827		$	156,628		$	413,397		$	498,088
Total assets:
Critical illness recovery hospital(2)	$	2,008,485		$	1,785,336		$	2,008,485		$	1,785,336
Rehabilitation hospital(2)	740,276			888,342			740,276			888,342
Outpatient rehabilitation	945,765			991,105			945,765			991,105
Concentra	1,332,012			2,201,869			1,332,012			2,201,869
Other	97,269			113,529			97,269			113,529
Total Company	$	5,123,807		$	5,980,181		$	5,123,807		$	5,980,181
Purchases of property and equipment, net:
Critical illness recovery hospital(2)	$	8,003		$	8,134		$	28,717		$	31,455
Rehabilitation hospital(2)	29,373			8,769			77,707			29,766
Outpatient rehabilitation	6,496			7,209			19,370			22,565
Concentra	5,369			12,539			21,656			29,281
Other	19,257			2,740			26,350			7,972
Total Company	$	68,498		$	39,391		$	173,800		$	121,039

16

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	46,873		$	22,581		$	29,298		$	40,003		$	(22,928	)
Depreciation and amortization	(10,932		)	(4,505		)	(5,964		)	(15,014		)	(2,357		)
Stock compensation expense	—			—			—			(212		)	(4,745		)
Income (loss) from operations	$	35,941		$	18,076		$	23,334		$	24,777		$	(30,030	)	$	72,098
Equity in earnings of unconsolidated subsidiaries																4,431
Interest expense																(37,688		)
Income before income taxes																$	38,841

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	53,292		$	25,343		$	34,531		$	68,754		$	(25,292	)
Depreciation and amortization	(11,136		)	(6,079		)	(6,597		)	(24,488		)	(2,227		)
Stock compensation expense	—			—			—			(767		)	(5,497		)
Income (loss) from operations	$	42,156		$	19,264		$	27,934		$	43,499		$	(33,016	)	$	99,837
Equity in earnings of unconsolidated subsidiaries																5,432
Non-operating gain																2,139
Interest expense																(50,669		)
Income before income taxes																$	56,739

 

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	194,253		$	62,038		$	102,575		$	125,656		$	(71,125	)
Depreciation and amortization	(34,891		)	(14,500		)	(18,182		)	(46,566		)	(5,505		)
Stock compensation expense	—			—			—			(782		)	(13,445		)
Income (loss) from operations	$	159,362		$	47,538		$	84,393		$	78,308		$	(90,075	)	$	279,526
Loss on early retirement of debt																(19,719		)
Equity in earnings of unconsolidated subsidiaries																15,618
Non-operating loss																(49		)
Interest expense																(116,196		)
Income before income taxes																$	159,180

17

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,989		$	80,314		$	107,003		$	199,119		$	(75,337	)
Depreciation and amortization	(34,146		)	(17,816		)	(19,938		)	(70,332		)	(6,790		)
Stock compensation expense	—			—			—			(2,116		)	(15,059		)
U.S. HealthWorks acquisition costs	—			—			—			(2,895		)	—
Income (loss) from operations	$	152,843		$	62,498		$	87,065		$	123,776		$	(97,186	)	$	328,996
Loss on early retirement of debt																(10,255		)
Equity in earnings of unconsolidated subsidiaries																14,914
Non-operating gain																9,016
Interest expense																(147,991		)
Income before income taxes																$	194,680

_______________________________________________________________________________

(1) Net operating revenues were retrospectively conformed to reflect the adoption Topic 606, Revenue from Contracts with Customers.

(2) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

18

7. Revenue from Contracts with Customers

Net operating revenues consist primarily of patient service revenues generated from services provided to patients and other revenues for services provided to healthcare institutions under contractual arrangements. The following tables disaggregate the Company’s net operating revenues by operating segment for the three and nine months ended September 30, 2017 and 2018:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	217,116	$	64,227	$	36,821	$	472
Non-Medicare	195,872		53,054		179,171		253,437
Total patient services revenues	412,988		117,281		215,992		253,909
Other revenues	3,946		40,218		30,652		1,972
Total net operating revenues	$	416,934	$	157,499	$	246,644	$	255,881

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	210,101	$	71,564	$	40,563	$	455
Non-Medicare	206,629		64,322		185,787		401,537
Total patient services revenues	416,730		135,886		226,350		401,992
Other revenues	3,378		40,999		39,577		2,489
Total net operating revenues	$	420,108	$	176,885	$	265,927	$	404,481

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	682,286	$	183,820	$	111,638	$	1,588
Non-Medicare	610,372		151,731		551,983		755,345
Total patient services revenues	1,292,658		335,551		663,621		756,933
Other revenues	8,593		118,151		88,378		6,424
Total net operating revenues	$	1,301,251	$	453,702	$	751,999	$	763,357

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	676,950	$	217,459	$	120,228	$	1,600
Non-Medicare	639,718		188,611		569,298		1,164,711
Total patient services revenues	1,316,668		406,070		689,526		1,166,311
Other revenues	10,568		119,358		100,965		7,109
Total net operating revenues	$	1,327,236	$	525,428	$	790,491	$	1,173,420

_______________________________________________________________________________

(1) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

19

Patient Services Revenue

Patient services revenue is recognized when obligations under the terms of the contract are satisfied; generally, this occurs as the Company provides healthcare services, as each service provided is distinct and future services rendered are not dependent on previously rendered services. Patient service revenues are recognized at an amount equal to the consideration the Company expects to receive in exchange for providing healthcare services to its patients. These amounts are due from patients; third-party payors, including health insurers and government programs; and other payors.

Medicare: Medicare is a federal program that provides medical insurance benefits to persons age 65 and over, some disabled persons, and persons with end stage renal disease. Amounts we receive for treatment of patients covered by the Medicare program are generally less than the standard billing rates; accordingly, the Company recognizes revenue based on amounts which are reimbursable by Medicare under prospective payment systems and provisions of cost-reimbursement and other payment methods. The amount reimbursed is derived based on the type of services provided.

Non-Medicare: The Company is reimbursed for healthcare services provided from various other payor sources which include insurance companies, workers’ compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies and employers, as well as patients. The Company is reimbursed by these payors using a variety of payment methodologies and the amounts the Company receives are generally less than the standard billing rates.

In the critical illness recovery hospital and rehabilitation hospital segments, the Company recognizes revenue based on known contractual provisions associated with the specific payor or, where the Company has a relatively homogeneous patient population, the Company will monitor individual payors’ historical reimbursement rates to derive a per diem rate which is used to determine the amount of revenue to be recognized for services rendered.

In the outpatient rehabilitation and Concentra segments, the Company recognizes revenue from payors based on known contractual provisions, negotiated amounts, or usual and customary amounts associated with the specific payor. The Company performs provision testing, using internally developed systems, whereby the Company monitors a payors’ historical reimbursement rates and compares them against the associated gross charges for the service provided. The percentage of historical reimbursed claims to gross charges is utilized to determine the amount of revenue to be recognized for services rendered.

The Company is subject to potential retrospective adjustments to net operating revenues in future periods for matters related to claims processing and other price concessions. These adjustments, which are estimated based on an analysis of historical experience by payor source, are accounted for as a constraint to the amount of revenue recognized by the Company in the period services are rendered.

Other Revenues

The Company recognizes revenue for services provided to healthcare institutions, principally management and employee leasing services, under contractual arrangements with related parties affiliated through the Company’s equity investments and other third-party healthcare institutions. Revenue is recognized when obligations under the terms of the contract are satisfied. Revenues from these services are measured as the amount of consideration the Company expects to receive for those services.

20

8. Income Taxes

In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law which made significant changes to the Internal Revenue Code. These changes included a corporate tax rate decrease from 35.0% to 21.0% effective after December 31, 2017. Reconciliations of the statutory federal income tax rate to the effective income tax rate are as follows:

	Three Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	4.0		5.0
Permanent differences	0.8		2.7
Valuation allowance	0.1		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.6	)	(1.0	)
Stock-based compensation	(2.3	)	(2.7	)
Other	(0.1	)	(0.3	)
Total effective income tax rate	36.1	%	24.8	%

	Nine Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	3.8		4.7
Permanent differences	1.1		2.1
Valuation allowance	0.2		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.8	)	(1.8	)
Stock-based compensation	(0.9	)	(2.6	)
Other	(0.2	)	0.9
Total effective income tax rate	37.4	%	24.4	%

9.  Income per Common Share

Holdings applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings.

The following table sets forth the calculation of income per share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	18,462	$	32,917	$	76,387	$	113,167
Less: Earnings allocated to unvested restricted stockholders	608		1,098		2,464		3,732
Net income available to common stockholders	$	17,854	$	31,819	$	73,923	$	109,435
Denominator:
Weighted average shares—basic	129,142		130,387		128,745		129,972
Effect of dilutive securities:
Stock options	180		60		171		94
Weighted average shares—diluted	129,322		130,447		128,916		130,066
Basic income per common share:	$	0.14	$	0.24	$	0.57	$	0.84
Diluted income per common share:	$	0.14	$	0.24	$	0.57	$	0.84

21

10.  Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned operations, the Company maintains insurance coverages under a combination of policies with a total annual aggregate limit of $35.0 million. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has numerous programs that are designed to respond to the risks of the specific joint venture. The annual aggregate limit under these programs ranges from $5.0 million to $20.0 million. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

 Evansville Litigation.    On October 19, 2015, the plaintiff‑relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital-Evansville, LLC (“SSH‑Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff‑relators on behalf of the United States under the federal False Claims Act. The plaintiff‑relators are the former CEO and two former case managers at SSH‑Evansville, and the defendants currently include the Company, SSH‑Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH‑Evansville. The plaintiff‑relators allege that SSH‑Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up‑coded diagnoses at admission, and admitted patients for whom long‑term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff‑relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

22

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff‑relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non‑retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However, the District Court ruled that the plaintiff‑relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present and allowing discovery that would facilitate the use of statistical sampling to prove liability, which the defendants opposed. In April 2018, a U.S. magistrate judge ruled that plaintiff‑relators’ discovery will be limited to only SSH-Evansville for the period from March 23, 2010 through September 30, 2016, and that the plaintiff‑relators will be required to prove the fraud that they allege on a claim-by-claim basis, rather than using statistical sampling. The plaintiff-relators have appealed this decision to the District Judge.

The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation.    On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital-Wilmington, Inc. (“SSH‑Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16‑347‑LPS. The Complaint was initially filed under seal in May 2016 by a former chief nursing officer at SSH‑Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention in January 2017. The corporate defendants were served in March 2017. In the complaint, the plaintiff‑relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH‑Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH‑Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, in May 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim. In March 2018, the District Court dismissed the plaintiff‑relator’s claims related to the alleged failure to properly examine medical practitioners’ credentials, her reverse false claims allegations, and her claim that defendants violated the Delaware False Claims and Reporting Act. It denied the defendants’ motion to dismiss claims that the allegedly falsified medical practitioner signatures violated the False Claims Act. Separately, the District Court dismissed the individual defendant due to plaintiff-relator’s failure to timely serve the amended complaint upon her.

In March 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH‑Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  In January 2018, the Court stayed the Delaware Complaint pending the outcome of the federal case.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

23

Contract Therapy Subpoena. On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

11.  Subsequent Events

Amendment to the Select Credit Facilities

On October 26, 2018, Select entered into Amendment No. 2 to the Select credit agreement (“Amendment No. 2”). Among other things, Amendment No. 2 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement) plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio (as defined in the Select credit agreement), and (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio. As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Select credit agreement are no longer subject to the currently applicable floor.

Amendment to the Concentra Credit Facilities

On October 26, 2018, Concentra entered into Amendment No. 4 to the Concentra first lien credit agreement (“Amendment No. 4”). Among other things, Amendment No. 4 (i) provided the applicable interest rate on the tranche B term loans under the Concentra first lien credit agreement is the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 2.50% to 2.75% (with 2.75% being the initial rate), or the Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 1.50% to 1.75% (with 1.75% being the initial rate), in each case subject to a specified credit rating, and (ii) decreased the applicable interest rate on the loans outstanding under the Concentra revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.75% to 3.00% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternate Base Rate plus a percentage ranging from 1.75% to 2.00% to the Alternate Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to Concentra’s first lien net leverage ratio (as defined in the Concentra first lien credit agreement). As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Concentra first lien credit agreement are no longer subject to the currently applicable floor.

12.  Condensed Consolidating Financial Information

Select’s 6.375% senior notes are fully and unconditionally and jointly and severally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly owned subsidiaries (the “Subsidiary Guarantors”). The Subsidiary Guarantors are defined as subsidiaries where Select, or a subsidiary of Select, holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries” and Concentra Group Holdings Parent and its subsidiaries, the “Non-Guarantor Concentra”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors, the Non-Guarantor Subsidiaries, and Non-Guarantor Concentra.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Certain reclassifications have been made to prior reported amounts in order to conform to the current year guarantor structure.

24

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	77		$	5,627	$	3,045		$	151,664	$	—			$	160,413
Accounts receivable	—			412,454		123,622			210,740		—				746,816
Intercompany receivables	—			1,722,475		75,391			—		(1,797,866		)	(a)	—
Prepaid income taxes	16,325			—		—			3,527		—				19,852
Other current assets	15,441			32,281		14,839			33,653		—				96,214
Total Current Assets	31,843			2,172,837		216,897			399,584		(1,797,866		)		1,023,295
Property and equipment, net	36,947			615,299		90,821			222,323		—				965,390
Investment in affiliates	4,448,449			123,809		—			—		(4,572,258		)	(b)(c)	—
Goodwill	—			2,102,444		—			1,209,015		—				3,311,459
Identifiable intangible assets, net	3			102,423		4,972			337,449		—				444,847
Other assets	38,861			137,897		33,902			33,498		(8,968		)	(e)	235,190
Total Assets	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181
Liabilities and Equity
Current Liabilities:
Overdrafts	$	23,291		$	—	$	—		$	—	$	—			$	23,291
Current portion of long-term debt and notes payable	15,508			268		3,631			4,768		—				24,175
Accounts payable	12,183			76,776		19,948			28,633		—				137,540
Intercompany payables	1,722,475			75,391		—			—		(1,797,866		)	(a)	—
Accrued payroll	12,061			95,717		4,935			63,508		—				176,221
Accrued vacation	4,394			58,590		13,584			29,458		—				106,026
Accrued interest	17,775			16		27			5,830		—				23,648
Accrued other	60,190			62,049		16,637			49,203		—				188,079
Income taxes payable	2,764			—		—			3,365		—				6,129
Total Current Liabilities	1,870,641			368,807		58,762			184,765		(1,797,866		)		685,109
Long-term debt, net of current portion	1,871,407			72		38,787			1,395,267		—				3,305,533
Non-current deferred tax liability	—			91,487		882			64,826		(8,968		)	(e)	148,227
Other non-current liabilities	39,463			62,354		8,730			63,623		—				174,170
Total Liabilities	3,781,511			522,720		107,161			1,708,481		(1,806,834		)		4,313,039
Redeemable non-controlling interests	—			—		—			19,402		760,172			(d)	779,574
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	964,683			—		—			—		—				964,683
Retained earnings (accumulated deficit)	(190,091		)	1,506,874		(33,181		)	11,504		(1,485,197		)	(c)(d)	(190,091		)
Subsidiary investment	—			3,225,115		272,612			456,854		(3,954,581		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	774,592			4,731,989		239,431			468,358		(5,439,778		)		774,592
Non-controlling interests	—			—		—			5,628		107,348			(d)	112,976
Total Equity	774,592			4,731,989		239,431			473,986		(5,332,430		)		887,568
Total Liabilities and Equity	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

25

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	675,059		$	187,861		$	404,481		$	—			$	1,267,401
Costs and expenses:
Cost of services	815			585,110			164,643			336,494			—				1,087,062
General and administrative	29,791			184			—			—			—				29,975
Depreciation and amortization	2,215			19,726			4,098			24,488			—				50,527
Total costs and expenses	32,821			605,020			168,741			360,982			—				1,167,564
Income (loss) from operations	(32,821		)	70,039			19,120			43,499			—				99,837
Other income and expense:
Intercompany interest and royalty fees	6,357			(2,578		)	(3,445		)	(334		)	—				—
Intercompany management fees	50,601			(39,262		)	(11,339		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			5,424			8			—			—				5,432
Non-operating gain	—			2,139			—			—			—				2,139
Interest income (expense)	(28,933		)	99			(207		)	(21,628		)	—				(50,669		)
Income (loss) before income taxes	(4,796		)	35,861			4,137			21,537			—				56,739
Income tax expense (benefit)	(1,428		)	9,923			112			5,453			—				14,060
Equity in earnings of consolidated subsidiaries	36,285			2,861			—			—			(39,146		)	(a)	—
Net income	32,917			28,799			4,025			16,084			(39,146		)		42,679
Less: Net income attributable to non-controlling interests	—			—			1,164			8,598			—				9,762
Net income attributable to Select Medical Corporation	$	32,917		$	28,799		$	2,861		$	7,486		$	(39,146	)		$	32,917

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

26

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	2,072,237		$	570,918		$	1,173,420		$	—			$	3,816,575
Costs and expenses:
Cost of services	2,340			1,782,843			486,006			976,417			—				3,247,606
General and administrative	87,806			250			—			2,895			—				90,951
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Total costs and expenses	96,923			1,842,801			498,211			1,049,644			—				3,487,579
Income (loss) from operations	(96,923		)	229,436			72,707			123,776			—				328,996
Other income and expense:
Intercompany interest and royalty fees	22,029			(10,502		)	(10,685		)	(842		)	—				—
Intercompany management fees	166,749			(132,733		)	(34,016		)	—			—				—
Loss on early retirement of debt	(2,229		)	—			—			(8,026		)	—				(10,255		)
Equity in earnings of unconsolidated subsidiaries	—			14,884			30			—			—				14,914
Non-operating gain	1,654			7,362			—			—			—				9,016
Interest income (expense)	(89,416		)	220			(544		)	(58,251		)	—				(147,991		)
Income before income taxes	1,864			108,667			27,492			56,657			—				194,680
Income tax expense (benefit)	(83		)	36,112			350			11,081			—				47,460
Equity in earnings of consolidated subsidiaries	111,220			17,984			—			—			(129,204		)	(a)	—
Net income	113,167			90,539			27,142			45,576			(129,204		)		147,220
Less: Net income attributable to non-controlling interests	—			97			9,158			24,798			—				34,053
Net income attributable to Select Medical Corporation	$	113,167		$	90,442		$	17,984		$	20,778		$	(129,204	)		$	113,167

 _______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

27

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	113,167		$	90,539		$	27,142		$	45,576		$	(129,204	)	(a)	$	147,220
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	—			10,700			34			—			—				10,734
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Provision for bad debts	—			(451		)	—			78			—				(373		)
Equity in earnings of unconsolidated subsidiaries	—			(14,884		)	(30		)	—			—				(14,914		)
Equity in earnings of consolidated subsidiaries	(111,220		)	(17,984		)	—			—			129,204			(a)	—
Loss on extinguishment of debt	115			—			—			369			—				484
Loss (gain) on sale of assets and businesses	(1,641		)	(7,493		)	5			—			—				(9,129		)
Stock compensation expense	15,059			—			—			2,116			—				17,175
Amortization of debt discount, premium and issuance costs	4,435			—			—			5,410			—				9,845
Deferred income taxes	1,804			2,527			103			(6,526		)	—				(2,092		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			37,490			(894		)	(13,101		)	—				23,495
Other current assets	(2,420		)	(2,100		)	(1,807		)	(3,947		)	—				(10,274		)
Other assets	(4,381		)	(8,576		)	1,604			16,181			—				4,828
Accounts payable	(42		)	(5,155		)	3,059			(1,369		)	—				(3,507		)
Accrued expenses	20,379			13,620			6,412			8,980			—				49,391
Income taxes	9,622			4,401			1			(4,952		)	—				9,072
Net cash provided by operating activities	51,654			162,342			47,834			119,147			—				380,977
Investing activities
Business combinations, net of cash acquired	—			(2,666		)	(22		)	(516,570		)	—				(519,258		)
Purchases of property and equipment	(6,412		)	(60,669		)	(24,677		)	(29,281		)	—				(121,039		)
Investment in businesses	—			(12,931		)	—			(5		)	—				(12,936		)
Proceeds from sale of assets and businesses	1,654			5,029			8			—			—				6,691
Net cash used in investing activities	(4,758		)	(71,237		)	(24,691		)	(545,856		)	—				(646,542		)
Financing activities
Borrowings on revolving facilities	420,000			—			—			—			—				420,000
Payments on revolving facilities	(585,000		)	—			—			—			—				(585,000		)
Proceeds from term loans (financing costs)	(11		)	—			—			779,915			—				779,904
Payments on term loans	(8,625		)	—			—			—			—				(8,625		)
Revolving facility debt issuance costs	(837		)	—			—			(496		)	—				(1,333		)
Borrowings of other debt	5,542			—			19,935			4,657			—				30,134
Principal payments on other debt	(8,455		)	(540		)	(4,504		)	(4,472		)	—				(17,971		)
Dividends paid to Holdings	(5,640		)	—			—			—			—				(5,640		)
Equity investment by Holdings	1,633			—			—			—			—				1,633
Intercompany	140,673			(88,344		)	(34,184		)	(18,145		)	—				—
Decrease in overdrafts	(6,172		)	—			—			—			—				(6,172		)
Proceeds from issuance of non-controlling interests	—			—			957			1,969			—				2,926
Distributions to non-controlling interests	—			(1,450		)	(6,863		)	(298,114		)	—				(306,427		)
Net cash provided by (used in) financing activities	(46,892		)	(90,334		)	(24,659		)	465,314			—				303,429
Net increase (decrease) in cash and cash equivalents	4			771			(1,516		)	38,605			—				37,864
Cash and cash equivalents at beginning of period	73			4,856			4,561			113,059			—				122,549
Cash and cash equivalents at end of period	$	77		$	5,627		$	3,045		$	151,664		$	—			$	160,413

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

28

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	73		$	4,856	$	4,561		$	113,059	$	—			$	122,549
Accounts receivable	—			449,493		122,728			119,511		—				691,732
Intercompany receivables	—			1,598,212		60,707			—		(1,658,919		)	(a)	—
Prepaid income taxes	22,704			5,703		31			2,949		—				31,387
Other current assets	13,021			30,209		13,031			18,897		—				75,158
Total Current Assets	35,798			2,088,473		201,058			254,416		(1,658,919		)		920,826
Property and equipment, net	39,836			623,085		79,013			170,657		—				912,591
Investment in affiliates	4,524,385			124,104		—			—		(4,648,489		)	(b)(c)	—
Goodwill	—			2,108,270		—			674,542		—				2,782,812
Identifiable intangible assets, net	—			104,067		5,046			217,406		—				326,519
Other assets	36,494			98,575		35,440			23,898		(9,989		)	(e)	184,418
Total Assets	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166
Liabilities and Equity
Current Liabilities:
Overdrafts	$	29,463		$	—	$	—		$	—	$	—			$	29,463
Current portion of long-term debt and notes payable	16,635			740		2,212			2,600		—				22,187
Accounts payable	12,504			85,489		17,475			12,726		—				128,194
Intercompany payables	1,598,212			60,707		—			—		(1,658,919		)	(a)	—
Accrued payroll	16,736			98,887		4,819			40,120		—				160,562
Accrued vacation	4,083			58,355		12,295			18,142		—				92,875
Accrued interest	17,479			7		6			2,393		—				19,885
Accrued other	39,219			57,378		12,599			33,970		—				143,166
Income taxes payable	—			1,302		30			7,739		—				9,071
Total Current Liabilities	1,734,331			362,865		49,436			117,690		(1,658,919		)		605,403
Long-term debt, net of current portion	2,042,555			127		24,730			610,303		—				2,677,715
Non-current deferred tax liability	—			88,376		780			45,750		(9,989		)	(e)	124,917
Other non-current liabilities	36,259			56,721		8,138			44,591		—				145,709
Total Liabilities	3,813,145			508,089		83,084			818,334		(1,668,908		)		3,553,744
Redeemable non-controlling interests	—			—		—			16,270		624,548			(d)	640,818
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	947,370			—		—			—		—				947,370
Retained earnings (accumulated deficit)	(124,002		)	1,416,857		(35,942		)	64,626		(1,445,541		)	(c)(d)	(124,002		)
Subsidiary investment	—			3,221,628		273,415			437,779		(3,932,822		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	823,368			4,638,485		237,473			502,405		(5,378,363		)		823,368
Non-controlling interests	—			—		—			3,910		105,326			(d)	109,236
Total Equity	823,368			4,638,485		237,473			506,315		(5,273,037		)		932,604
Total Liabilities and Equity	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

29

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	56		$	654,964		$	166,113		$	255,881		$	—			$	1,077,014
Costs and expenses:
Cost of services	667			574,250			148,072			216,090			—				939,079
General and administrative	27,028			37			—			—			—				27,065
Depreciation and amortization	2,355			18,015			3,388			15,014			—				38,772
Total costs and expenses	30,050			592,302			151,460			231,104			—				1,004,916
Income (loss) from operations	(29,994		)	62,662			14,653			24,777			—				72,098
Other income and expense:
Intercompany interest and royalty fees	7,865			(4,328		)	(3,537		)	—			—				—
Intercompany management fees	51,241			(41,031		)	(10,210		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			4,416			15			—			—				4,431
Interest income (expense)	(30,240		)	271			(20		)	(7,699		)	—				(37,688		)
Income before income taxes	(1,128		)	21,990			901			17,078			—				38,841
Income tax expense (benefit)	(1,032		)	8,562			145			6,342			—				14,017
Equity in earnings of consolidated subsidiaries	18,558			397			—			—			(18,955		)	(a)	—
Net income	18,462			13,825			756			10,736			(18,955		)		24,824
Less: Net income attributable to non-controlling interests	—			24			359			5,979			—				6,362
Net income attributable to Select Medical Corporation	$	18,462		$	13,801		$	397		$	4,757		$	(18,955	)		$	18,462

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

30

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	687		$	2,019,581		$	487,371		$	763,357		$	—			$	3,270,996
Costs and expenses:
Cost of services	1,843			1,725,060			423,025			638,483			—				2,788,411
General and administrative	83,291			124			—			—			—				83,415
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Total costs and expenses	90,637			1,782,752			433,032			685,049			—				2,991,470
Income (loss) from operations	(89,950		)	236,829			54,339			78,308			—				279,526
Other income and expense:
Intercompany interest and royalty fees	24,760			(14,029		)	(10,731		)	—			—				—
Intercompany management fees	176,443			(147,042		)	(29,401		)	—			—				—
Loss on early retirement of debt	(19,719		)	—			—			—			—				(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			15,555			63			—			—				15,618
Non-operating loss	—			(49		)	—			—			—				(49		)
Interest income (expense)	(93,725		)	270			(105		)	(22,636		)	—				(116,196		)
Income (loss) before income taxes	(2,191		)	91,534			14,165			55,672			—				159,180
Income tax expense (benefit)	(3,230		)	42,135			428			20,260			—				59,593
Equity in earnings of consolidated subsidiaries	75,348			10,131			—			—			(85,479		)	(a)	—
Net income	76,387			59,530			13,737			35,412			(85,479		)		99,587
Less: Net income attributable to non-controlling interests	—			21			3,606			19,573			—				23,200
Net income attributable to Select Medical Corporation	$	76,387		$	59,509		$	10,131		$	15,839		$	(85,479	)		$	76,387

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

31

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	76,387		$	59,530		$	13,737		$	35,412		$	(85,479	)	(a)	$	99,587
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			14,493			49			—			—				14,542
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Provision for bad debts	—			864			—			50			—				914
Equity in earnings of unconsolidated subsidiaries	—			(15,555		)	(63		)	—			—				(15,618		)
Equity in earnings of consolidated subsidiaries	(75,348		)	(10,131		)	—			—			85,479			(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—				6,527
Loss (gain) on sale of assets and businesses	(8		)	(4,824		)	(4,687		)	20			—				(9,499		)
Stock compensation expense	13,445			—			—			782			—				14,227
Amortization of debt discount, premium and issuance costs	6,113			—			—			2,433			—				8,546
Deferred income taxes	5,014			—			—			(11,140		)	—				(6,126		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(105,536		)	(22,820		)	(14,952		)	—				(143,308		)
Other current assets	1,016			3,857			(6,772		)	(778		)	—				(2,677		)
Other assets	1,633			(3,709		)	3,044			439			—				1,407
Accounts payable	2,375			(823		)	1,580			781			—				3,913
Accrued expenses	164			(1,175		)	10,281			9,482			—				18,752
Income taxes	3,776			—			—			15,365			—				19,141
Net cash provided by (used in) operating activities	46,597			(5,441		)	4,356			84,460			—				129,972
Investing activities
Business combinations, net of cash acquired	—			(3,356		)	(295		)	(15,720		)	—				(19,371		)
Purchases of property and equipment	(26,350		)	(102,342		)	(23,452		)	(21,656		)	—				(173,800		)
Investment in businesses	—			(11,374		)	—			—			—				(11,374		)
Proceeds from sale of assets and businesses	8			15,007			19,537			3			—				34,555
Net cash used in investing activities	(26,342		)	(102,065		)	(4,210		)	(37,373		)	—				(169,990		)
Financing activities
Borrowings on revolving facilities	805,000			—			—			—			—				805,000
Payments on revolving facilities	(705,000		)	—			—			—			—				(705,000		)
Proceeds from term loans	1,139,487			—			—			—			—				1,139,487
Payments on term loans	(1,153,502		)	—			—			(23,065		)	—				(1,176,567		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—				(4,392		)
Borrowings of other debt	21,572			—			3,232			2,767			—				27,571
Principal payments on other debt	(10,122		)	(306		)	(2,150		)	(2,534		)	—				(15,112		)
Dividends paid to Holdings	(3,603		)	—			—			—			—				(3,603		)
Equity investment by Holdings	1,634			—			—			—			—				1,634
Intercompany	(101,888		)	107,834			(5,946		)	—			—				—
Decrease in overdrafts	(20,439		)	—			—			—			—				(20,439		)
Proceeds from issuance of non-controlling interests	—			—			8,986			—			—				8,986
Distributions to non-controlling interests	—			(130		)	(4,776		)	(4,370		)	—				(9,276		)
Net cash provided by (used in) financing activities	(31,253		)	107,398			(654		)	(27,202		)	—				48,289
Net increase (decrease) in cash and cash equivalents	(10,998		)	(108		)	(508		)	19,885			—				8,271
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—				99,029
Cash and cash equivalents at end of period	$	73		$	6,359		$	4,548		$	96,320		$	—			$	107,300

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

32

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend,” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

• changes in government reimbursement for our services and/or new payment policies may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;

• the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

• the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

• a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

• acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

• our plans and expectations related to the acquisition of U.S. HealthWorks by Concentra and our ability to realize anticipated synergies;

• private third-party payors for our services may adopt payment policies that could limit our future net operating revenues and profitability;

• the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

• shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;

• competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

• the loss of key members of our management team could significantly disrupt our operations;

• the effect of claims asserted against us could subject us to substantial uninsured liabilities;

• a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and

• other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, as such risk factors may be updated from time to time in our periodic filings with the SEC.

33

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

 We are one of the largest operators of critical illness recovery hospitals (previously referred to as long term acute care hospitals), rehabilitation hospitals (previously referred to as inpatient rehabilitation facilities), outpatient rehabilitation clinics and occupational health centers in the United States based on the number of facilities. Our reportable segments include the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. As of September 30, 2018, we operated 97 critical illness recovery hospitals in 27 states, 26 rehabilitation hospitals in 11 states, and 1,649 outpatient rehabilitation clinics in 37 states and the District of Columbia. Concentra, which is operated through a joint venture subsidiary, operated 525 occupational health centers in 41 states as of September 30, 2018 after giving effect to the closing of the acquisition of U.S. HealthWorks on February 1, 2018. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics, or “CBOCs.” As of September 30, 2018, we had operations in 47 states and the District of Columbia.

We had net operating revenues of $3,816.6 million for the nine months ended September 30, 2018. Of this total, we earned approximately 34% of our net operating revenues from our critical illness recovery hospital segment, approximately 14% from our rehabilitation hospital segment, approximately 21% from our outpatient rehabilitation segment, and approximately 31% from our Concentra segment. Patients are typically admitted to the Company’s critical illness recovery and rehabilitation hospitals from general acute care hospitals. These patients have specialized needs, with serious and often complex medical conditions. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of occupational health centers and contract services provided at employer worksites that deliver occupational medicine, physical therapy, and consumer health services. Additionally, our Concentra segment delivers veteran’s healthcare through its Department of Veterans Affairs CBOCs.

34

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA, as defined below, is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating segments. Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, acquisition costs associated with U.S. HealthWorks, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The table below reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
	(in thousands)
Net income	$	24,824		$	42,679		$	99,587		$	147,220
Income tax expense	14,017			14,060			59,593			47,460
Interest expense	37,688			50,669			116,196			147,991
Non-operating loss (gain)	—			(2,139		)	49			(9,016		)
Equity in earnings of unconsolidated subsidiaries	(4,431		)	(5,432		)	(15,618		)	(14,914		)
Loss on early retirement of debt	—			—			19,719			10,255
Income from operations	72,098			99,837			279,526			328,996
Stock compensation expense:
Included in general and administrative	4,079			4,683			11,603			12,720
Included in cost of services	878			1,581			2,624			4,455
Depreciation and amortization	38,772			50,527			119,644			149,022
U.S. HealthWorks acquisition costs	—			—			—			2,895
Adjusted EBITDA	$	115,827		$	156,628		$	413,397		$	498,088

Summary Financial Results

Three Months Ended September 30, 2018

For the three months ended September 30, 2018, our net operating revenues increased 17.7% to $1,267.4 million, compared to $1,077.0 million for the three months ended September 30, 2017. Income from operations increased 38.5% to $99.8 million for the three months ended September 30, 2018, compared to $72.1 million for the three months ended September 30, 2017.

Net income increased 71.9% to $42.7 million for the three months ended September 30, 2018, compared to $24.8 million for the three months ended September 30, 2017. Net income for the three months ended September 30, 2018 included a pre-tax non-operating gain of $2.1 million.

Adjusted EBITDA increased 35.2% to $156.6 million for the three months ended September 30, 2018, compared to $115.8 million for the three months ended September 30, 2017. Our Adjusted EBITDA margin was 12.4% for the three months ended September 30, 2018, compared to 10.8% for the three months ended September 30, 2017.

35

The following tables reconcile our segment performance measures to our consolidated operating results:

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)			Rehabilitation Hospital(1)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Net operating revenues	$	420,108		$	176,885		$	265,927		$	404,481		$	—		$	1,267,401
Operating expenses	366,816			151,542			231,396			336,494			30,789			1,117,037
Depreciation and amortization	11,136			6,079			6,597			24,488			2,227			50,527
Income (loss) from operations	$	42,156		$	19,264		$	27,934		$	43,499		$	(33,016	)	$	99,837
Depreciation and amortization	11,136			6,079			6,597			24,488			2,227			50,527
Stock compensation expense	—			—			—			767			5,497			6,264
U.S. HealthWorks acquisition costs	—			—			—			—			—			—
Adjusted EBITDA	$	53,292		$	25,343		$	34,531		$	68,754		$	(25,292	)	$	156,628
Adjusted EBITDA margin	12.7		%	14.3		%	13.0		%	17.0		%	N/M			12.4		%

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)			Rehabilitation Hospital(1)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Net operating revenues	$	416,934		$	157,499		$	246,644		$	255,881		$	56		$	1,077,014
Operating expenses	370,061			134,918			217,346			216,090			27,729			966,144
Depreciation and amortization	10,932			4,505			5,964			15,014			2,357			38,772
Income (loss) from operations	$	35,941		$	18,076		$	23,334		$	24,777		$	(30,030	)	$	72,098
Depreciation and amortization	10,932			4,505			5,964			15,014			2,357			38,772
Stock compensation expense	—			—			—			212			4,745			4,957
Adjusted EBITDA	$	46,873		$	22,581		$	29,298		$	40,003		$	(22,928	)	$	115,827
Adjusted EBITDA margin	11.2		%	14.3		%	11.9		%	15.6		%	N/M			10.8		%

The following table summarizes changes in segment performance measures for the three months ended September 30, 2018, compared to the three months ended September 30, 2017:

	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra		Other		Total
Change in net operating revenues	0.8	%	12.3	%	7.8	%	58.1	%	N/M		17.7	%
Change in income from operations	17.3	%	6.6	%	19.7	%	75.6	%	(9.9	)%	38.5	%
Change in Adjusted EBITDA	13.7	%	12.2	%	17.9	%	71.9	%	(10.3	)%	35.2	%

_______________________________________________________________________________

(1) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

N/M —     Not meaningful.

36

Nine Months Ended September 30, 2018

For the nine months ended September 30, 2018, our net operating revenues increased 16.7% to $3,816.6 million, compared to $3,271.0 million for the nine months ended September 30, 2017. Income from operations increased 17.7% to $329.0 million for the nine months ended September 30, 2018, compared to $279.5 million for the nine months ended September 30, 2017.

Net income increased 47.8% to $147.2 million for the nine months ended September 30, 2018, compared to $99.6 million for the nine months ended September 30, 2017. Net income for the nine months ended September 30, 2018 included a pre-tax loss on early retirement of debt of $10.3 million, pre-tax non-operating gains of $9.0 million, and pre-tax U.S. HealthWorks acquisition costs of $2.9 million. Net income for the nine months ended September 30, 2017 included a pre-tax loss on early retirement of debt of $19.7 million.

Adjusted EBITDA increased 20.5% to $498.1 million for the nine months ended September 30, 2018, compared to $413.4 million for the nine months ended September 30, 2017. Our Adjusted EBITDA margin was 13.1% for the nine months ended September 30, 2018, compared to 12.6% for the nine months ended September 30, 2017.

The following tables reconcile our segment performance measures to our consolidated operating results:

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)			Rehabilitation Hospital(1)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Net operating revenues	$	1,327,236		$	525,428		$	790,491		$	1,173,420		$	—		$	3,816,575
Operating expenses	1,140,247			445,114			683,488			979,312			90,396			3,338,557
Depreciation and amortization	34,146			17,816			19,938			70,332			6,790			149,022
Income (loss) from operations	$	152,843		$	62,498		$	87,065		$	123,776		$	(97,186	)	$	328,996
Depreciation and amortization	34,146			17,816			19,938			70,332			6,790			149,022
Stock compensation expense	—			—			—			2,116			15,059			17,175
U.S. HealthWorks acquisition costs	—			—			—			2,895			—			2,895
Adjusted EBITDA	$	186,989		$	80,314		$	107,003		$	199,119		$	(75,337	)	$	498,088
Adjusted EBITDA margin	14.1		%	15.3		%	13.5		%	17.0		%	N/M			13.1		%

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)			Rehabilitation Hospital(1)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Net operating revenues	$	1,301,251		$	453,702		$	751,999		$	763,357		$	687		$	3,270,996
Operating expenses	1,106,998			391,664			649,424			638,483			85,257			2,871,826
Depreciation and amortization	34,891			14,500			18,182			46,566			5,505			119,644
Income (loss) from operations	$	159,362		$	47,538		$	84,393		$	78,308		$	(90,075	)	$	279,526
Depreciation and amortization	34,891			14,500			18,182			46,566			5,505			119,644
Stock compensation expense	—			—			—			782			13,445			14,227
Adjusted EBITDA	$	194,253		$	62,038		$	102,575		$	125,656		$	(71,125	)	$	413,397
Adjusted EBITDA margin	14.9		%	13.7		%	13.6		%	16.5		%	N/M			12.6		%

37

The following table summarizes changes in segment performance measures for the nine months ended September 30, 2018, compared to the nine months ended September 30, 2017:

	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra		Other		Total
Change in net operating revenues	2.0	%	15.8	%	5.1	%	53.7	%	N/M		16.7	%
Change in income from operations	(4.1	)%	31.5	%	3.2	%	58.1	%	(7.9	)%	17.7	%
Change in Adjusted EBITDA	(3.7	)%	29.5	%	4.3	%	58.5	%	(5.9	)%	20.5	%

_______________________________________________________________________________

(1) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

N/M —     Not meaningful.

38

Significant Events

Acquisition of U.S. HealthWorks

On February 1, 2018, Concentra acquired all of the issued and outstanding shares of stock of U.S. HealthWorks, an occupational medicine and urgent care provider, pursuant to the terms of the Purchase Agreement.

In connection with the closing of the transaction, Concentra Group Holdings made distributions to its equity holders and redeemed certain of its outstanding equity interests from existing minority equity holders. Subsequently, Concentra Group Holdings and a wholly owned subsidiary of Concentra Group Holdings Parent merged, with Concentra Group Holdings surviving the merger and becoming a wholly owned subsidiary of Concentra Group Holdings Parent. As a result of the merger, the equity interests of Concentra Group Holdings outstanding after the redemption described above were exchanged for membership interests in Concentra Group Holdings Parent.

Concentra acquired U.S. HealthWorks for $753.0 million. The Purchase Agreement provides for certain post-closing adjustments for cash, indebtedness, transaction expenses, and working capital. DHHC, a subsidiary of Dignity Health, was issued a 20% equity interest in Concentra Group Holdings Parent, which was valued at $238.0 million. Select retained a majority voting interest in Concentra Group Holdings Parent following the closing of the transaction.

Concentra used borrowings under the Concentra first lien credit agreement and the Concentra second lien credit agreement, as described below, together with cash on hand, to pay the cash purchase price for all of the issued and outstanding stock of U.S. HealthWorks to DHHC, to finance the redemption and reorganization transactions executed under the Purchase Agreement, and to pay fees and expenses associated with the financing.

Amendment to the Concentra Credit Facilities

On February 1, 2018, in connection with the transactions executed under the Purchase Agreement, Concentra amended the Concentra first lien credit agreement to, among other things, provide for (i) an additional $555.0 million in tranche B term loans that, along with the existing tranche B term loans under the Concentra first lien credit agreement, have a maturity date of June 1, 2022 and (ii) an additional $25.0 million to the $50.0 million, five-year revolving credit facility under the terms of the existing Concentra first lien credit agreement. The tranche B term loans bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus 2.75% (subject to an Adjusted LIBO Rate floor of 1.00%) for Eurodollar Borrowings (as defined in the Concentra first lien credit agreement), or Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus 1.75% (subject to an Alternate Base Rate floor of 2.00%) for ABR Borrowings (as defined in the Concentra first lien credit agreement). All other material terms and conditions applicable to the original tranche B term loan commitments are applicable to the additional tranche B term loans created under the Concentra first lien credit agreement.

In addition, Concentra entered into the Concentra second lien credit agreement that provided for $240.0 million in term loans with a maturity date of June 1, 2023. Borrowings under the Concentra second lien credit agreement bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra second lien credit agreement) plus 6.50% (subject to an Adjusted LIBO Rate floor of 1.00%), or Alternate Base Rate (as defined in the Concentra second lien credit agreement) plus 5.50% (subject to an Alternate Base Rate floor of 2.00%).

On October 26, 2018, Concentra entered into Amendment No. 4 to the Concentra first lien credit agreement. Among other things, Amendment No. 4 (i) provided the applicable interest rate on the tranche B term loans under the Concentra first lien credit agreement is the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 2.50% to 2.75% (with 2.75% being the initial rate), or the Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 1.50% to 1.75% (with 1.75% being the initial rate), in each case subject to a specified credit rating, and (ii) decreased the applicable interest rate on the loans outstanding under the Concentra revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.75% to 3.00% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternate Base Rate plus a percentage ranging from 1.75% to 2.00% to the Alternate Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to Concentra’s first lien net leverage ratio (as defined in the Concentra first lien credit agreement). As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Concentra first lien credit agreement are no longer subject to the currently applicable floor.

39

Amendment to the Select Credit Facilities

On March 22, 2018, Select entered into Amendment No. 1 to the Select credit agreement dated March 6, 2017. Amendment No. 1 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement and subject to an Adjusted LIBO floor of 1.00%) plus 3.50% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate (as defined in the Select credit agreement and subject to an Alternate Base Rate floor of 2.00%) plus 2.50% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio (as defined in the Select credit agreement); (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 3.00% to 3.25% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate plus a percentage ranging from 2.00% to 2.25% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio; (iii) extended the maturity date for the Select term loans from March 6, 2024 to March 6, 2025; and (iv) made certain other technical amendments to the Select credit agreement as set forth therein.

On October 26, 2018, Select entered into Amendment No. 2 to the Select credit agreement. Among other things, Amendment No. 2 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement) plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio (as defined in the Select credit agreement), and (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio. As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Select credit agreement are no longer subject to the currently applicable floor.

40

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on February 22, 2018, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services and CMS. Net operating revenues generated directly from the Medicare program represented approximately 27% of our net operating revenues for the nine months ended September 30, 2018, and 30% of our net operating revenues for the year ended December 31, 2017.

Medicare Reimbursement of Critical Illness Recovery Hospital Services

There have been significant regulatory changes affecting our critical illness recovery hospitals, which are certified by Medicare as long term care hospitals (“LTCHs”), that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies. We have been subject to regulatory changes that occur through the rulemaking procedures of CMS. All Medicare payments to our critical illness recovery hospitals are made in accordance with the long term care hospital prospective payment system (“LTCH-PPS”). Proposed rules specifically related to LTCH-PPS are generally published in May, finalized in August and effective on October 1 of each year.

The following is a summary of significant changes to LTCH-PPS which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations.

Fiscal Year 2017. On August 22, 2016, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard federal rate was set at $42,476, an increase from the standard federal rate applicable during fiscal year 2016 of $41,763. The update to the standard federal rate for fiscal year 2017 included a market basket increase of 2.8%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. The fixed‑loss amount for high cost outlier cases paid under LTCH‑PPS was set at $21,943, an increase from the fixed‑loss amount in the 2016 fiscal year of $16,423. The fixed‑loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $23,573, an increase from the fixed‑loss amount in the 2016 fiscal year of $22,538.

Fiscal Year 2018. On August 14, 2017, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2018 (affecting discharges and cost reporting periods beginning on or after October 1, 2017 through September 30, 2018). Certain errors in the final rule were corrected in a final rule published October 4, 2017. The standard federal rate was set at $41,415, a decrease from the standard federal rate applicable during fiscal year 2017 of $42,476. The update to the standard federal rate for fiscal year 2018 included a market basket increase of 2.7%, less a productivity adjustment of 0.6%, and less a reduction of 0.75% mandated by the ACA. The update to the standard federal rate for fiscal year 2018 was impacted further by the Medicare Access and CHIP Reauthorization Act of 2015, which limits the update for fiscal year 2018 to 1.0%. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $27,381, an increase from the fixed-loss amount in the 2017 fiscal year of $21,943. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $26,537, an increase from the fixed-loss amount in the 2017 fiscal year of $23,573.

Fiscal Year 2019. On August 17, 2018, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2019 (affecting discharges and cost reporting periods beginning on or after October 1, 2018 through September 30, 2019). Certain errors in the final rule were corrected in a final rule published October 3, 2018. The standard federal rate was set at $41,559, an increase from the standard federal rate applicable during fiscal year 2018 of $41,415. The update to the standard federal rate for fiscal year 2019 included a market basket increase of 2.9%, less a productivity adjustment of 0.8%, and less a reduction of 0.75% mandated by the ACA. The standard federal rate also included an area wage budget neutrality factor of 0.999215 and a temporary, one-time budget neutrality adjustment of 0.990878 in connection with the elimination of the 25 Percent Rule (discussed further below). The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $27,121, which is a decrease from the fixed-loss amount in the 2018 fiscal year of $27,381. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $25,743, a decrease from the fixed-loss amount in the 2018 fiscal year of $26,537.

41

25 Percent Rule

The “25 Percent Rule” was a downward payment adjustment that applied if the percentage of Medicare patients discharged from LTCHs who were admitted from a referring hospital (regardless of whether the LTCH or LTCH satellite is co-located with the referring hospital) exceeded the applicable percentage admissions threshold during a particular cost reporting period. Specifically, the payment rate for only Medicare patients above the percentage admissions threshold were subject to a downward payment adjustment. For Medicare patients above the applicable percentage admissions threshold, the LTCH was reimbursed at a rate equivalent to that under general acute care hospital inpatient prospective payment system, or “IPPS,” which was generally lower than LTCH-PPS rates. Cases that reach outlier status in the referring hospital did not count toward the admissions threshold and were paid under LTCH-PPS.

CMS was precluded from applying the 25 Percent Rule for freestanding LTCHs to cost reporting years beginning before July 1, 2016 and for discharges occurring on or after October 1, 2016 and before October 1, 2017. In addition, the law applied higher percentage admissions thresholds for most LTCHs operating as a hospital within a hospital (“HIH”) and satellites for cost reporting years beginning before July 1, 2016 and effective for discharges occurring on or after October 1, 2016 and before October 1, 2017. For most HIHs and satellites the percentage admissions threshold was raised from 25% to 50% during the relief periods. In the special case of rural LTCHs, LTCHs co-located with an urban single hospital, or LTCHs co-located with a Metropolitan Statistical Area (“MSA”) dominant hospital the referral percentage was raised from 50% to 75%. Grandfathered HIHs were exempt from the 25 Percent Rule regulations.

For fiscal year 2018, CMS adopted a regulatory moratorium on the implementation of the 25 Percent Rule.

For fiscal year 2019 and thereafter, CMS eliminated the 25 Percent Rule entirely. The elimination of the 25 Percent Rule is being implemented in a budget neutral manner by adjusting the standard federal payment rates down such that the projection of aggregate LTCH payments would equal the projection of aggregate LTCH payments that would have been paid if the moratorium ended and the 25 Percent Rule went into effect on October 1, 2018. As a result, the elimination of the 25 Percent Rule includes a temporary, one-time adjustment of 0.990878 to the fiscal year 2019 LTCH-PPS standard federal payment rate, a temporary, one-time adjustment of 0.990737 to the fiscal year 2020 LTCH-PPS standard federal payment rate, and a permanent, one-time adjustment of 0.991249 to the LTCH-PPS standard federal payment rate in fiscal years 2021 and subsequent years.

Short Stay Outlier Policy

CMS established a different payment methodology for Medicare patients with a length of stay less than or equal to five‑sixths of the geometric average length of stay for that particular Medicare severity long-term care diagnosis-related group (“MS-LTC-DRG”), referred to as a short stay outlier, or “SSO.” For discharges before October 1, 2017, SSO cases were paid based on the lesser of (i) 100% of the average cost of the case, (ii) 120% of the MS-LTC-DRG specific per diem amount multiplied by the patient’s length of stay, (iii) the full MS-LTC-DRG payment, or (iv) a per diem rate derived from blending 120% of the MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS.

The SSO rule also had a category referred to as a “very short stay outlier,” which applied to cases with a length of stay that is less than the average length of stay plus one standard deviation for the same Medicare severity diagnosis-related group (“MS-DRG”) under IPPS, referred to as the so-called “IPPS comparable threshold.” The LTCH payment for very short stay outlier cases was equivalent to the general acute care hospital IPPS per diem rate.

CMS adopted changes to the SSO policy such that all SSO cases discharged on or after October 1, 2017 are paid based on a per diem rate derived from blending 120% of the MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS (i.e., the fourth option under the prior policy). Under this policy, as the length of stay of a SSO case increases, the percentage of the per diem payment amounts based on the full MS-LTCH-DRG standard federal payment rate increases and the percentage of the payment based on the IPPS comparable amount decreases. In addition, the very short stay outlier category was eliminated.

42

Medicare Reimbursement of Rehabilitation Hospital Services

The following is a summary of significant regulatory changes affecting our rehabilitation hospitals, which are certified by Medicare as inpatient rehabilitation facilities (“IRFs”), as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our rehabilitation hospitals are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

The following is a summary of significant changes to IRF-PPS which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations.

Fiscal Year 2017. On August 5, 2016, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard payment conversion factor for discharges for fiscal year 2017 was set at $15,708, an increase from the standard payment conversion factor applicable during fiscal year 2016 of $15,478. The update to the standard payment conversion factor for fiscal year 2017 included a market basket increase of 2.7%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2017 to $7,984 from $8,658 established in the final rule for fiscal year 2016.

Fiscal Year 2018. On August 3, 2017, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2018 (affecting discharges and cost reporting periods beginning on or after October 1, 2017 through September 30, 2018). The standard payment conversion factor for discharges for fiscal year 2018 was set at $15,838, an increase from the standard payment conversion factor applicable during fiscal year 2017 of $15,708. The update to the standard payment conversion factor for fiscal year 2018 included a market basket increase of 2.6%, less a productivity adjustment of 0.6%, and less a reduction of 0.75% mandated by the ACA. The standard payment conversion factor for fiscal year 2018 was impacted further by the Medicare Access and CHIP Reauthorization Act of 2015, which limits the update for fiscal year 2018 to 1.0%. CMS increased the outlier threshold amount for fiscal year 2018 to $8,679 from $7,984 established in the final rule for fiscal year 2017.

Fiscal Year 2019. On August 6, 2018, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2019 (affecting discharges and cost reporting periods beginning on or after October 1, 2018 through September 30, 2019). The standard payment conversion factor for discharges for fiscal year 2019 was set at $16,021, an increase from the standard payment conversion factor applicable during fiscal year 2018 of $15,838. The update to the standard payment conversion factor for fiscal year 2019 included a market basket increase of 2.9%, less a productivity adjustment of 0.8%, and less a reduction of 0.75% mandated by the ACA. CMS increased the outlier threshold amount for fiscal year 2019 to $9,402 from $8,679 established in the final rule for fiscal year 2018.

Medicare Reimbursement of Outpatient Rehabilitation Clinic Services

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. For services provided in 2017 through 2019, a 0.5% update will be applied each year to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit‑Based Incentive Payment System (“MIPS”). For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and the alternative payment models (“APMs”). In 2026 and subsequent years eligible professionals participating in APMs that meet certain criteria would receive annual updates of 0.75%, while all other professionals would receive annual updates of 0.25%.

Beginning in 2019, payments under the fee schedule are subject to adjustment based on performance in MIPS, which measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. Under the MIPS requirements a provider’s performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional’s payment for a year. Each year from 2019 through 2024 professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors. MIPS and APM applies to physicians and other practitioners included within the definition of “eligible clinicians.” Currently, physical therapists and occupational therapists may voluntarily participate in MIPS and APM. In the Medicare Physician Fee Schedule proposed rule for calendar year 2019, CMS proposes to include physical therapists and occupational therapists as “eligible clinicians” which, if the proposed rule is adopted, would require physical therapists and occupational therapists to participate in these programs beginning in 2021. CMS requested public comment on requiring speech-language pathologists to participate in these programs beginning in 2021. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, remain subject to future notice and comment rule‑making.

43

Therapy Caps

Outpatient therapy providers reimbursed under the Medicare physician fee schedule have been subject to annual limits for therapy expenses. For example, for the calendar year beginning January 1, 2017, the annual limit on outpatient therapy services was $1,980 for combined physical and speech language pathology services and $1,980 for occupational therapy services. The Bipartisan Budget Act of 2018 repealed the annual limits on outpatient therapy.

The annual limits for therapy expenses historically did not apply to services furnished and billed by outpatient hospital departments. However, the Medicare Access and CHIP Reauthorization Act of 2015, and prior legislation, extended the annual limits on therapy expenses in hospital outpatient department settings through December 31, 2017. The application of annual limits to hospital outpatient department settings sunset on December 31, 2017.

Prior to calendar year 2028, all therapy claims exceeding $3,000 are subject to a manual medical review process. The $3,000 threshold is applied to physical therapy and speech therapy services combined and separately applied to occupational therapy. CMS will continue to require that an appropriate modifier be included on claims over the current exception threshold indicating that the therapy services are medically necessary. Beginning in 2028 and in each calendar year thereafter, the threshold amount for claims requiring manual medical review will increase by the percentage increase in the Medicare Economic Index.

Modifiers to Identify Services of Physical Therapy Assistants or Occupational Therapy Assistants

In the Medicare Physician Fee Schedule proposed rule for calendar year 2019, CMS proposes to establish two new therapy modifiers to identify the services furnished in whole or in part by physical therapy assistants (“PTAs”) or occupational therapy assistants (“OTAs”) beginning January 1, 2020. This change, which was mandated by the Bipartisan Budget Act of 2018, establishes modifiers to be used whenever a PTA or OTA furnishes all or part of any covered outpatient therapy service. CMS intends to use these modifiers to develop a proposed planned payment differential that would reimburse services provided by PTAs and OTAs at 85% of the fee schedule rate beginning in calendar year 2022. CMS proposes the creation of a voluntary reporting system for the new modifiers beginning in 2019.

Critical Accounting Matters

Revenue Adjustments

Net operating revenues include amounts estimated by us to be reimbursable by Medicare under prospective payment systems and provisions of cost-reimbursement and other payment methods. The amount reimbursed is derived based on the type of services provided. Additionally, we are reimbursed for healthcare services provided from various other payor sources which include insurance companies, workers’ compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies and employers, as well as patients. We are reimbursed by these payors using a variety of payment methodologies.

On January 1, 2018, we adopted Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, we recognize a contractual allowance for fixed discounts based on the difference between our standard billing rates and the fees legislated, negotiated or otherwise arranged between us and our patients. Additionally, we are subject to potential retrospective adjustments to net operating revenues in future periods, such as for matters related to claims processing and other price concessions. These adjustments, which are estimated based on an analysis of historical experience by payor source, are recognized as a constraint to revenue in the period services are rendered. Under the previous standard, these adjustments were classified as a component of bad debt expense.

In the critical illness recovery hospital and rehabilitation hospital segments, we estimate our contractual allowances based on known contractual provisions associated with the specific payor or, where we have a relatively homogeneous patient population, we will monitor individual payors’ historical reimbursement rates to estimate a per diem rate. The estimated per diem rate is used to derive the contractual allowance recognized in the period services are rendered. In the outpatient rehabilitation and Concentra segments, we estimate our contractual allowances based on known contractual provisions, negotiated amounts, or usual and customary amounts associated with the specific payor. We estimate our contractual allowances using internally developed systems in which we monitor a payors’ historical reimbursement rates and compare them against the associated gross charges for the service provided. The percentage of historical reimbursed claims to gross charges is used to estimate the contractual allowance recognized in the period services are rendered. In each of our segments, estimates for potential retrospective adjustments are recognized as an additional contractual allowance during the period services are rendered.

44

Operating Statistics

The following table sets forth operating statistics for our operating segments for each of the periods presented. The operating statistics reflect data for the period of time we managed these operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
Critical illness recovery hospital data:(1)
Number of hospitals owned—start of period	101			98			102			99
Number of hospitals acquired	—			—			1			—
Number of hospital start-ups	1			—			1			1
Number of hospitals closed/sold	(2		)	(1		)	(4		)	(3		)
Number of hospitals owned—end of period	100			97			100			97
Number of hospitals managed—end of period	1			—			1			—
Total number of hospitals (all)—end of period	101			97			101			97
Available licensed beds(2)	4,146			4,095			4,146			4,095
Admissions(2)	8,670			8,651			26,880			27,605
Patient days(2)	248,002			243,891			754,401			765,863
Average length of stay (days)(2)	29			28			28			28
Net revenue per patient day(2)(3)(5)	$	1,661		$	1,705		$	1,708		$	1,716
Occupancy rate(2)	65		%	65		%	66		%	68		%
Percent patient days—Medicare(2)	53		%	53		%	54		%	53		%
Rehabilitation hospital data:(1)
Number of facilities owned—start of period	13			17			13			16
Number of facilities acquired	—			—			—			—
Number of facilities start-ups	1			—			1			1
Number of facilities closed/sold	—			—			—			—
Number of facilities owned—end of period	14			17			14			17
Number of facilities managed—end of period	8			9			8			9
Total number of facilities (all)—end of period	22			26			22			26
Available licensed beds(2)	1,013			1,189			1,013			1,189
Admissions(2)	4,816			5,370			13,762			16,219
Patient days(2)	68,168			79,232			196,018			233,537
Average length of stay (days)(2)	14			15			14			15
Net revenue per patient day(2)(3)(5)	$	1,573		$	1,582		$	1,554		$	1,604
Occupancy rate(2)	73		%	72		%	72		%	73		%
Percent patient days—Medicare(2)	53		%	53		%	53		%	54		%
Outpatient rehabilitation data:
Number of clinics owned—start of period	1,441			1,435			1,445			1,447
Number of clinics acquired	4			—			5			14
Number of clinic start-ups	3			8			17			26
Number of clinics closed/sold	(13		)	(23		)	(32		)	(67		)
Number of clinics owned—end of period	1,435			1,420			1,435			1,420
Number of clinics managed—end of period	169			229			169			229
Total number of clinics (all)—end of period	1,604			1,649			1,604			1,649
Number of visits(2)	1,986,213			2,039,462			6,168,763			6,251,582
Net revenue per visit(2)(4)(5)	$	102		$	103		$	101		$	103

45

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
Concentra data:
Number of centers owned—start of period	315			527			300			312
Number of centers acquired	—			1			11			220
Number of clinic start-ups	—			—			4			—
Number of centers closed/sold	(3		)	(3		)	(3		)	(7		)
Number of centers owned—end of period	312			525			312			525
Number of visits(2)	1,979,481			2,984,832			5,848,551			8,605,012
Net revenue per visit(2)(4)(5)	$	113		$	124		$	114		$	124

_____________________________________________________________

(1) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

(2) Data excludes locations managed by the Company. For purposes of our Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

(3) Net revenue per patient day is calculated by dividing direct patient service revenues by the total number of patient days.

(4) Net revenue per visit is calculated by dividing direct patient service revenue by the total number of visits. For purposes of this computation for our Concentra segment, direct patient service revenue does not include onsite clinics and community-based outpatient clinics.

(5) Net revenue per patient day and net revenue per visit were retrospectively conformed to reflect the impact of Topic 606, Revenue from Contracts with Customers.

Results of Operations

The following table outlines selected operating data as a percentage of net operating revenues for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	87.2		85.8		85.2		85.1
General and administrative	2.5		2.4		2.6		2.4
Depreciation and amortization	3.6		3.9		3.7		3.9
Income from operations	6.7		7.9		8.5		8.6
Loss on early retirement of debt	—		—		(0.6	)	(0.3	)
Equity in earnings of unconsolidated subsidiaries	0.4		0.4		0.5		0.4
Non-operating gain (loss)	—		0.2		(0.0	)	0.2
Interest expense	(3.5	)	(4.0	)	(3.5	)	(3.8	)
Income before income taxes	3.6		4.5		4.9		5.1
Income tax expense	1.3		1.1		1.9		1.2
Net income	2.3		3.4		3.0		3.9
Net income attributable to non-controlling interests	0.6		0.8		0.7		0.9
Net income attributable to Holdings and Select	1.7	%	2.6	%	2.3	%	3.0	%

_______________________________________________________________________________

(1) Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

46

The following table summarizes selected financial data by business segment for the periods indicated:

	Three Months Ended September 30,								Nine Months Ended September 30,
	2017			2018			% Change		2017			2018			% Change
	(in thousands)
Net operating revenues:(1)
Critical illness recovery hospital(2)	$	416,934		$	420,108		0.8	%	$	1,301,251		$	1,327,236		2.0	%
Rehabilitation hospital(2)	157,499			176,885			12.3		453,702			525,428			15.8
Outpatient rehabilitation	246,644			265,927			7.8		751,999			790,491			5.1
Concentra	255,881			404,481			58.1		763,357			1,173,420			53.7
Other(3)	56			—			N/M		687			—			N/M
Total Company	$	1,077,014		$	1,267,401		17.7	%	$	3,270,996		$	3,816,575		16.7	%
Income (loss) from operations:
Critical illness recovery hospital(2)	$	35,941		$	42,156		17.3	%	$	159,362		$	152,843		(4.1	)%
Rehabilitation hospital(2)	18,076			19,264			6.6		47,538			62,498			31.5
Outpatient rehabilitation	23,334			27,934			19.7		84,393			87,065			3.2
Concentra	24,777			43,499			75.6		78,308			123,776			58.1
Other(3)	(30,030		)	(33,016		)	(9.9	)	(90,075		)	(97,186		)	(7.9	)
Total Company	$	72,098		$	99,837		38.5	%	$	279,526		$	328,996		17.7	%
Adjusted EBITDA:
Critical illness recovery hospital(2)	$	46,873		$	53,292		13.7	%	$	194,253		$	186,989		(3.7	)%
Rehabilitation hospital(2)	22,581			25,343			12.2		62,038			80,314			29.5
Outpatient rehabilitation	29,298			34,531			17.9		102,575			107,003			4.3
Concentra	40,003			68,754			71.9		125,656			199,119			58.5
Other(3)	(22,928		)	(25,292		)	(10.3	)	(71,125		)	(75,337		)	(5.9	)
Total Company	$	115,827		$	156,628		35.2	%	$	413,397		$	498,088		20.5	%
Adjusted EBITDA margins:
Critical illness recovery hospital(2)	11.2		%	12.7		%			14.9		%	14.1		%
Rehabilitation hospital(2)	14.3			14.3					13.7			15.3
Outpatient rehabilitation	11.9			13.0					13.6			13.5
Concentra	15.6			17.0					16.5			17.0
Other(3)	N/M			N/M					N/M			N/M
Total Company	10.8		%	12.4		%			12.6		%	13.1		%
Total assets:
Critical illness recovery hospital(2)	$	2,008,485		$	1,785,336				$	2,008,485		$	1,785,336
Rehabilitation hospital(2)	740,276			888,342					740,276			888,342
Outpatient rehabilitation	945,765			991,105					945,765			991,105
Concentra	1,332,012			2,201,869					1,332,012			2,201,869
Other(3)	97,269			113,529					97,269			113,529
Total Company	$	5,123,807		$	5,980,181				$	5,123,807		$	5,980,181
Purchases of property and equipment, net:
Critical illness recovery hospital(2)	$	8,003		$	8,134				$	28,717		$	31,455
Rehabilitation hospital(2)	29,373			8,769					77,707			29,766
Outpatient rehabilitation	6,496			7,209					19,370			22,565
Concentra	5,369			12,539					21,656			29,281
Other(3)	19,257			2,740					26,350			7,972
Total Company	$	68,498		$	39,391				$	173,800		$	121,039

_______________________________________________________________________________

(1) Net operating revenues were retrospectively conformed to reflect the adoption Topic 606, Revenue from Contracts with Customers.

(2) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

(3) Other includes our corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses.

N/M —     Not meaningful.

47

Three Months Ended September 30, 2018, Compared to Three Months Ended September 30, 2017

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, equity in earnings of unconsolidated subsidiaries, non-operating gain (loss), interest expense, income taxes, and net income attributable to non-controlling interests, which, in each case, are the same for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased 17.7% to $1,267.4 million for the three months ended September 30, 2018, compared to $1,077.0 million for the three months ended September 30, 2017.

Critical Illness Recovery Hospital Segment.    Net operating revenues increased 0.8% to $420.1 million for the three months ended September 30, 2018, compared to $416.9 million for the three months ended September 30, 2017. Our net revenue per patient day increased 2.6% to $1,705 for the three months ended September 30, 2018, compared to $1,661 for the three months ended September 30, 2017. The increase principally resulted from changes we experienced in our non-Medicare net revenue per patient day during the three months ended September 30, 2018. We had 243,891 patient days for the three months ended September 30, 2018, compared to 248,002 days for the three months ended September 30, 2017.

Rehabilitation Hospital Segment.    Net operating revenues increased 12.3% to $176.9 million for the three months ended September 30, 2018, compared to $157.5 million for the three months ended September 30, 2017. The increase in net operating revenues was principally attributable to an increase in patient volumes during the three months ended September 30, 2018. Our patient days increased 16.2% to 79,232 days for the three months ended September 30, 2018, compared to 68,168 days for the three months ended September 30, 2017. The increase in patient days was principally due to the maturation of our rehabilitation hospitals which commenced operations during 2016 and 2017. We also experienced an increase in our net revenue per patient day, which increased 0.6% to $1,582 for the three months ended September 30, 2018, compared to $1,573 for the three months ended September 30, 2017.

Outpatient Rehabilitation Segment.    Net operating revenues increased 7.8% to $265.9 million for the three months ended September 30, 2018, compared to $246.6 million for the three months ended September 30, 2017. The increase in net operating revenues was primarily attributable to an increase in visits, which increased 2.7% to 2,039,462 visits for the three months ended September 30, 2018, compared to 1,986,213 visits for the three months ended September 30, 2017. The increase in visits resulted from both start-up and newly acquired outpatient rehabilitation clinics, as well as growth within our existing clinics. Our net revenue per visit increased 1.0% to $103 for the three months ended September 30, 2018, compared to $102 for the three months ended September 30, 2017. Our net revenue per visit benefited from improved contracted rates with some of our payors. During the three months ended September 30, 2018, we also experienced an increase in net operating revenues related to contracted labor services provided to our equity investments. Our net operating revenues for the three months ended September 30, 2017 were impacted by Hurricanes Harvey and Irma, which caused an estimated $2.9 million decrease in net operating revenues.

Concentra Segment.    Net operating revenues increased 58.1% to $404.5 million for the three months ended September 30, 2018, compared to $255.9 million for the three months ended September 30, 2017. The increase in net operating revenues was principally due to the acquisition of U.S. HealthWorks on February 1, 2018, which contributed $133.3 million of net operating revenues during the quarter. Visits in our centers increased 50.8% to 2,984,832 visits for the three months ended September 30, 2018, compared to 1,979,481 visits for the three months ended September 30, 2017. Net revenue per visit increased 9.7% to $124 for the three months ended September 30, 2018, compared to $113 for the three months ended September 30, 2017. The increase in net revenue per visit was driven principally by U.S. HealthWorks visits, which yield higher per visit rates, as well as an increase in workers’ compensation and employer services reimbursement rates in our existing Concentra centers. Our net operating revenues for the three months ended September 30, 2017 were impacted by Hurricanes Harvey and Irma, which caused an estimated $1.2 million decrease in net operating revenues.

48

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were $1,117.0 million, or 88.2% of net operating revenues, for the three months ended September 30, 2018, compared to $966.1 million, or 89.7% of net operating revenues, for the three months ended September 30, 2017. Our cost of services, a major component of which is labor expense, was $1,087.1 million, or 85.8% of net operating revenues, for the three months ended September 30, 2018, compared to $939.1 million, or 87.2% of net operating revenues, for the three months ended September 30, 2017. The decrease in our operating expenses relative to our net operating revenues was principally due to the improved operating performance of our critical illness recovery hospital and outpatient rehabilitation segments during the three months ended September 30, 2018. We also experienced lower relative operating costs within our Concentra segment as a result of the U.S. HealthWorks acquisition. Facility rent expense was $68.4 million for the three months ended September 30, 2018, compared to $57.9 million for the three months ended September 30, 2017. The increase in our facility rent expense was primarily attributable to the acquisition of U.S. HealthWorks. General and administrative expenses were $30.0 million, or 2.4% of net operating revenues, for the three months ended September 30, 2018, compared to $27.1 million, or 2.5% of net operating revenues, for the three months ended September 30, 2017.

Adjusted EBITDA

Critical Illness Recovery Hospital Segment.    Adjusted EBITDA increased 13.7% to $53.3 million for the three months ended September 30, 2018, compared to $46.9 million for the three months ended September 30, 2017. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 12.7% for the three months ended September 30, 2018, compared to 11.2% for the three months ended September 30, 2017. Our Adjusted EBITDA and Adjusted EBITDA margin increased principally as a result of an increase in net revenue per patient day, as discussed above under “Net Operating Revenues,” without a corresponding increase in operating costs.

Rehabilitation Hospital Segment.    Adjusted EBITDA increased 12.2% to $25.3 million for the three months ended September 30, 2018, compared to $22.6 million for the three months ended September 30, 2017. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 14.3% for both the third quarters ended September 30, 2018 and 2017. The increase in Adjusted EBITDA for our rehabilitation hospital segment was primarily driven by an increase in patient volume, as discussed above under “Net Operating Revenues.” Adjusted EBITDA losses in our start-up hospitals were $0.8 million for the three months ended September 30, 2018, compared to $1.3 million for the three months ended September 30, 2017.

Outpatient Rehabilitation Segment.    Adjusted EBITDA increased 17.9% to $34.5 million for the three months ended September 30, 2018, compared to $29.3 million for the three months ended September 30, 2017. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 13.0% for the three months ended September 30, 2018, compared to 11.9% for the three months ended September 30, 2017. Our Adjusted EBITDA and Adjusted EBITDA margin increased as a result of an increase in net revenue per visit, as discussed above under “Net Operating Revenues,” and a reduction in operating expenses. Adjusted EBITDA for the three months ended September 30, 2017 was impacted by Hurricanes Harvey and Irma, as discussed above under “Net Operating Revenues.”

Concentra Segment.    Adjusted EBITDA increased 71.9% to $68.8 million for the three months ended September 30, 2018, compared to $40.0 million for the three months ended September 30, 2017. The increase in Adjusted EBITDA was principally due to the operating results of U.S. HealthWorks, which we acquired on February 1, 2018. Our Adjusted EBITDA margin for the Concentra segment was 17.0% for the three months ended September 30, 2018, compared to 15.6% for the three months ended September 30, 2017. The increase in Adjusted EBITDA margin resulted from achieving lower relative operating costs across our combined Concentra and U.S. HealthWorks businesses. Adjusted EBITDA for the three months ended September 30, 2017 was impacted by Hurricanes Harvey and Irma, as discussed above under “Net Operating Revenues.”

Other.    The Adjusted EBITDA loss was $25.3 million for the three months ended September 30, 2018, compared to an Adjusted EBITDA loss of $22.9 million for the three months ended September 30, 2017. The increase in our Adjusted EBITDA loss was due to an increase in general and administrative costs, which encompass our corporate shared service activities.

Depreciation and Amortization

Depreciation and amortization expense was $50.5 million for the three months ended September 30, 2018, compared to $38.8 million for the three months ended September 30, 2017.The increase principally occurred within our Concentra segment due to the acquisition of U.S. HealthWorks.

49

Income from Operations

For the three months ended September 30, 2018, we had income from operations of $99.8 million, compared to $72.1 million for the three months ended September 30, 2017. The increase in income from operations resulted principally from the growth of our Concentra segment, as discussed above.

Equity in Earnings of Unconsolidated Subsidiaries

Our equity in earnings of unconsolidated subsidiaries principally relates to rehabilitation businesses in which we are a minority owner. For the three months ended September 30, 2018, we had equity in earnings of unconsolidated subsidiaries of $5.4 million, compared to $4.4 million for the three months ended September 30, 2017.

Non-Operating Gain

We recognized a non-operating gain of $2.1 million during the three months ended September 30, 2018. The non-operating gain was attributable to the sale of outpatient rehabilitation clinics to a non-consolidating subsidiary.

Interest Expense

Interest expense was $50.7 million for the three months ended September 30, 2018, compared to $37.7 million for the three months ended September 30, 2017. The increase in interest expense was principally due to an increase in our indebtedness as a result of the acquisition of U.S. HealthWorks.

Income Taxes

We recorded income tax expense of $14.1 million for the three months ended September 30, 2018, which represented an effective tax rate of 24.8%. We recorded income tax expense of $14.0 million for the three months ended September 30, 2017, which represented an effective tax rate of 36.1%. The lower effective tax rate for the three months ended September 30, 2018 resulted primarily from the effects of the federal tax reform legislation enacted on December 22, 2017.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was $9.8 million for the three months ended September 30, 2018, compared to $6.4 million for the three months ended September 30, 2017. The increase resulted principally from the growth of our Concentra segment.

50

Nine Months Ended September 30, 2018, Compared to Nine Months Ended September 30, 2017

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, loss on early retirement of debt, equity in earnings of unconsolidated subsidiaries, non-operating gain (loss), interest expense, income taxes, and net income attributable to non-controlling interests, which, in each case, are the same for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased 16.7% to $3,816.6 million for the nine months ended September 30, 2018, compared to $3,271.0 million for the nine months ended September 30, 2017.

Critical Illness Recovery Hospital Segment.    Net operating revenues increased 2.0% to $1,327.2 million for the nine months ended September 30, 2018, compared to $1,301.3 million for the nine months ended September 30, 2017. Our patient days increased 1.5% to 765,863 days for the nine months ended September 30, 2018, compared to 754,401 days for the nine months ended September 30, 2017, which was the principal cause of the increase in net operating revenues during the nine months ended September 30, 2018. Our net revenue per patient day increased to $1,716 for the nine months ended September 30, 2018, compared to $1,708 for the nine months ended September 30, 2017. The increase principally resulted from changes we experienced in our non-Medicare net revenue per patient day during the nine months ended September 30, 2018.

Rehabilitation Hospital Segment.    Net operating revenues increased 15.8% to $525.4 million for the nine months ended September 30, 2018, compared to $453.7 million for the nine months ended September 30, 2017. The increase in net operating revenues resulted primarily from an increase in patient volumes during the nine months ended September 30, 2018. Our patient days increased 19.1% to 233,537 days for the nine months ended September 30, 2018, compared to 196,018 days for the nine months ended September 30, 2017. The increase in patient days was principally attributable to our rehabilitation hospitals which commenced operations during 2016 and 2017. Our net revenue per patient day increased 3.2% to $1,604 for the nine months ended September 30, 2018, compared to $1,554 for the nine months ended September 30, 2017.

Outpatient Rehabilitation Segment.    Net operating revenues increased 5.1% to $790.5 million for the nine months ended September 30, 2018, compared to $752.0 million for the nine months ended September 30, 2017. The increase in net operating revenues was principally attributable to an increase in our net revenue per visit, which increased 2.0% to $103 for the nine months ended September 30, 2018, compared to $101 for the nine months ended September 30, 2017. Our net revenue per visit benefited from improved contracted rates with some of our payors. Additionally, visits increased 1.3% to 6,251,582 for the nine months ended September 30, 2018, compared to 6,168,763 visits for the nine months ended September 30, 2017. The increase in visits resulted from both start-up and newly acquired outpatient rehabilitation clinics, as well as growth within our existing clinics. During the nine months ended September 30, 2018, we also experienced an increase in net operating revenues related to contracted labor services provided to our equity investments.

Concentra Segment.    Net operating revenues increased 53.7% to $1,173.4 million for the nine months ended September 30, 2018, compared to $763.4 million for the nine months ended September 30, 2017. The increase in net operating revenues was principally due to the acquisition of U.S. HealthWorks on February 1, 2018, which contributed $362.7 million of net operating revenues during the period. Visits in our centers increased 47.1% to 8,605,012 for the nine months ended September 30, 2018, compared to 5,848,551 visits for the nine months ended September 30, 2017. Net revenue per visit increased 8.8% to $124 for the nine months ended September 30, 2018, compared to $114 for the nine months ended September 30, 2017. The increase in net revenue per visit was driven principally by U.S. HealthWorks visits, which yield higher per visit rates, as well as an increase in workers’ compensation and employer services reimbursement rates in our existing Concentra centers.

51

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were $3,338.6 million, or 87.5% of net operating revenues, for the nine months ended September 30, 2018, compared to $2,871.8 million, or 87.8% of net operating revenues, for the nine months ended September 30, 2017. Our cost of services, a major component of which is labor expense, was $3,247.6 million, or 85.1% of net operating revenues, for the nine months ended September 30, 2018, compared to $2,788.4 million, or 85.2% of net operating revenues, for the nine months ended September 30, 2017. The decrease in our operating expenses relative to our net operating revenues was principally due to the improved operating performance of our rehabilitation hospital segment. Facility rent expense was $200.5 million for the nine months ended September 30, 2018, compared to $171.7 million for the nine months ended September 30, 2017. The increase in our facility rent expense was primarily attributable to the acquisition of U.S. HealthWorks. General and administrative expenses were $91.0 million, or 2.4% of net operating revenues, for the nine months ended September 30, 2018, which included $2.9 million of U.S. HealthWorks acquisition costs. General and administrative expenses were $83.4 million, or 2.6% of net operating revenues, for the nine months ended September 30, 2017.

Adjusted EBITDA

Critical Illness Recovery Hospital Segment.    Adjusted EBITDA was $187.0 million for the nine months ended September 30, 2018, compared to $194.3 million for the nine months ended September 30, 2017. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 14.1% for the nine months ended September 30, 2018, compared to 14.9% for the nine months ended September 30, 2017. Our Adjusted EBITDA and Adjusted EBITDA margin were impacted by increases in wages, benefits, and other operating costs, relative to our net operating revenues, during the nine months ended September 30, 2018, as compared to the nine months ended September 30, 2017.

Rehabilitation Hospital Segment.    Adjusted EBITDA increased 29.5% to $80.3 million for the nine months ended September 30, 2018, compared to $62.0 million for the nine months ended September 30, 2017. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 15.3% for the nine months ended September 30, 2018, compared to 13.7% for the nine months ended September 30, 2017. The increases in Adjusted EBITDA and Adjusted EBITDA margin for our rehabilitation hospital segment were primarily driven by increases in patient volume within our rehabilitation hospitals that commenced operations during 2016 and 2017, which allowed our facilities to operate at lower relative costs compared to the prior period. The increases in Adjusted EBITDA and Adjusted EBITDA margins also resulted from an increase in net revenue per patient day, as discussed above under “Net Operating Revenues.” Adjusted EBITDA losses in our start-up hospitals were $3.8 million for the nine months ended September 30, 2018, compared to $4.5 million for the nine months ended September 30, 2017.

Outpatient Rehabilitation Segment.    Adjusted EBITDA increased 4.3% to $107.0 million for the nine months ended September 30, 2018, compared to $102.6 million for the nine months ended September 30, 2017. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 13.5% for the nine months ended September 30, 2018, compared to 13.6% for the nine months ended September 30, 2017. For the nine months ended September 30, 2018, our Adjusted EBITDA increased as a result of an increase in patient visits and net revenue per visit, as discussed above under “Net Operating Revenues.”

Concentra Segment.    Adjusted EBITDA increased 58.5% to $199.1 million for the nine months ended September 30, 2018, compared to $125.7 million for the nine months ended September 30, 2017. The increase in Adjusted EBITDA was principally due to the operating results of U.S. HealthWorks, which we acquired on February 1, 2018. Our Adjusted EBITDA margin for the Concentra segment was 17.0% for the nine months ended September 30, 2018, compared to 16.5% for the nine months ended September 30, 2017. The increase in Adjusted EBITDA margin resulted from achieving lower relative operating costs across our combined Concentra and U.S. HealthWorks businesses.

Other.    The Adjusted EBITDA loss was $75.3 million for the nine months ended September 30, 2018, compared to an Adjusted EBITDA loss of $71.1 million for the nine months ended September 30, 2017. The increase in our Adjusted EBITDA loss was due to an increase in general and administrative costs, which encompass our corporate shared service activities.

Depreciation and Amortization

Depreciation and amortization expense was $149.0 million for the nine months ended September 30, 2018, compared to $119.6 million for the nine months ended September 30, 2017. The increase principally occurred within our Concentra segment due to the acquisition of U.S. HealthWorks.

52

Income from Operations

For the nine months ended September 30, 2018, we had income from operations of $329.0 million, compared to $279.5 million for the nine months ended September 30, 2017. The increase in income from operations resulted principally from the improved performance of our rehabilitation hospital segment and the growth of our Concentra segment, as discussed above.

Loss on Early Retirement of Debt

During the nine months ended September 30, 2018, we amended both Select’s and Concentra’s credit facilities, as discussed above under “Significant Events,” which resulted in losses on early retirement of debt of $10.3 million.

During the nine months ended September 30, 2017, we refinanced Select’s senior secured credit facilities which resulted in a loss on early retirement of debt of $19.7 million.

Equity in Earnings of Unconsolidated Subsidiaries

Our equity in earnings of unconsolidated subsidiaries principally relates to rehabilitation businesses in which we are a minority owner. For the nine months ended September 30, 2018, we had equity in earnings of unconsolidated subsidiaries of $14.9 million, compared to $15.6 million for the nine months ended September 30, 2017.

Non-Operating Gain

We recognized non-operating gains of $9.0 million during the nine months ended September 30, 2018. The non-operating gains were principally attributable to the sales of outpatient rehabilitation clinics to non-consolidating subsidiaries.

Interest Expense

Interest expense was $148.0 million for the nine months ended September 30, 2018, compared to $116.2 million for the nine months ended September 30, 2017. The increase in interest expense was principally due to an increase in our indebtedness as a result of the acquisition of U.S. HealthWorks.

Income Taxes

We recorded income tax expense of $47.5 million for the nine months ended September 30, 2018, which represented an effective tax rate of 24.4%. We recorded income tax expense of $59.6 million for the nine months ended September 30, 2017, which represented an effective tax rate of 37.4%. The lower effective tax rate for the nine months ended September 30, 2018 resulted primarily from the effects of the federal tax reform legislation enacted on December 22, 2017 and the discrete tax benefits realized from certain equity interests that were redeemed as part of the closing of the U.S. HealthWorks transaction during the first quarter of 2018.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was $34.1 million for the nine months ended September 30, 2018, compared to $23.2 million for the nine months ended September 30, 2017. The increase was principally due to the improved operating performance of several of our joint venture rehabilitation hospitals and the growth of our Concentra segment.

53

Liquidity and Capital Resources

Cash Flows for the Nine Months Ended September 30, 2018 and Nine Months Ended September 30, 2017

In the following, we discuss cash flows from operating activities, investing activities, and financing activities, which, in each case, are the same for Holdings and Select.

	Nine Months Ended September 30,
	2017			2018
	(in thousands)
Cash flows provided by operating activities	$	129,972		$	380,977
Cash flows used in investing activities	(169,990		)	(646,542		)
Cash flows provided by financing activities	48,289			303,429
Net increase in cash and cash equivalents	8,271			37,864
Cash and cash equivalents at beginning of period	99,029			122,549
Cash and cash equivalents at end of period	$	107,300		$	160,413

Operating activities provided $381.0 million of cash flows for the nine months ended September 30, 2018, compared to $130.0 million of cash flows for the nine months ended September 30, 2017. The increase in operating cash flows for the nine months ended September 30, 2018, compared to the nine months ended September 30, 2017, was principally driven by the change in our accounts receivable in their respective periods. Our days sales outstanding decreased from 58 days at December 31, 2017 to 54 days at September 30, 2018 while our days sales outstanding increased from 51 days at December 31, 2016 to 61 days at September 30, 2017. The decrease in days sales outstanding during the nine months ended September 30, 2018 resulted from the recoupment of Medicare periodic interim underpayments from prior periods. The increase in days sales outstanding during the nine months ended September 30, 2017 was caused by the significant underpayments we received through the Medicare periodic interim payment program in our critical illness recovery hospitals. Additionally, we received overpayments during 2016 which were repaid during the first quarter of 2017. Our days sales outstanding will fluctuate based upon variability in our collection cycles.

Investing activities used $646.5 million of cash flows for the nine months ended September 30, 2018. The principal uses of cash were $515.0 million related to the acquisition of U.S. HealthWorks and $121.0 million for purchases of property and equipment. Investing activities used $170.0 million of cash flows for the nine months ended September 30, 2017. The principal uses of cash were $173.8 million for purchases of property and equipment and $19.4 million for acquisition-related payments, offset in part by $34.6 million of proceeds from the sale of assets.

Financing activities provided $303.4 million of cash flows for the nine months ended September 30, 2018. The principal source of cash was from the issuance of term loans under the Concentra credit facilities which resulted in net proceeds of $779.9 million. This was offset in part by $306.4 million of distributions to non-controlling interests, of which $294.9 million related to the redemption and reorganization transactions executed under the Purchase Agreement in connection with the acquisition of U.S. HealthWorks by our Concentra segment, and $165.0 million of net repayments under the Select revolving credit facility.

Financing activities provided $48.3 million of cash flows for the nine months ended September 30, 2017. The principal source of cash was net borrowings under the Select revolving facility of $100.0 million, offset in part by $23.1 million of cash used for a principal prepayment associated with the Concentra credit facilities, $5.8 million of cash used for a term loan payment associated with the Select credit facilities, and $9.2 million of cash used for financing costs.

54

Capital Resources

Working capital.  We had net working capital of $338.2 million at September 30, 2018, compared to $315.4 million at December 31, 2017. The increase in net working capital was primarily due to the acquisition of U.S. HealthWorks and an increase in our accounts receivable.

Select credit facilities. 

On March 22, 2018, Select entered into Amendment No. 1 to the Select credit agreement dated March 6, 2017. Amendment No. 1 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement and subject to an Adjusted LIBO floor of 1.00%) plus 3.50% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate (as defined in the Select credit agreement and subject to an Alternate Base Rate floor of 2.00%) plus 2.50% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio (as defined in the Select credit agreement); (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 3.00% to 3.25% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate plus a percentage ranging from 2.00% to 2.25% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio; (iii) extended the maturity date for the Select term loans from March 6, 2024 to March 6, 2025; and (iv) made certain other technical amendments to the Select credit agreement as set forth therein.

On October 26, 2018, Select entered into Amendment No. 2 to the Select credit agreement. Among other things, Amendment No. 2 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement) plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio (as defined in the Select credit agreement), and (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio. As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Select credit agreement are no longer subject to the currently applicable floor.

At September 30, 2018, Select had outstanding borrowings under the Select credit facilities consisting of $1,132.8 million in Select term loans (excluding unamortized discounts and debt issuance costs of $22.1 million) and borrowings of $65.0 million (excluding letters of credit) under the Select revolving facility. At September 30, 2018, Select had $347.5 million of availability under the Select revolving facility after giving effect to $37.5 million of outstanding letters of credit.

Concentra credit facilities.  Select and Holdings are not parties to the Concentra credit facilities and are not obligors with respect to Concentra’s debt under such agreements. While this debt is non-recourse to Select, it is included in Select’s consolidated financial statements.

On February 1, 2018, in connection with the acquisition of U.S. HealthWorks, Concentra amended the Concentra first lien credit agreement to, among other things, provide for (i) an additional $555.0 million in tranche B term loans that, along with the existing tranche B term loans under the Concentra first lien credit agreement, have a maturity date of June 1, 2022 and (ii) an additional $25.0 million to the $50.0 million, five-year revolving credit facility under the terms of the existing Concentra first lien credit agreement. The tranche B term loans bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus 2.75% (subject to an Adjusted LIBO Rate floor of 1.00%) for Eurodollar Borrowings (as defined in the Concentra first lien credit agreement), or Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus 1.75% (subject to an Alternate Base Rate floor of 2.00%) for ABR Borrowings (as defined in the Concentra first lien credit agreement). All other material terms and conditions applicable to the original tranche B term loan commitments are applicable to the additional tranche B term loans created under the Concentra first lien credit agreement.

In addition, on February 1, 2018, Concentra entered into the Concentra second lien credit agreement. The Concentra second lien credit agreement provided for a $240.0 million Concentra second lien term loan with a maturity date of June 1, 2023. Borrowings under the Concentra second lien credit agreement bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra second lien credit agreement) plus 6.50% (subject to an Adjusted LIBO Rate floor of 1.00%), or Alternate Base Rate (as defined in the Concentra second lien credit agreement) plus 5.50% (subject to an Alternate Base Rate floor of 2.00%).

55

In the event that, on or prior to February 1, 2019, Concentra prepays any of the Concentra second lien term loan to refinance such term loans, Concentra shall pay a premium of 2.00% of the aggregate principal amount of the Concentra second lien term loan prepaid. If Concentra prepays any of the Concentra second lien term loan to refinance such term loans on or prior to February 1, 2020, Concentra shall pay a premium of 1.00% of the aggregate principal amount of the Concentra second lien term loan prepaid.

On October 26, 2018, Concentra entered into Amendment No. 4 to the Concentra first lien credit agreement. Among other things, Amendment No. 4 (i) provided the applicable interest rate on the tranche B term loans under the Concentra first lien credit agreement is the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 2.50% to 2.75% (with 2.75% being the initial rate), or the Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 1.50% to 1.75% (with 1.75% being the initial rate), in each case subject to a specified credit rating, and (ii) decreased the applicable interest rate on the loans outstanding under the Concentra revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.75% to 3.00% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternate Base Rate plus a percentage ranging from 1.75% to 2.00% to the Alternate Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to Concentra’s first lien net leverage ratio (as defined in the Concentra first lien credit agreement). As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Concentra first lien credit agreement are no longer subject to the currently applicable floor.

Concentra will be required to prepay borrowings under the Concentra second lien term loan with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (iii) 50% of excess cash flow (as defined in the Concentra second lien credit agreement) if Concentra’s leverage ratio is greater than 4.25 to 1.00 and 25% of excess cash flow if Concentra’s leverage ratio is less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00, in each case, reduced by the aggregate amount of term loans and certain debt optionally prepaid during the applicable fiscal year and the aggregate amount of senior revolving commitments reduced permanently during the applicable fiscal year (other than in connection with a refinancing). Concentra will not be required to prepay borrowings with excess cash flow if Concentra’s leverage ratio is less than or equal to 3.75 to 1.00.

The Concentra second lien credit agreement also contains a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Concentra second lien credit agreement contains events of default for non-payment of principal and interest when due (subject to a grace period for interest), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

The borrowings under the Concentra second lien term loan are guaranteed, on a second lien basis, by Concentra Holdings, Inc., Concentra, and certain domestic subsidiaries of Concentra and will be guaranteed by Concentra’s future domestic subsidiaries (other than Excluded Subsidiaries and Consolidated Practices, each as defined in the Concentra second lien credit agreement). The borrowings under the Concentra second lien term loan are secured by substantially all of Concentra’s and its domestic subsidiaries’ existing and future property and assets and by a pledge of Concentra’s capital stock, the capital stock of certain of Concentra’s domestic subsidiaries and up to 65% of the voting capital stock and 100% of the non-voting capital stock of Concentra’s foreign subsidiaries, if any.

Concentra used borrowings under the Concentra first lien credit agreement and the Concentra second lien credit agreement, together with cash on hand, to pay the cash purchase price for all of the issued and outstanding stock of U.S. HealthWorks to DHHC and to finance the redemption and reorganization transactions executed under the Purchase Agreement.

At September 30, 2018, Concentra had outstanding borrowings under the Concentra credit facilities consisting of $1,414.2 million of term loans (excluding unamortized discounts and debt issuance costs of $23.5 million). Concentra did not have any borrowings under the Concentra revolving facility. At September 30, 2018, Concentra had $62.3 million of availability under its revolving facility after giving effect to $12.7 million of outstanding letters of credit.

Stock Repurchase Program.  Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2019, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under the Select revolving facility. Holdings did not repurchase shares during the three months ended September 30, 2018. Since the inception of the program through September 30, 2018, Holdings has repurchased 35,924,128 shares at a cost of approximately $314.7 million, or $8.76 per share, which includes transaction costs.

56

Liquidity.  We believe our internally generated cash flows and borrowing capacity under the Select and Concentra credit facilities will be sufficient to finance operations over the next twelve months. We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Use of Capital Resources.  We may from time to time pursue opportunities to develop new joint venture relationships with significant health systems and other healthcare providers and from time to time we may also develop new rehabilitation hospitals and occupational health centers. We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions, such as the acquisition of U.S. HealthWorks.

Recent Accounting Pronouncements

Lease Accounting

Beginning in February 2016, the Financial Accounting Standards Board (the “FASB”) issued several Accounting Standards Updates (“ASU”) which established Topic 842, Leases (the “standard”). This standard includes a lessee accounting model that recognizes two types of leases: finance and operating. This standard requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in the standard will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. There are two transition approaches available under the standard: a modified retrospective approach for leases that exist, or are entered into, after the beginning of the earliest comparative period in the financial statements or a cumulative-effect approach with an adjustment to the opening balance of retained earnings in the period of adoption.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight‑line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019, using the cumulative-effect approach, without adjusting the comparative periods. The Company has completed its inventory of leases and has begun to implement a new technology platform to account for leases under the new standard.  The Company has substantially completed validating its lease data to ensure it is complete and accurate. The Company’s remaining implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

Cloud Computing Arrangements

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the impacts that adoption of this ASU will have on its consolidated financial statements.

57

Recently Adopted Accounting Pronouncements

Revenue from Contracts with Customers

Beginning in May 2014, the FASB issued several ASUs which established Topic 606, Revenue from Contracts with Customers (the “revenue recognition standard”). This revenue recognition standard supersedes existing revenue recognition requirements and seeks to eliminate most industry-specific guidance under current GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company adopted the new revenue recognition standard on January 1, 2018, using the full retrospective transition method. Adoption of the revenue recognition standard impacted the Company’s reported results as follows:

	Three Months Ended September 30, 2017
	As Reported		As Adjusted(1)		Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	1,097,166	$	1,077,014	$	(20,152	)
Bad debt expense	20,321		169		(20,152		)

	Nine Months Ended September 30, 2017
	As Reported			As Adjusted(1)			Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	3,329,202		$	3,270,996		$	(58,206	)
Bad debt expense	59,120			914			(58,206		)
Condensed Consolidated Statements of Cash Flows
Provision for bad debts	$	59,120		$	914		$	(58,206	)
Changes in accounts receivable	(201,514		)	(143,308		)	58,206

 _____________________________________________________________

(1) Bad debt expense is now included in cost of services on the condensed consolidated statements of operations.

	December 31, 2017
	As Reported		As Adjusted		Adoption Impact
	(in thousands)
Condensed Consolidated Balance Sheets
Accounts receivable	$	767,276	$	691,732	$	(75,544	)
Allowance for doubtful accounts	75,544		—		(75,544		)
Accounts receivable	$	691,732	$	691,732	$	—

The Company has presented the applicable disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers in Note 7 of the Company’s condensed consolidated financial statements.

Income Taxes

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), and Intra-Entity Transfers of Assets Other Than Inventory. Previous GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra‑entity transfer of an asset other than inventory when the transfer occurs. The Company adopted the guidance effective January 1, 2018. Adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.

58

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under the Select credit facilities and Concentra credit facilities.

At September 30, 2018, Select had outstanding borrowings under the Select credit facilities consisting of $1,132.8 million of Select term loans (excluding unamortized discounts and debt issuance costs of $22.1 million) and borrowings of $65.0 million (excluding letters of credit) under the Select revolving facility, which bear interest at variable rates.

At September 30, 2018, Concentra had outstanding borrowings under the Concentra credit facilities consisting of $1,414.2 million of Concentra term loans (excluding unamortized discounts and debt issuance costs of $23.5 million), which bear interest at variable rates. Concentra did not have any borrowings under the Concentra revolving facility.

As of September 30, 2018, each 0.25% increase in market interest rates will impact the interest expense on Select’s and Concentra’s variable rate debt by $6.5 million per annum.

ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of September 30, 2018, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

U.S. HealthWorks Acquisition

On February 1, 2018, Concentra consummated the acquisition of U.S. HealthWorks. SEC guidance permits management to omit an assessment of an acquired business’ internal control over financial reporting from management’s assessment of internal control over financial reporting for a period not to exceed one year from the date of the acquisition.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the third quarter ended September 30, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

On February 1, 2018, Concentra consummated the acquisition of U.S. HealthWorks. Effective from that date, we began integrating U.S. HealthWorks into our existing control procedures. The U.S. HealthWorks integration may lead us to modify certain controls in future periods, but we do not expect changes to significantly affect our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

59

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned operations, the Company maintains insurance coverages under a combination of policies with a total annual aggregate limit of $35.0 million. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has numerous programs that are designed to respond to the risks of the specific joint venture. The annual aggregate limit under these programs ranges from $5.0 million to $20.0 million. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

 Evansville Litigation.    On October 19, 2015, the plaintiff‑relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital-Evansville, LLC (“SSH‑Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff‑relators on behalf of the United States under the federal False Claims Act. The plaintiff‑relators are the former CEO and two former case managers at SSH‑Evansville, and the defendants currently include the Company, SSH‑Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH‑Evansville. The plaintiff‑relators allege that SSH‑Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up‑coded diagnoses at admission, and admitted patients for whom long‑term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff‑relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

60

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff‑relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non‑retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However, the District Court ruled that the plaintiff‑relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present and allowing discovery that would facilitate the use of statistical sampling to prove liability, which the defendants opposed. In April 2018, a U.S. magistrate judge ruled that plaintiff‑relators’ discovery will be limited to only SSH-Evansville for the period from March 23, 2010 through September 30, 2016, and that the plaintiff‑relators will be required to prove the fraud that they allege on a claim-by-claim basis, rather than using statistical sampling. The plaintiff-relators have appealed this decision to the District Judge.

The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Knoxville Litigation.    On July 13, 2015, the United States District Court for the Eastern District of Tennessee unsealed a qui tam Complaint in Armes v. Garman, et al, No. 3:14‑cv‑00172‑TAV‑CCS, which named as defendants Select, Select Specialty Hospital-Knoxville, Inc. (“SSH‑Knoxville”), Select Specialty Hospital-North Knoxville, Inc. and ten current or former employees of these facilities. The Complaint was unsealed after the United States and the State of Tennessee notified the court on July 13, 2015 that each had decided not to intervene in the case. The Complaint is a civil action that was filed under seal on April 29, 2014 by a respiratory therapist formerly employed at SSH‑Knoxville. The Complaint alleges violations of the federal False Claims Act and the Tennessee Medicaid False Claims Act based on extending patient stays to increase reimbursement and to increase average length of stay; artificially prolonging the lives of patients to increase Medicare reimbursements and decrease inspections; admitting patients who do not require medically necessary care; performing unnecessary procedures and services; and delaying performance of procedures to increase billing. The Complaint was served on some of the defendants during October 2015.

In November 2015, the defendants filed a Motion to Dismiss the Complaint on multiple grounds. The defendants first argued that False Claims Act’s first‑to‑file bar required dismissal of plaintiff‑relator’s claims. Under the first‑to‑file bar, if a qui tam case is pending, no person may bring a related action based on the facts underlying the first action. The defendants asserted that the plaintiff‑relator’s claims were based on the same underlying facts as were asserted in the Evansville litigation, discussed above. The defendants also argued that the plaintiff‑relator’s claims must be dismissed under the public disclosure bar, and because the plaintiff‑relator did not plead his claims with sufficient particularity.

In June 2016, the District Court granted the defendants’ Motion to Dismiss and dismissed with prejudice the plaintiff‑relator’s lawsuit in its entirety. The District Court ruled that the first‑to‑file bar precludes all but one of the plaintiff‑relator’s claims, and that the remaining claim must also be dismissed because the plaintiff‑relator failed to plead it with sufficient particularity. In July 2016, the plaintiff‑relator filed a Notice of Appeal to the United States Court of Appeals for the Sixth Circuit. Then, on October 11, 2016, the plaintiff‑relator filed a Motion to Remand the case to the District Court for further proceedings, arguing that the September 30, 2016 decision in the Evansville litigation, discussed above, undermines the basis for the District Court’s dismissal. After the Court of Appeals denied the Motion to Remand, the plaintiff‑relator then sought an indicative ruling from the District Court that it would vacate its prior dismissal ruling and allow plaintiff‑relator to supplement his Complaint, but the District Court denied such request. In December 2017, the Court of Appeals, relying on the public disclosure bar, denied the appeal of the plaintiff‑relator and affirmed the judgment of the District Court. In February 2018, the Court of Appeals denied a petition for rehearing that the plaintiff-relator filed in January 2018, and in July 2018, the deadline expired for the plaintiff-relator to file a petition for certiorari to the Supreme Court of the United States.

61

Wilmington Litigation.    On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital-Wilmington, Inc. (“SSH‑Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16‑347‑LPS. The Complaint was initially filed under seal in May 2016 by a former chief nursing officer at SSH‑Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention in January 2017. The corporate defendants were served in March 2017. In the complaint, the plaintiff‑relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH‑Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH‑Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, in May 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim. In March 2018, the District Court dismissed the plaintiff‑relator’s claims related to the alleged failure to properly examine medical practitioners’ credentials, her reverse false claims allegations, and her claim that defendants violated the Delaware False Claims and Reporting Act. It denied the defendants’ motion to dismiss claims that the allegedly falsified medical practitioner signatures violated the False Claims Act. Separately, the District Court dismissed the individual defendant due to plaintiff-relator’s failure to timely serve the amended complaint upon her.

In March 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH‑Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  In January 2018, the Court stayed the Delaware Complaint pending the outcome of the federal case.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

Contract Therapy Subpoena. On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2017.

62

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2019 and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings did not repurchase shares during the three months ended September 30, 2018 under the authorized common stock repurchase program.

The following table provides information regarding repurchases of our common stock during the three months ended September 30, 2018. As set forth below, the shares repurchased during the three months ended September 30, 2018 relate entirely to shares of common stock surrendered to us to satisfy tax withholding obligations associated with the vesting of restricted shares issued to employees, pursuant to the provisions of our equity incentive plans.

	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
July 1 - July 31, 2018	—	$	—	—	$	185,249,408
August 1 - August 31, 2018	235,782	20.15		—	185,249,408
September 1 - September 30, 2018	—	—		—	185,249,408
Total	235,782	$	20.15	—	$	185,249,408

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

63

ITEM 6. EXHIBITS

Number	Description
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

64

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrants have duly caused this Report to be signed on their behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL CORPORATION
By:	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer
	(Duly Authorized Officer)
By:	/s/ Scott A. Romberger
	Scott A. Romberger
	Senior Vice President, Chief Accounting Officer and Controller
	(Principal Accounting Officer)

Dated:  November 1, 2018

SELECT MEDICAL HOLDINGS CORPORATION
By:	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer
	(Duly Authorized Officer)
By:	/s/  Scott A. Romberger
	Scott A. Romberger
	Senior Vice President, Chief Accounting Officer and Controller
	(Principal Accounting Officer)

Dated:  November 1, 2018

65

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION AND

SELECT MEDICAL CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, David S. Chernow, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2018	/s/ David S. Chernow
	David S. Chernow
	President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION AND

SELECT MEDICAL CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Martin F. Jackson, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2018	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation (together, the “Company”) for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, David S. Chernow and Martin F. Jackson, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

November 1, 2018

/s/ David S. Chernow

David S. Chernow

President and Chief Executive Officer

/s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018
Document and Entity Information
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Central Index Key	0001320414
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		135,331,864
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3

XML

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 160,413	$ 122,549
Accounts receivable	746,816	691,732
Prepaid income taxes	19,852	31,387
Other current assets	96,214	75,158
Total Current Assets	1,023,295	920,826
Property and equipment, net	965,390	912,591
Goodwill	3,311,459	2,782,812
Identifiable intangible assets, net	444,847	326,519
Other assets	235,190	184,418
Total Assets	5,980,181	5,127,166
Current Liabilities:
Overdrafts	23,291	29,463
Current portion of long-term debt and notes payable	24,175	22,187
Accounts payable	137,540	128,194
Accrued payroll	176,221	160,562
Accrued vacation	106,026	92,875
Accrued interest	23,648	19,885
Accrued other	188,079	143,166
Income taxes payable	6,129	9,071
Total Current Liabilities	685,109	605,403
Long-term debt, net of current portion	3,305,533	2,677,715
Non-current deferred tax liability	148,227	124,917
Other non-current liabilities	174,170	145,709
Total Liabilities	4,313,039	3,553,744
Commitments and contingencies (Note 10)
Redeemable non-controlling interests	779,574	640,818
Stockholders’ Equity:
Common stock	135	134
Capital in excess of par	477,822	463,499
Retained earnings (accumulated deficit)	296,635	359,735
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	774,592	823,368
Non-controlling interests	112,976	109,236
Total Equity	887,568	932,604
Total Liabilities and Equity	5,980,181	5,127,166
Select Medical Corporation
Current Assets:
Cash and cash equivalents	160,413	122,549
Accounts receivable	746,816	691,732
Prepaid income taxes	19,852	31,387
Other current assets	96,214	75,158
Total Current Assets	1,023,295	920,826
Property and equipment, net	965,390	912,591
Goodwill	3,311,459	2,782,812
Identifiable intangible assets, net	444,847	326,519
Other assets	235,190	184,418
Total Assets	5,980,181	5,127,166
Current Liabilities:
Overdrafts	23,291	29,463
Current portion of long-term debt and notes payable	24,175	22,187
Accounts payable	137,540	128,194
Accrued payroll	176,221	160,562
Accrued vacation	106,026	92,875
Accrued interest	23,648	19,885
Accrued other	188,079	143,166
Income taxes payable	6,129	9,071
Total Current Liabilities	685,109	605,403
Long-term debt, net of current portion	3,305,533	2,677,715
Non-current deferred tax liability	148,227	124,917
Other non-current liabilities	174,170	145,709
Total Liabilities	4,313,039	3,553,744
Commitments and contingencies (Note 10)
Redeemable non-controlling interests	779,574	640,818
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	964,683	947,370
Retained earnings (accumulated deficit)	(190,091)	(124,002)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	774,592	823,368
Non-controlling interests	112,976	109,236
Total Equity	887,568	932,604
Total Liabilities and Equity	$ 5,980,181	$ 5,127,166

XML

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	700,000,000	700,000,000
Common stock, shares issued (in shares)	135,140,269	134,114,715
Common stock, shares outstanding (in shares)	135,140,269	134,114,715
Select Medical Corporation
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	100	100
Common stock, shares outstanding (in shares)	100	100

XML

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net operating revenues	$ 1,267,401	$ 1,077,014	$ 3,816,575	$ 3,270,996
Costs and expenses:
Cost of services	1,087,062	939,079	3,247,606	2,788,411
General and administrative	29,975	27,065	90,951	83,415
Depreciation and amortization	50,527	38,772	149,022	119,644
Total costs and expenses	1,167,564	1,004,916	3,487,579	2,991,470
Income (loss) from operations	99,837	72,098	328,996	279,526
Other income and expense:
Loss on early retirement of debt			(10,255)	(19,719)
Equity in earnings of unconsolidated subsidiaries	5,432	4,431	14,914	15,618
Non-operating gain	2,139	0	9,016	(49)
Interest expense	(50,669)	(37,688)	(147,991)	(116,196)
Income (loss) before income taxes	56,739	38,841	194,680	159,180
Income tax expense	14,060	14,017	47,460	59,593
Net income	42,679	24,824	147,220	99,587
Less: Net income attributable to non-controlling interests	9,762	6,362	34,053	23,200
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 32,917	$ 18,462	$ 113,167	$ 76,387
Income per common share:
Basic (in dollars per share)	$ 0.24	$ 0.14	$ 0.84	$ 0.57
Diluted (in dollars per share)	$ 0.24	$ 0.14	$ 0.84	$ 0.57
Weighted average shares outstanding:
Basic (in shares)	130,387	129,142	129,972	128,745
Diluted (in shares)	130,447	129,322	130,066	128,916
Select Medical Corporation
Net operating revenues	$ 1,267,401	$ 1,077,014	$ 3,816,575	$ 3,270,996
Costs and expenses:
Cost of services	1,087,062	939,079	3,247,606	2,788,411
General and administrative	29,975	27,065	90,951	83,415
Depreciation and amortization	50,527	38,772	149,022	119,644
Total costs and expenses	1,167,564	1,004,916	3,487,579	2,991,470
Income (loss) from operations	99,837	72,098	328,996	279,526
Other income and expense:
Loss on early retirement of debt			(10,255)	(19,719)
Equity in earnings of unconsolidated subsidiaries	5,432	4,431	14,914	15,618
Non-operating gain	2,139	0	9,016	(49)
Interest expense	(50,669)	(37,688)	(147,991)	(116,196)
Income (loss) before income taxes	56,739	38,841	194,680	159,180
Income tax expense	14,060	14,017	47,460	59,593
Net income	42,679	24,824	147,220	99,587
Less: Net income attributable to non-controlling interests	9,762	6,362	34,053	23,200
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 32,917	$ 18,462	$ 113,167	$ 76,387

XML

Condensed Consolidated Statements of Changes in Equity and Income (unaudited) - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Total	Select Medical Corporation	Common Stock	Common Stock Select Medical Corporation	Capital in Excess of Par	Capital in Excess of Par Select Medical Corporation	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Select Medical Corporation	Total Stockholders’ Equity	Total Stockholders’ Equity Select Medical Corporation	Non-controlling Interests	Non-controlling Interests Select Medical Corporation
Balance at Dec. 31, 2017	$ 640,818	$ 640,818
Redeemable Non-controlling Interests
Net income attributable to non-controlling interests	25,896	25,896
Issuance and exchange of non-controlling interests	163,659	163,659
Distributions to and purchases of non-controlling interests	(215,847)	(215,847)
Redemption adjustment on non-controlling interests	164,065	164,065
Other	983	983
Balance at Sep. 30, 2018	$ 779,574	$ 779,574
Balance (in shares) at Dec. 31, 2017	134,114,715	100	134,115,000	0
Balance at Dec. 31, 2017	$ 932,604	$ 932,604	$ 134	$ 0	$ 463,499	$ 947,370	$ 359,735	$ (124,002)	$ 823,368	$ 823,368	$ 109,236	$ 109,236
Increase (Decrease) in Stockholders' Equity
Net income	113,167	113,167					113,167	113,167	113,167	113,167
Net income attributable to non-controlling interests	8,157	8,157									8,157	8,157
Issuance of restricted stock (in shares)			1,222,000
Issuance of restricted stock	0		$ 1		(1)
Forfeitures of unvested restricted stock (in shares)			(88,000)
Forfeitures of unvested restricted stock	0		$ 0		0
Vesting of restricted stock	15,059				15,059				15,059
Repurchase of common shares (in shares)			(285,000)
Repurchase of common shares	(5,640)		$ 0		(2,989)		(2,651)		(5,640)
Exercise of stock options (in shares)			176,000
Exercise of stock options	1,633		$ 0		1,633				1,633
Additional investment by Holdings		1,633				1,633				1,633
Dividends declared and paid to Holdings		(5,640)						(5,640)		(5,640)
Contribution related to restricted stock award issuances by Holdings		15,059				15,059				15,059
Issuance and exchange of non-controlling interests	77,815	77,815			1,553	1,553	74,341	74,341	75,894	75,894	1,921	1,921
Distributions to and purchases of non-controlling interests	(92,020)	(92,020)			(932)	(932)	(83,617)	(83,617)	(84,549)	(84,549)	(7,471)	(7,471)
Redemption adjustment on non-controlling interests	(164,065)	(164,065)					(164,065)	(164,065)	(164,065)	(164,065)
Other	$ 858	$ 858					(275)	(275)	(275)	(275)	1,133	1,133
Balance (in shares) at Sep. 30, 2018	135,140,269	100	135,140,000	0
Balance at Sep. 30, 2018	$ 887,568	$ 887,568	$ 135	$ 0	$ 477,822	$ 964,683	$ 296,635	$ (190,091)	$ 774,592	$ 774,592	$ 112,976	$ 112,976

XML

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net income	$ 147,220	$ 99,587
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	10,734	14,542
Depreciation and amortization	149,022	119,644
Provision for bad debts	(373)	914
Equity in earnings of unconsolidated subsidiaries	(14,914)	(15,618)
Loss on extinguishment of debt	484	6,527
Gain on sale of assets and businesses	(9,129)	(9,499)
Stock compensation expense	17,175	14,227
Amortization of debt discount, premium and issuance costs	9,845	8,546
Deferred income taxes	(2,092)	(6,126)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	23,495	(143,308)
Other current assets	(10,274)	(2,677)
Other assets	4,828	1,407
Accounts payable	(3,507)	3,913
Accrued expenses	49,391	18,752
Income taxes	9,072	19,141
Net cash provided by (used in) operating activities	380,977	129,972
Investing activities
Business combinations, net of cash acquired	(519,258)	(19,371)
Purchases of property and equipment	(121,039)	(173,800)
Investment in businesses	(12,936)	(11,374)
Proceeds from sale of assets and businesses	6,691	34,555
Net cash used in investing activities	(646,542)	(169,990)
Financing activities
Borrowings on revolving facilities	420,000	805,000
Payments on revolving facilities	(585,000)	(705,000)
Proceeds from term loans	779,904	1,139,487
Payments on term loans	(8,625)	(1,176,567)
Revolving facility debt issuance costs	(1,333)	(4,392)
Borrowings of other debt	30,134	27,571
Principal payments on other debt	(17,971)	(15,112)
Repurchase of common stock	(5,640)	(3,603)
Dividends paid to Holdings	0	0
Proceeds from exercise of stock options	1,633	1,634
Equity investment by Holdings	0	0
Decrease in overdrafts	(6,172)	(20,439)
Proceeds from issuance of non-controlling interests	2,926	8,986
Distributions to non-controlling interests	(306,427)	(9,276)
Net cash provided by (used in) financing activities	303,429	48,289
Net increase (decrease) in cash and cash equivalents	37,864	8,271
Cash and cash equivalents at beginning of period	122,549	99,029
Cash and cash equivalents at end of period	160,413	107,300
Supplemental Information
Cash paid for interest	134,378	101,341
Cash paid for taxes	40,460	46,553
Non-cash equity exchange for acquisition of U.S. HealthWorks	238,000	0
Select Medical Corporation
Operating activities
Net income	147,220	99,587
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	10,734	14,542
Depreciation and amortization	149,022	119,644
Provision for bad debts	(373)	914
Equity in earnings of unconsolidated subsidiaries	(14,914)	(15,618)
Loss on extinguishment of debt	484	6,527
Gain on sale of assets and businesses	(9,129)	(9,499)
Stock compensation expense	17,175	14,227
Amortization of debt discount, premium and issuance costs	9,845	8,546
Deferred income taxes	(2,092)	(6,126)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	23,495	(143,308)
Other current assets	(10,274)	(2,677)
Other assets	4,828	1,407
Accounts payable	(3,507)	3,913
Accrued expenses	49,391	18,752
Income taxes	9,072	19,141
Net cash provided by (used in) operating activities	380,977	129,972
Investing activities
Business combinations, net of cash acquired	(519,258)	(19,371)
Purchases of property and equipment	(121,039)	(173,800)
Investment in businesses	(12,936)	(11,374)
Proceeds from sale of assets and businesses	6,691	34,555
Net cash used in investing activities	(646,542)	(169,990)
Financing activities
Borrowings on revolving facilities	420,000	805,000
Payments on revolving facilities	(585,000)	(705,000)
Proceeds from term loans	779,904	1,139,487
Payments on term loans	(8,625)	(1,176,567)
Revolving facility debt issuance costs	(1,333)	(4,392)
Borrowings of other debt	30,134	27,571
Principal payments on other debt	(17,971)	(15,112)
Repurchase of common stock	0	0
Dividends paid to Holdings	(5,640)	(3,603)
Proceeds from exercise of stock options	0	0
Equity investment by Holdings	1,633	1,634
Decrease in overdrafts	(6,172)	(20,439)
Proceeds from issuance of non-controlling interests	2,926	8,986
Distributions to non-controlling interests	(306,427)	(9,276)
Net cash provided by (used in) financing activities	303,429	48,289
Net increase (decrease) in cash and cash equivalents	37,864	8,271
Cash and cash equivalents at beginning of period	122,549	99,029
Cash and cash equivalents at end of period	160,413	107,300
Supplemental Information
Cash paid for interest	134,378	101,341
Cash paid for taxes	40,460	46,553
Non-cash equity exchange for acquisition of U.S. HealthWorks	$ 238,000	$ 0

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings and Select and its subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of September 30, 2018, and for the three and nine month periods ended September 30, 2017 and 2018, have been prepared pursuant to the rules and regulations of the Securities Exchange Commission (the “SEC”) for interim reporting and accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and nine months ended September 30, 2018, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 22, 2018.

XML

Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Accounting Policies

Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Lease Accounting

Beginning in February 2016, the Financial Accounting Standards Board (the “FASB”) issued several Accounting Standards Updates (“ASU”) which established Topic 842, Leases (the “standard”). This standard includes a lessee accounting model that recognizes two types of leases: finance and operating. This standard requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in the standard will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. There are two transition approaches available under the standard: a modified retrospective approach for leases that exist, or are entered into, after the beginning of the earliest comparative period in the financial statements or a cumulative-effect approach with an adjustment to the opening balance of retained earnings in the period of adoption.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019, using the cumulative-effect approach, without adjusting the comparative periods. The Company has completed its inventory of leases and has begun to implement a new technology platform to account for leases under the new standard.  The Company has substantially completed validating its lease data to ensure it is complete and accurate. The Company’s remaining implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

Cloud Computing Arrangements

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the impacts that adoption of this ASU will have on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

Revenue from Contracts with Customers

Beginning in May 2014, the FASB issued several ASUs which established Topic 606, Revenue from Contracts with Customers (the “revenue recognition standard”). This revenue recognition standard supersedes existing revenue recognition requirements and seeks to eliminate most industry-specific guidance under current GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company adopted the new revenue recognition standard on January 1, 2018, using the full retrospective transition method. Adoption of the revenue recognition standard impacted the Company’s reported results as follows:

	Three Months Ended September 30, 2017
	As Reported		As Adjusted(1)		Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	1,097,166	$	1,077,014	$	(20,152	)
Bad debt expense	20,321		169		(20,152		)

	Nine Months Ended September 30, 2017
	As Reported			As Adjusted(1)			Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	3,329,202		$	3,270,996		$	(58,206	)
Bad debt expense	59,120			914			(58,206		)
Condensed Consolidated Statements of Cash Flows
Provision for bad debts	$	59,120		$	914		$	(58,206	)
Changes in accounts receivable	(201,514		)	(143,308		)	58,206

 _____________________________________________________________

(1) Bad debt expense is now included in cost of services on the condensed consolidated statements of operations.

	December 31, 2017
	As Reported		As Adjusted		Adoption Impact
	(in thousands)
Condensed Consolidated Balance Sheets
Accounts receivable	$	767,276	$	691,732	$	(75,544	)
Allowance for doubtful accounts	75,544		—		(75,544		)
Accounts receivable	$	691,732	$	691,732	$	—

The Company has presented the applicable disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers in Note 7.

Income Taxes

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), and Intra-Entity Transfers of Assets Other Than Inventory. Previous GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra‑entity transfer of an asset other than inventory when the transfer occurs. The Company adopted the guidance effective January 1, 2018. Adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.

XML

Acquisitions

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Acquisitions

Acquisitions

U.S. HealthWorks Acquisition

On February 1, 2018, Concentra Inc. (“Concentra”) acquired all of the issued and outstanding shares of stock of U.S. HealthWorks, Inc. (“U.S. HealthWorks”), an occupational medicine and urgent care service provider, pursuant to the terms of an Equity Purchase and Contribution Agreement (the “Purchase Agreement”) dated as of October 22, 2017, by and among Concentra, U.S. HealthWorks, Concentra Group Holdings, LLC (“Concentra Group Holdings”), Concentra Group Holdings Parent, LLC (“Concentra Group Holdings Parent”) and Dignity Health Holding Corporation (“DHHC”). For the nine months ended September 30, 2018, the Company recognized $2.9 million of U.S. HealthWorks acquisition costs which are included in general and administrative expense.

In connection with the closing of the transaction, Concentra Group Holdings made distributions to its equity holders and redeemed certain of its outstanding equity interests from existing minority equity holders. Subsequently, Concentra Group Holdings and a wholly owned subsidiary of Concentra Group Holdings Parent merged, with Concentra Group Holdings surviving the merger and becoming a wholly owned subsidiary of Concentra Group Holdings Parent. As a result of the merger, the equity interests of Concentra Group Holdings outstanding after the redemption described above were exchanged for membership interests in Concentra Group Holdings Parent.

Concentra acquired U.S. HealthWorks for $753.0 million. The Purchase Agreement provides for certain post-closing adjustments for cash, indebtedness, transaction expenses, and working capital. DHHC, a subsidiary of Dignity Health, was issued a 20% equity interest in Concentra Group Holdings Parent, which was valued at $238.0 million. The remainder of the purchase price was paid in cash. Select retained a majority voting interest in Concentra Group Holdings Parent following the closing of the transaction.

For the U.S. HealthWorks acquisition, the Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values in accordance with the provisions of Accounting Standards Codification Topic 805, Business Combinations. The Company is in the process of completing its assessment of the acquisition-date fair values of the assets acquired and the liabilities assumed and determining the estimated useful lives of long-lived assets and finite-lived intangible assets; therefore, the values set forth below are subject to adjustment during the measurement period. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price allocation activities by December 31, 2018.

The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):

Identifiable tangible assets	$	184,163
Identifiable intangible assets	140,406
Goodwill	533,124
Total assets	857,693
Total liabilities	104,693
Consideration given	$	753,000

The preliminary fair value assigned to identifiable intangible assets was determined through the use of the income and cost approaches. Both valuation methods rely on management judgment including expected future cash flows, customer attrition rates, contributory effects of other assets utilized in the business, peer group cost of capital and royalty rates, and other factors. Useful lives for identifiable intangible assets were determined based upon the remaining useful economic lives of the identifiable intangible assets that are expected to contribute directly or indirectly to future cash flows. The valuations of tangible assets were derived using a combination of the market and cost approaches. Significant judgments used in valuing tangible assets include estimated reproduction or replacement cost, useful lives of assets, and estimated selling prices.

	Fair Value		Weighted Average Amortization Period
	(in thousands)		(in years)
Customer relationships	$	135,000	15.0 years
Trademarks	5,000		1.0 year
Favorable leasehold interests	406		2.9 years
Identifiable intangible assets	$	140,406

The customer relationships and trademarks are being amortized on a straight-line basis over their expected useful lives. Favorable leasehold interests are being amortized over their remaining lease terms at the time of acquisition.

A preliminary estimate for goodwill of $533.1 million has been recognized for the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from U.S. HealthWorks’ future earnings potential and its assembled workforce. Goodwill has been assigned to the Concentra reporting unit and is not deductible for tax purposes. However, prior to its acquisition by the Company, U.S. HealthWorks completed certain acquisitions that resulted in tax deductible goodwill with an estimated value of $83.1 million, which the Company will deduct through 2032.

For the three months ended September 30, 2018, U.S. HealthWorks had net operating revenues of $133.3 million which is reflected in the Company’s consolidated statements of operations. For the period February 1, 2018 through September 30, 2018, U.S. HealthWorks had net operating revenues of $362.7 million which is reflected in the Company’s consolidated statements of operations for the nine months ended September 30, 2018. Due to the integrated nature of our operations, it is not practicable to separately identify earnings of U.S. HealthWorks on a stand-alone basis.

Pro Forma Results

The following pro forma unaudited results of operations have been prepared assuming the acquisition of U.S. HealthWorks occurred on January 1, 2017. These results are not necessarily indicative of results of future operations nor of the results that would have occurred had the acquisition been consummated on the aforementioned date.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Net revenue	$	1,215,869	$	1,267,401	$	3,687,574	$	3,864,155
Net income	21,929		45,721		85,317		153,144
Net income attributable to the Company	17,011		34,441		69,237		116,135
Income per common share:
Basic	$	0.13	$	0.26	$	0.52	$	0.86
Diluted	$	0.13	$	0.26	$	0.52	$	0.86

 The pro forma financial information is based on the preliminary allocation of the purchase price of the U.S. HealthWorks acquisition and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period. The net income tax impact was calculated at a statutory rate, as if U.S. HealthWorks had been a subsidiary of the Company as of January 1, 2017.

For the nine months ended September 30, 2017, pro forma results were adjusted to include the U.S. HealthWorks acquisition costs recognized by the Company during 2017 and 2018, which were approximately $5.7 million. For the nine months ended September 30, 2018, pro forma results were adjusted to exclude approximately $2.9 million of U.S. HealthWorks acquisition costs which were recognized by the Company during the period.

XML

Intangible Assets

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets

Goodwill

The following table shows changes in the carrying amounts of goodwill by reporting unit for the nine months ended September 30, 2018:

	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation			Concentra			Total
	(in thousands)
Balance as of December 31, 2017	$	1,045,220	$	415,528	$	647,522		$	674,542		$	2,782,812
Acquired	—		1,118		2,465			536,945			540,528
Measurement period adjustment	—		—		—			(2,472		)	(2,472		)
Sold	—		—		(9,409		)	—			(9,409		)
Balance as of September 30, 2018	$	1,045,220	$	416,646	$	640,578		$	1,209,015		$	3,311,459

_______________________________________________________________________________

(1) The critical illness recovery hospital reporting unit was previously referred to as the long term acute care reporting unit. The rehabilitation hospital reporting unit was previously referred to as the inpatient rehabilitation reporting unit.

Identifiable Intangible Assets

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company’s identifiable intangible assets:

	December 31, 2017							September 30, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived intangible assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	19,155		—			19,155		19,118		—			19,118
Accreditations	1,895		—			1,895		1,857		—			1,857
Finite-lived intangible assets:
Trademarks	—		—			—		5,000		(3,333		)	1,667
Customer relationships	143,953		(38,281		)	105,672		279,967		(55,760		)	224,207
Favorable leasehold interests	13,295		(4,319		)	8,976		13,553		(5,653		)	7,900
Non-compete agreements	28,023		(3,900		)	24,123		28,953		(5,553		)	23,400
Total identifiable intangible assets	$	373,019	$	(46,500	)	$	326,519	$	515,146	$	(70,299	)	$	444,847

 The Company’s accreditations and indefinite-lived trademarks have renewal terms and the costs to renew these intangible assets are expensed as incurred. At September 30, 2018, the accreditations and indefinite-lived trademarks have a weighted average time until next renewal of 1.5 years and 8.4 years, respectively.

The Company’s finite-lived customer relationships, non-compete agreements, and trademarks amortize over their estimated useful lives. Amortization expense was $4.4 million and $7.9 million for the three months ended September 30, 2017 and 2018, respectively. Amortization expense was $13.1 million and $22.1 million for the nine months ended September 30, 2017 and 2018, respectively. The Company’s leasehold interests have finite lives and are amortized to rent expense over the remaining term of their respective leases to reflect a market rent per period based upon the market conditions present at the acquisition date.

Estimated amortization expense for the Company’s finite-lived customer relationships, non-compete agreements, and trademarks for the remaining period of 2018 and each of the four succeeding years is as follows:

	2018		2019		2020		2021		2022
	(in thousands)
Amortization expense	$	7,811	$	26,490	$	25,864	$	25,648	$	25,443

XML

Long-Term Debt and Notes Payable

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Long-Term Debt and Notes Payable

Long-Term Debt and Notes Payable

For purposes of this indebtedness footnote, references to Select exclude Concentra because the Concentra credit facilities are non-recourse to Holdings and Select.

As of September 30, 2018, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	607		$	(5,122	)	$	705,485	$	718,875
Credit facilities:
Revolving facility	65,000		—			—			65,000		59,800
Term loans	1,132,750		(11,000		)	(11,058		)	1,110,692		1,139,830
Other	49,004		—			(508		)	48,496		48,496
Total Select debt	1,956,754		(10,393		)	(16,688		)	1,929,673		1,967,001
Concentra:
Credit facilities:
Term loans	1,414,175		(3,078		)	(20,417		)	1,390,680		1,427,181
Other	9,355		—			—			9,355		9,355
Total Concentra debt	1,423,530		(3,078		)	(20,417		)	1,400,035		1,436,536
Total debt	$	3,380,284	$	(13,471	)	$	(37,105	)	$	3,329,708	$	3,403,537

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2018		2019		2020		2021		2022		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	710,000	$	—	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		65,000		—		65,000
Term loans	2,875		11,500		11,500		11,500		11,500		1,083,875		1,132,750
Other	3,992		5,391		24,285		221		—		15,115		49,004
Total Select debt	6,867		16,891		35,785		721,721		76,500		1,098,990		1,956,754
Concentra:
Credit facilities:
Term loans	—		—		5,719		12,365		1,156,091		240,000		1,414,175
Other	1,341		3,625		346		346		324		3,373		9,355
Total Concentra debt	1,341		3,625		6,065		12,711		1,156,415		243,373		1,423,530
Total debt	$	8,208	$	20,516	$	41,850	$	734,432	$	1,232,915	$	1,342,363	$	3,380,284

As of December 31, 2017, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	778		$	(6,553	)	$	704,225	$	727,750
Credit facilities:
Revolving facility	230,000		—			—			230,000		211,600
Term loans	1,141,375		(12,445		)	(12,500		)	1,116,430		1,154,215
Other	36,877		—			(533		)	36,344		36,344
Total Select debt	2,118,252		(11,667		)	(19,586		)	2,086,999		2,129,909
Concentra:
Credit facilities:
Term loans	619,175		(2,257		)	(10,668		)	606,250		625,173
Other	6,653		—			—			6,653		6,653
Total Concentra debt	625,828		(2,257		)	(10,668		)	612,903		631,826
Total debt	$	2,744,080	$	(13,924	)	$	(30,254	)	$	2,699,902	$	2,761,735

 Select Credit Facilities

On March 22, 2018, Select entered into Amendment No. 1 to the senior secured credit agreement (the “Select credit agreement”) dated March 6, 2017. The Select credit agreement originally provided for $1.6 billion in senior secured credit facilities comprised of $1.15 billion in term loans (the “Select term loans”) and a $450.0 million revolving credit facility (the “Select revolving facility” and together with the Select term loans, the “Select credit facilities”), including a $75.0 million sublimit for the issuance of standby letters of credit.

Amendment No. 1 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement and subject to an Adjusted LIBO floor of 1.00%) plus 3.50% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate (as defined in the Select credit agreement and subject to an Alternate Base Rate floor of 2.00%) plus 2.50% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio (as defined in the Select credit agreement); (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 3.00% to 3.25% to the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75%, or from the Alternative Base Rate plus a percentage ranging from 2.00% to 2.25% to the Alternative Base Rate plus a percentage ranging from 1.50% to 1.75%, in each case based on Select’s total net leverage ratio; (iii) extended the maturity date for the Select term loans from March 6, 2024 to March 6, 2025; and (iv) made certain other technical amendments to the Select credit agreement as set forth therein.

Concentra Credit Facilities

Concentra First Lien Credit Agreement

On February 1, 2018, Concentra entered into an amendment to its first lien credit agreement (the “Concentra first lien credit agreement”) dated June 1, 2015, by and among Concentra, as the borrower, Concentra Holdings, Inc., a subsidiary of Concentra Group Holdings Parent, JPMorgan Chase Bank, N.A., as the administrative agent and the collateral agent, and the other lenders party thereto. Concentra used borrowings under the Concentra first lien credit agreement and the Concentra second lien credit agreement, as described below, together with cash on hand, to pay the cash purchase price for all of the issued and outstanding stock of U.S. HealthWorks to DHHC and to finance the redemption and reorganization transactions executed under the Purchase Agreement (as described in Note 3), as well as to pay fees and expenses associated with the financing.

Concentra amended the Concentra first lien credit agreement to, among other things, provide for (i) an additional $555.0 million in tranche B term loans that, along with the existing tranche B term loans under the Concentra first lien credit agreement, have a maturity date of June 1, 2022 (collectively, the “Concentra first lien term loan”) and (ii) an additional $25.0 million to the $50.0 million, five-year revolving credit facility under the terms of the existing Concentra first lien credit agreement. The tranche B term loans bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus 2.75% (subject to an Adjusted LIBO Rate floor of 1.00%) for Eurodollar Borrowings (as defined in the Concentra first lien credit agreement), or Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus 1.75% (subject to an Alternate Base Rate floor of 2.00%) for ABR Borrowings (as defined in the Concentra first lien credit agreement). All other material terms and conditions applicable to the original tranche B term loan commitments are applicable to the additional tranche B term loans created under the Concentra first lien credit agreement.

Concentra Second Lien Credit Agreement

On February 1, 2018, Concentra entered into a second lien credit agreement (the “Concentra second lien credit agreement” and, together with the Concentra first lien credit agreement, the “Concentra credit facilities”) with Concentra Holdings, Inc., Wells Fargo Bank, National Association, as the administrative agent and the collateral agent, and the other lenders party thereto.

The Concentra second lien credit agreement provided for $240.0 million in term loans (the “Concentra second lien term loan” and, together with the Concentra first lien term loan, the “Concentra term loans”) with a maturity date of June 1, 2023. Borrowings under the Concentra second lien credit agreement bear interest at a rate equal to the Adjusted LIBO Rate (as defined in the Concentra second lien credit agreement) plus 6.50% (subject to an Adjusted LIBO Rate floor of 1.00%), or Alternate Base Rate (as defined in the Concentra second lien credit agreement) plus 5.50% (subject to an Alternate Base Rate floor of 2.00%).

In the event that, on or prior to February 1, 2019, Concentra prepays any of the Concentra second lien term loan to refinance such term loans, Concentra shall pay a premium of 2.00% of the aggregate principal amount of the Concentra second lien term loan prepaid. If Concentra prepays any of the Concentra second lien term loan to refinance such term loans on or prior to February 1, 2020, Concentra shall pay a premium of 1.00% of the aggregate principal amount of the Concentra second lien term loan prepaid.

Concentra will be required to prepay borrowings under the Concentra second lien term loan with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (iii) 50% of excess cash flow (as defined in the Concentra second lien credit agreement) if Concentra’s leverage ratio is greater than 4.25 to 1.00 and 25% of excess cash flow if Concentra’s leverage ratio is less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00, in each case, reduced by the aggregate amount of term loans and certain debt optionally prepaid during the applicable fiscal year and the aggregate amount of senior revolving commitments reduced permanently during the applicable fiscal year (other than in connection with a refinancing). Concentra will not be required to prepay borrowings with excess cash flow if Concentra’s leverage ratio is less than or equal to 3.75 to 1.00.

The Concentra second lien credit agreement also contains a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Concentra second lien credit agreement contains events of default for non-payment of principal and interest when due (subject to a grace period for interest), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

The borrowings under the Concentra second lien term loan are guaranteed, on a second lien basis, by Concentra Holdings, Inc., Concentra, and certain domestic subsidiaries of Concentra and will be guaranteed by Concentra’s future domestic subsidiaries (other than Excluded Subsidiaries and Consolidated Practices, each as defined in the Concentra second lien credit agreement). The borrowings under the Concentra second lien term loan are secured by substantially all of Concentra’s and its domestic subsidiaries’ existing and future property and assets and by a pledge of Concentra’s capital stock, the capital stock of certain of Concentra’s domestic subsidiaries and up to 65% of the voting capital stock and 100% of the non-voting capital stock of Concentra’s foreign subsidiaries, if any.

Loss on Early Retirement of Debt

The amendments to the Select credit facilities and Concentra credit facilities resulted in losses on early retirement of debt totaling $10.3 million for the nine months ended September 30, 2018. The losses on early retirement of debt consisted of $0.5 million of debt extinguishment losses and $9.8 million of debt modification losses during the nine months ended September 30, 2018.

Fair Value

The Company considers the inputs in the valuation process to be Level 2 in the fair value hierarchy for Select’s 6.375% senior notes and for its credit facilities. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly, which includes quoted prices for identical assets or liabilities in markets that are not active.

The fair values of the Select credit facilities and the Concentra credit facilities were based on quoted market prices for this debt in the syndicated loan market. The fair value of Select’s 6.375% senior notes was based on quoted market prices. The carrying amount of other debt, principally short-term notes payable, approximates fair value.

XML

Segment Information

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company identifies its operating segments according to how the chief operating decision maker evaluates financial performance and allocates resources. During the year ended December 31, 2017, the Company changed its internal segment reporting structure which is reflective of how the Company now manages its business operations, reviews operating performance, and allocates resources. The Company’s reportable segments include the critical illness recovery hospital segment (previously referred to as the long term acute care segment), rehabilitation hospital segment (previously referred to as the inpatient rehabilitation segment), outpatient rehabilitation segment, and Concentra segment. Prior year results for the three and nine months ended September 30, 2017, presented herein have been recast to conform to the current presentation. The Company previously disclosed financial information for the following reportable segments: specialty hospitals, outpatient rehabilitation, and Concentra.

Other activities include the Company’s corporate shared services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, acquisition costs associated with U.S. HealthWorks, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
	(in thousands)
Net operating revenues:(1)
Critical illness recovery hospital(2)	$	416,934		$	420,108		$	1,301,251		$	1,327,236
Rehabilitation hospital(2)	157,499			176,885			453,702			525,428
Outpatient rehabilitation	246,644			265,927			751,999			790,491
Concentra	255,881			404,481			763,357			1,173,420
Other	56			—			687			—
Total Company	$	1,077,014		$	1,267,401		$	3,270,996		$	3,816,575
Adjusted EBITDA:
Critical illness recovery hospital(2)	$	46,873		$	53,292		$	194,253		$	186,989
Rehabilitation hospital(2)	22,581			25,343			62,038			80,314
Outpatient rehabilitation	29,298			34,531			102,575			107,003
Concentra	40,003			68,754			125,656			199,119
Other	(22,928		)	(25,292		)	(71,125		)	(75,337		)
Total Company	$	115,827		$	156,628		$	413,397		$	498,088
Total assets:
Critical illness recovery hospital(2)	$	2,008,485		$	1,785,336		$	2,008,485		$	1,785,336
Rehabilitation hospital(2)	740,276			888,342			740,276			888,342
Outpatient rehabilitation	945,765			991,105			945,765			991,105
Concentra	1,332,012			2,201,869			1,332,012			2,201,869
Other	97,269			113,529			97,269			113,529
Total Company	$	5,123,807		$	5,980,181		$	5,123,807		$	5,980,181
Purchases of property and equipment, net:
Critical illness recovery hospital(2)	$	8,003		$	8,134		$	28,717		$	31,455
Rehabilitation hospital(2)	29,373			8,769			77,707			29,766
Outpatient rehabilitation	6,496			7,209			19,370			22,565
Concentra	5,369			12,539			21,656			29,281
Other	19,257			2,740			26,350			7,972
Total Company	$	68,498		$	39,391		$	173,800		$	121,039

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	46,873		$	22,581		$	29,298		$	40,003		$	(22,928	)
Depreciation and amortization	(10,932		)	(4,505		)	(5,964		)	(15,014		)	(2,357		)
Stock compensation expense	—			—			—			(212		)	(4,745		)
Income (loss) from operations	$	35,941		$	18,076		$	23,334		$	24,777		$	(30,030	)	$	72,098
Equity in earnings of unconsolidated subsidiaries																4,431
Interest expense																(37,688		)
Income before income taxes																$	38,841

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	53,292		$	25,343		$	34,531		$	68,754		$	(25,292	)
Depreciation and amortization	(11,136		)	(6,079		)	(6,597		)	(24,488		)	(2,227		)
Stock compensation expense	—			—			—			(767		)	(5,497		)
Income (loss) from operations	$	42,156		$	19,264		$	27,934		$	43,499		$	(33,016	)	$	99,837
Equity in earnings of unconsolidated subsidiaries																5,432
Non-operating gain																2,139
Interest expense																(50,669		)
Income before income taxes																$	56,739

 

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	194,253		$	62,038		$	102,575		$	125,656		$	(71,125	)
Depreciation and amortization	(34,891		)	(14,500		)	(18,182		)	(46,566		)	(5,505		)
Stock compensation expense	—			—			—			(782		)	(13,445		)
Income (loss) from operations	$	159,362		$	47,538		$	84,393		$	78,308		$	(90,075	)	$	279,526
Loss on early retirement of debt																(19,719		)
Equity in earnings of unconsolidated subsidiaries																15,618
Non-operating loss																(49		)
Interest expense																(116,196		)
Income before income taxes																$	159,180

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,989		$	80,314		$	107,003		$	199,119		$	(75,337	)
Depreciation and amortization	(34,146		)	(17,816		)	(19,938		)	(70,332		)	(6,790		)
Stock compensation expense	—			—			—			(2,116		)	(15,059		)
U.S. HealthWorks acquisition costs	—			—			—			(2,895		)	—
Income (loss) from operations	$	152,843		$	62,498		$	87,065		$	123,776		$	(97,186	)	$	328,996
Loss on early retirement of debt																(10,255		)
Equity in earnings of unconsolidated subsidiaries																14,914
Non-operating gain																9,016
Interest expense																(147,991		)
Income before income taxes																$	194,680

_______________________________________________________________________________

(1) Net operating revenues were retrospectively conformed to reflect the adoption Topic 606, Revenue from Contracts with Customers.

(2)

The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

XML

Revenue from Contracts with Customers

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue from Contracts with Customers

Net operating revenues consist primarily of patient service revenues generated from services provided to patients and other revenues for services provided to healthcare institutions under contractual arrangements. The following tables disaggregate the Company’s net operating revenues by operating segment for the three and nine months ended September 30, 2017 and 2018:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	217,116	$	64,227	$	36,821	$	472
Non-Medicare	195,872		53,054		179,171		253,437
Total patient services revenues	412,988		117,281		215,992		253,909
Other revenues	3,946		40,218		30,652		1,972
Total net operating revenues	$	416,934	$	157,499	$	246,644	$	255,881

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	210,101	$	71,564	$	40,563	$	455
Non-Medicare	206,629		64,322		185,787		401,537
Total patient services revenues	416,730		135,886		226,350		401,992
Other revenues	3,378		40,999		39,577		2,489
Total net operating revenues	$	420,108	$	176,885	$	265,927	$	404,481

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	682,286	$	183,820	$	111,638	$	1,588
Non-Medicare	610,372		151,731		551,983		755,345
Total patient services revenues	1,292,658		335,551		663,621		756,933
Other revenues	8,593		118,151		88,378		6,424
Total net operating revenues	$	1,301,251	$	453,702	$	751,999	$	763,357

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	676,950	$	217,459	$	120,228	$	1,600
Non-Medicare	639,718		188,611		569,298		1,164,711
Total patient services revenues	1,316,668		406,070		689,526		1,166,311
Other revenues	10,568		119,358		100,965		7,109
Total net operating revenues	$	1,327,236	$	525,428	$	790,491	$	1,173,420

_______________________________________________________________________________

(1) The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

Patient Services Revenue

Patient services revenue is recognized when obligations under the terms of the contract are satisfied; generally, this occurs as the Company provides healthcare services, as each service provided is distinct and future services rendered are not dependent on previously rendered services. Patient service revenues are recognized at an amount equal to the consideration the Company expects to receive in exchange for providing healthcare services to its patients. These amounts are due from patients; third-party payors, including health insurers and government programs; and other payors.

Medicare: Medicare is a federal program that provides medical insurance benefits to persons age 65 and over, some disabled persons, and persons with end stage renal disease. Amounts we receive for treatment of patients covered by the Medicare program are generally less than the standard billing rates; accordingly, the Company recognizes revenue based on amounts which are reimbursable by Medicare under prospective payment systems and provisions of cost-reimbursement and other payment methods. The amount reimbursed is derived based on the type of services provided.

Non-Medicare: The Company is reimbursed for healthcare services provided from various other payor sources which include insurance companies, workers’ compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies and employers, as well as patients. The Company is reimbursed by these payors using a variety of payment methodologies and the amounts the Company receives are generally less than the standard billing rates.

In the critical illness recovery hospital and rehabilitation hospital segments, the Company recognizes revenue based on known contractual provisions associated with the specific payor or, where the Company has a relatively homogeneous patient population, the Company will monitor individual payors’ historical reimbursement rates to derive a per diem rate which is used to determine the amount of revenue to be recognized for services rendered.

In the outpatient rehabilitation and Concentra segments, the Company recognizes revenue from payors based on known contractual provisions, negotiated amounts, or usual and customary amounts associated with the specific payor. The Company performs provision testing, using internally developed systems, whereby the Company monitors a payors’ historical reimbursement rates and compares them against the associated gross charges for the service provided. The percentage of historical reimbursed claims to gross charges is utilized to determine the amount of revenue to be recognized for services rendered.

The Company is subject to potential retrospective adjustments to net operating revenues in future periods for matters related to claims processing and other price concessions. These adjustments, which are estimated based on an analysis of historical experience by payor source, are accounted for as a constraint to the amount of revenue recognized by the Company in the period services are rendered.

Other Revenues

The Company recognizes revenue for services provided to healthcare institutions, principally management and employee leasing services, under contractual arrangements with related parties affiliated through the Company’s equity investments and other third-party healthcare institutions. Revenue is recognized when obligations under the terms of the contract are satisfied. Revenues from these services are measured as the amount of consideration the Company expects to receive for those services.

XML

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law which made significant changes to the Internal Revenue Code. These changes included a corporate tax rate decrease from 35.0% to 21.0% effective after December 31, 2017. Reconciliations of the statutory federal income tax rate to the effective income tax rate are as follows:

	Three Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	4.0		5.0
Permanent differences	0.8		2.7
Valuation allowance	0.1		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.6	)	(1.0	)
Stock-based compensation	(2.3	)	(2.7	)
Other	(0.1	)	(0.3	)
Total effective income tax rate	36.1	%	24.8	%

	Nine Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	3.8		4.7
Permanent differences	1.1		2.1
Valuation allowance	0.2		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.8	)	(1.8	)
Stock-based compensation	(0.9	)	(2.6	)
Other	(0.2	)	0.9
Total effective income tax rate	37.4	%	24.4	%

XML

Income per Common Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Income per Common Share

Income per Common Share

Holdings applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings.

The following table sets forth the calculation of income per share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	18,462	$	32,917	$	76,387	$	113,167
Less: Earnings allocated to unvested restricted stockholders	608		1,098		2,464		3,732
Net income available to common stockholders	$	17,854	$	31,819	$	73,923	$	109,435
Denominator:
Weighted average shares—basic	129,142		130,387		128,745		129,972
Effect of dilutive securities:
Stock options	180		60		171		94
Weighted average shares—diluted	129,322		130,447		128,916		130,066
Basic income per common share:	$	0.14	$	0.24	$	0.57	$	0.84
Diluted income per common share:	$	0.14	$	0.24	$	0.57	$	0.84

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned operations, the Company maintains insurance coverages under a combination of policies with a total annual aggregate limit of $35.0 million. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has numerous programs that are designed to respond to the risks of the specific joint venture. The annual aggregate limit under these programs ranges from $5.0 million to $20.0 million. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

 Evansville Litigation.    On October 19, 2015, the plaintiff‑relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital-Evansville, LLC (“SSH‑Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff‑relators on behalf of the United States under the federal False Claims Act. The plaintiff‑relators are the former CEO and two former case managers at SSH‑Evansville, and the defendants currently include the Company, SSH‑Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH‑Evansville. The plaintiff‑relators allege that SSH‑Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up‑coded diagnoses at admission, and admitted patients for whom long‑term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff‑relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff‑relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non‑retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However, the District Court ruled that the plaintiff‑relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present and allowing discovery that would facilitate the use of statistical sampling to prove liability, which the defendants opposed. In April 2018, a U.S. magistrate judge ruled that plaintiff‑relators’ discovery will be limited to only SSH-Evansville for the period from March 23, 2010 through September 30, 2016, and that the plaintiff‑relators will be required to prove the fraud that they allege on a claim-by-claim basis, rather than using statistical sampling. The plaintiff-relators have appealed this decision to the District Judge.

The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation.    On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital-Wilmington, Inc. (“SSH‑Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16‑347‑LPS. The Complaint was initially filed under seal in May 2016 by a former chief nursing officer at SSH‑Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention in January 2017. The corporate defendants were served in March 2017. In the complaint, the plaintiff‑relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH‑Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH‑Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, in May 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim. In March 2018, the District Court dismissed the plaintiff‑relator’s claims related to the alleged failure to properly examine medical practitioners’ credentials, her reverse false claims allegations, and her claim that defendants violated the Delaware False Claims and Reporting Act. It denied the defendants’ motion to dismiss claims that the allegedly falsified medical practitioner signatures violated the False Claims Act. Separately, the District Court dismissed the individual defendant due to plaintiff-relator’s failure to timely serve the amended complaint upon her.

In March 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH‑Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  In January 2018, the Court stayed the Delaware Complaint pending the outcome of the federal case.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

Contract Therapy Subpoena. On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

XML

Subsequent Events

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Amendment to the Select Credit Facilities

On October 26, 2018, Select entered into Amendment No. 2 to the Select credit agreement (“Amendment No. 2”). Among other things, Amendment No. 2 (i) decreased the applicable interest rate on the Select term loans from the Adjusted LIBO Rate (as defined in the Select credit agreement) plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio (as defined in the Select credit agreement), and (ii) decreased the applicable interest rate on the loans outstanding under the Select revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.50% to 2.75% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternative Base Rate (as defined in the Select credit agreement) plus a percentage ranging from 1.50% to 1.75% to the Alternative Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to a specified total net leverage ratio. As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Select credit agreement are no longer subject to the currently applicable floor.

Amendment to the Concentra Credit Facilities

On October 26, 2018, Concentra entered into Amendment No. 4 to the Concentra first lien credit agreement (“Amendment No. 4”). Among other things, Amendment No. 4 (i) provided the applicable interest rate on the tranche B term loans under the Concentra first lien credit agreement is the Adjusted LIBO Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 2.50% to 2.75% (with 2.75% being the initial rate), or the Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus a percentage ranging from 1.50% to 1.75% (with 1.75% being the initial rate), in each case subject to a specified credit rating, and (ii) decreased the applicable interest rate on the loans outstanding under the Concentra revolving credit facility from the Adjusted LIBO Rate plus a percentage ranging from 2.75% to 3.00% to the Adjusted LIBO Rate plus a percentage ranging from 2.25% to 2.50%, or from the Alternate Base Rate plus a percentage ranging from 1.75% to 2.00% to the Alternate Base Rate plus a percentage ranging from 1.25% to 1.50%, in each case subject to Concentra’s first lien net leverage ratio (as defined in the Concentra first lien credit agreement). As amended, the Adjusted LIBO Rate and Alternate Base Rate under the Concentra first lien credit agreement are no longer subject to the currently applicable floor.

XML

Condensed Consolidating Financial Information

9 Months Ended

Sep. 30, 2018

Disclosure Text Block Supplement [Abstract]

Condensed Consolidating Financial Information

Condensed Consolidating Financial Information

Select’s 6.375% senior notes are fully and unconditionally and jointly and severally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly owned subsidiaries (the “Subsidiary Guarantors”). The Subsidiary Guarantors are defined as subsidiaries where Select, or a subsidiary of Select, holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries” and Concentra Group Holdings Parent and its subsidiaries, the “Non-Guarantor Concentra”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors, the Non-Guarantor Subsidiaries, and Non-Guarantor Concentra.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Certain reclassifications have been made to prior reported amounts in order to conform to the current year guarantor structure.

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	77		$	5,627	$	3,045		$	151,664	$	—			$	160,413
Accounts receivable	—			412,454		123,622			210,740		—				746,816
Intercompany receivables	—			1,722,475		75,391			—		(1,797,866		)	(a)	—
Prepaid income taxes	16,325			—		—			3,527		—				19,852
Other current assets	15,441			32,281		14,839			33,653		—				96,214
Total Current Assets	31,843			2,172,837		216,897			399,584		(1,797,866		)		1,023,295
Property and equipment, net	36,947			615,299		90,821			222,323		—				965,390
Investment in affiliates	4,448,449			123,809		—			—		(4,572,258		)	(b)(c)	—
Goodwill	—			2,102,444		—			1,209,015		—				3,311,459
Identifiable intangible assets, net	3			102,423		4,972			337,449		—				444,847
Other assets	38,861			137,897		33,902			33,498		(8,968		)	(e)	235,190
Total Assets	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181
Liabilities and Equity
Current Liabilities:
Overdrafts	$	23,291		$	—	$	—		$	—	$	—			$	23,291
Current portion of long-term debt and notes payable	15,508			268		3,631			4,768		—				24,175
Accounts payable	12,183			76,776		19,948			28,633		—				137,540
Intercompany payables	1,722,475			75,391		—			—		(1,797,866		)	(a)	—
Accrued payroll	12,061			95,717		4,935			63,508		—				176,221
Accrued vacation	4,394			58,590		13,584			29,458		—				106,026
Accrued interest	17,775			16		27			5,830		—				23,648
Accrued other	60,190			62,049		16,637			49,203		—				188,079
Income taxes payable	2,764			—		—			3,365		—				6,129
Total Current Liabilities	1,870,641			368,807		58,762			184,765		(1,797,866		)		685,109
Long-term debt, net of current portion	1,871,407			72		38,787			1,395,267		—				3,305,533
Non-current deferred tax liability	—			91,487		882			64,826		(8,968		)	(e)	148,227
Other non-current liabilities	39,463			62,354		8,730			63,623		—				174,170
Total Liabilities	3,781,511			522,720		107,161			1,708,481		(1,806,834		)		4,313,039
Redeemable non-controlling interests	—			—		—			19,402		760,172			(d)	779,574
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	964,683			—		—			—		—				964,683
Retained earnings (accumulated deficit)	(190,091		)	1,506,874		(33,181		)	11,504		(1,485,197		)	(c)(d)	(190,091		)
Subsidiary investment	—			3,225,115		272,612			456,854		(3,954,581		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	774,592			4,731,989		239,431			468,358		(5,439,778		)		774,592
Non-controlling interests	—			—		—			5,628		107,348			(d)	112,976
Total Equity	774,592			4,731,989		239,431			473,986		(5,332,430		)		887,568
Total Liabilities and Equity	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	675,059		$	187,861		$	404,481		$	—			$	1,267,401
Costs and expenses:
Cost of services	815			585,110			164,643			336,494			—				1,087,062
General and administrative	29,791			184			—			—			—				29,975
Depreciation and amortization	2,215			19,726			4,098			24,488			—				50,527
Total costs and expenses	32,821			605,020			168,741			360,982			—				1,167,564
Income (loss) from operations	(32,821		)	70,039			19,120			43,499			—				99,837
Other income and expense:
Intercompany interest and royalty fees	6,357			(2,578		)	(3,445		)	(334		)	—				—
Intercompany management fees	50,601			(39,262		)	(11,339		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			5,424			8			—			—				5,432
Non-operating gain	—			2,139			—			—			—				2,139
Interest income (expense)	(28,933		)	99			(207		)	(21,628		)	—				(50,669		)
Income (loss) before income taxes	(4,796		)	35,861			4,137			21,537			—				56,739
Income tax expense (benefit)	(1,428		)	9,923			112			5,453			—				14,060
Equity in earnings of consolidated subsidiaries	36,285			2,861			—			—			(39,146		)	(a)	—
Net income	32,917			28,799			4,025			16,084			(39,146		)		42,679
Less: Net income attributable to non-controlling interests	—			—			1,164			8,598			—				9,762
Net income attributable to Select Medical Corporation	$	32,917		$	28,799		$	2,861		$	7,486		$	(39,146	)		$	32,917

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	2,072,237		$	570,918		$	1,173,420		$	—			$	3,816,575
Costs and expenses:
Cost of services	2,340			1,782,843			486,006			976,417			—				3,247,606
General and administrative	87,806			250			—			2,895			—				90,951
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Total costs and expenses	96,923			1,842,801			498,211			1,049,644			—				3,487,579
Income (loss) from operations	(96,923		)	229,436			72,707			123,776			—				328,996
Other income and expense:
Intercompany interest and royalty fees	22,029			(10,502		)	(10,685		)	(842		)	—				—
Intercompany management fees	166,749			(132,733		)	(34,016		)	—			—				—
Loss on early retirement of debt	(2,229		)	—			—			(8,026		)	—				(10,255		)
Equity in earnings of unconsolidated subsidiaries	—			14,884			30			—			—				14,914
Non-operating gain	1,654			7,362			—			—			—				9,016
Interest income (expense)	(89,416		)	220			(544		)	(58,251		)	—				(147,991		)
Income before income taxes	1,864			108,667			27,492			56,657			—				194,680
Income tax expense (benefit)	(83		)	36,112			350			11,081			—				47,460
Equity in earnings of consolidated subsidiaries	111,220			17,984			—			—			(129,204		)	(a)	—
Net income	113,167			90,539			27,142			45,576			(129,204		)		147,220
Less: Net income attributable to non-controlling interests	—			97			9,158			24,798			—				34,053
Net income attributable to Select Medical Corporation	$	113,167		$	90,442		$	17,984		$	20,778		$	(129,204	)		$	113,167

 _______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	113,167		$	90,539		$	27,142		$	45,576		$	(129,204	)	(a)	$	147,220
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	—			10,700			34			—			—				10,734
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Provision for bad debts	—			(451		)	—			78			—				(373		)
Equity in earnings of unconsolidated subsidiaries	—			(14,884		)	(30		)	—			—				(14,914		)
Equity in earnings of consolidated subsidiaries	(111,220		)	(17,984		)	—			—			129,204			(a)	—
Loss on extinguishment of debt	115			—			—			369			—				484
Loss (gain) on sale of assets and businesses	(1,641		)	(7,493		)	5			—			—				(9,129		)
Stock compensation expense	15,059			—			—			2,116			—				17,175
Amortization of debt discount, premium and issuance costs	4,435			—			—			5,410			—				9,845
Deferred income taxes	1,804			2,527			103			(6,526		)	—				(2,092		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			37,490			(894		)	(13,101		)	—				23,495
Other current assets	(2,420		)	(2,100		)	(1,807		)	(3,947		)	—				(10,274		)
Other assets	(4,381		)	(8,576		)	1,604			16,181			—				4,828
Accounts payable	(42		)	(5,155		)	3,059			(1,369		)	—				(3,507		)
Accrued expenses	20,379			13,620			6,412			8,980			—				49,391
Income taxes	9,622			4,401			1			(4,952		)	—				9,072
Net cash provided by operating activities	51,654			162,342			47,834			119,147			—				380,977
Investing activities
Business combinations, net of cash acquired	—			(2,666		)	(22		)	(516,570		)	—				(519,258		)
Purchases of property and equipment	(6,412		)	(60,669		)	(24,677		)	(29,281		)	—				(121,039		)
Investment in businesses	—			(12,931		)	—			(5		)	—				(12,936		)
Proceeds from sale of assets and businesses	1,654			5,029			8			—			—				6,691
Net cash used in investing activities	(4,758		)	(71,237		)	(24,691		)	(545,856		)	—				(646,542		)
Financing activities
Borrowings on revolving facilities	420,000			—			—			—			—				420,000
Payments on revolving facilities	(585,000		)	—			—			—			—				(585,000		)
Proceeds from term loans (financing costs)	(11		)	—			—			779,915			—				779,904
Payments on term loans	(8,625		)	—			—			—			—				(8,625		)
Revolving facility debt issuance costs	(837		)	—			—			(496		)	—				(1,333		)
Borrowings of other debt	5,542			—			19,935			4,657			—				30,134
Principal payments on other debt	(8,455		)	(540		)	(4,504		)	(4,472		)	—				(17,971		)
Dividends paid to Holdings	(5,640		)	—			—			—			—				(5,640		)
Equity investment by Holdings	1,633			—			—			—			—				1,633
Intercompany	140,673			(88,344		)	(34,184		)	(18,145		)	—				—
Decrease in overdrafts	(6,172		)	—			—			—			—				(6,172		)
Proceeds from issuance of non-controlling interests	—			—			957			1,969			—				2,926
Distributions to non-controlling interests	—			(1,450		)	(6,863		)	(298,114		)	—				(306,427		)
Net cash provided by (used in) financing activities	(46,892		)	(90,334		)	(24,659		)	465,314			—				303,429
Net increase (decrease) in cash and cash equivalents	4			771			(1,516		)	38,605			—				37,864
Cash and cash equivalents at beginning of period	73			4,856			4,561			113,059			—				122,549
Cash and cash equivalents at end of period	$	77		$	5,627		$	3,045		$	151,664		$	—			$	160,413

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	73		$	4,856	$	4,561		$	113,059	$	—			$	122,549
Accounts receivable	—			449,493		122,728			119,511		—				691,732
Intercompany receivables	—			1,598,212		60,707			—		(1,658,919		)	(a)	—
Prepaid income taxes	22,704			5,703		31			2,949		—				31,387
Other current assets	13,021			30,209		13,031			18,897		—				75,158
Total Current Assets	35,798			2,088,473		201,058			254,416		(1,658,919		)		920,826
Property and equipment, net	39,836			623,085		79,013			170,657		—				912,591
Investment in affiliates	4,524,385			124,104		—			—		(4,648,489		)	(b)(c)	—
Goodwill	—			2,108,270		—			674,542		—				2,782,812
Identifiable intangible assets, net	—			104,067		5,046			217,406		—				326,519
Other assets	36,494			98,575		35,440			23,898		(9,989		)	(e)	184,418
Total Assets	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166
Liabilities and Equity
Current Liabilities:
Overdrafts	$	29,463		$	—	$	—		$	—	$	—			$	29,463
Current portion of long-term debt and notes payable	16,635			740		2,212			2,600		—				22,187
Accounts payable	12,504			85,489		17,475			12,726		—				128,194
Intercompany payables	1,598,212			60,707		—			—		(1,658,919		)	(a)	—
Accrued payroll	16,736			98,887		4,819			40,120		—				160,562
Accrued vacation	4,083			58,355		12,295			18,142		—				92,875
Accrued interest	17,479			7		6			2,393		—				19,885
Accrued other	39,219			57,378		12,599			33,970		—				143,166
Income taxes payable	—			1,302		30			7,739		—				9,071
Total Current Liabilities	1,734,331			362,865		49,436			117,690		(1,658,919		)		605,403
Long-term debt, net of current portion	2,042,555			127		24,730			610,303		—				2,677,715
Non-current deferred tax liability	—			88,376		780			45,750		(9,989		)	(e)	124,917
Other non-current liabilities	36,259			56,721		8,138			44,591		—				145,709
Total Liabilities	3,813,145			508,089		83,084			818,334		(1,668,908		)		3,553,744
Redeemable non-controlling interests	—			—		—			16,270		624,548			(d)	640,818
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	947,370			—		—			—		—				947,370
Retained earnings (accumulated deficit)	(124,002		)	1,416,857		(35,942		)	64,626		(1,445,541		)	(c)(d)	(124,002		)
Subsidiary investment	—			3,221,628		273,415			437,779		(3,932,822		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	823,368			4,638,485		237,473			502,405		(5,378,363		)		823,368
Non-controlling interests	—			—		—			3,910		105,326			(d)	109,236
Total Equity	823,368			4,638,485		237,473			506,315		(5,273,037		)		932,604
Total Liabilities and Equity	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	56		$	654,964		$	166,113		$	255,881		$	—			$	1,077,014
Costs and expenses:
Cost of services	667			574,250			148,072			216,090			—				939,079
General and administrative	27,028			37			—			—			—				27,065
Depreciation and amortization	2,355			18,015			3,388			15,014			—				38,772
Total costs and expenses	30,050			592,302			151,460			231,104			—				1,004,916
Income (loss) from operations	(29,994		)	62,662			14,653			24,777			—				72,098
Other income and expense:
Intercompany interest and royalty fees	7,865			(4,328		)	(3,537		)	—			—				—
Intercompany management fees	51,241			(41,031		)	(10,210		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			4,416			15			—			—				4,431
Interest income (expense)	(30,240		)	271			(20		)	(7,699		)	—				(37,688		)
Income before income taxes	(1,128		)	21,990			901			17,078			—				38,841
Income tax expense (benefit)	(1,032		)	8,562			145			6,342			—				14,017
Equity in earnings of consolidated subsidiaries	18,558			397			—			—			(18,955		)	(a)	—
Net income	18,462			13,825			756			10,736			(18,955		)		24,824
Less: Net income attributable to non-controlling interests	—			24			359			5,979			—				6,362
Net income attributable to Select Medical Corporation	$	18,462		$	13,801		$	397		$	4,757		$	(18,955	)		$	18,462

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	687		$	2,019,581		$	487,371		$	763,357		$	—			$	3,270,996
Costs and expenses:
Cost of services	1,843			1,725,060			423,025			638,483			—				2,788,411
General and administrative	83,291			124			—			—			—				83,415
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Total costs and expenses	90,637			1,782,752			433,032			685,049			—				2,991,470
Income (loss) from operations	(89,950		)	236,829			54,339			78,308			—				279,526
Other income and expense:
Intercompany interest and royalty fees	24,760			(14,029		)	(10,731		)	—			—				—
Intercompany management fees	176,443			(147,042		)	(29,401		)	—			—				—
Loss on early retirement of debt	(19,719		)	—			—			—			—				(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			15,555			63			—			—				15,618
Non-operating loss	—			(49		)	—			—			—				(49		)
Interest income (expense)	(93,725		)	270			(105		)	(22,636		)	—				(116,196		)
Income (loss) before income taxes	(2,191		)	91,534			14,165			55,672			—				159,180
Income tax expense (benefit)	(3,230		)	42,135			428			20,260			—				59,593
Equity in earnings of consolidated subsidiaries	75,348			10,131			—			—			(85,479		)	(a)	—
Net income	76,387			59,530			13,737			35,412			(85,479		)		99,587
Less: Net income attributable to non-controlling interests	—			21			3,606			19,573			—				23,200
Net income attributable to Select Medical Corporation	$	76,387		$	59,509		$	10,131		$	15,839		$	(85,479	)		$	76,387

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	76,387		$	59,530		$	13,737		$	35,412		$	(85,479	)	(a)	$	99,587
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			14,493			49			—			—				14,542
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Provision for bad debts	—			864			—			50			—				914
Equity in earnings of unconsolidated subsidiaries	—			(15,555		)	(63		)	—			—				(15,618		)
Equity in earnings of consolidated subsidiaries	(75,348		)	(10,131		)	—			—			85,479			(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—				6,527
Loss (gain) on sale of assets and businesses	(8		)	(4,824		)	(4,687		)	20			—				(9,499		)
Stock compensation expense	13,445			—			—			782			—				14,227
Amortization of debt discount, premium and issuance costs	6,113			—			—			2,433			—				8,546
Deferred income taxes	5,014			—			—			(11,140		)	—				(6,126		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(105,536		)	(22,820		)	(14,952		)	—				(143,308		)
Other current assets	1,016			3,857			(6,772		)	(778		)	—				(2,677		)
Other assets	1,633			(3,709		)	3,044			439			—				1,407
Accounts payable	2,375			(823		)	1,580			781			—				3,913
Accrued expenses	164			(1,175		)	10,281			9,482			—				18,752
Income taxes	3,776			—			—			15,365			—				19,141
Net cash provided by (used in) operating activities	46,597			(5,441		)	4,356			84,460			—				129,972
Investing activities
Business combinations, net of cash acquired	—			(3,356		)	(295		)	(15,720		)	—				(19,371		)
Purchases of property and equipment	(26,350		)	(102,342		)	(23,452		)	(21,656		)	—				(173,800		)
Investment in businesses	—			(11,374		)	—			—			—				(11,374		)
Proceeds from sale of assets and businesses	8			15,007			19,537			3			—				34,555
Net cash used in investing activities	(26,342		)	(102,065		)	(4,210		)	(37,373		)	—				(169,990		)
Financing activities
Borrowings on revolving facilities	805,000			—			—			—			—				805,000
Payments on revolving facilities	(705,000		)	—			—			—			—				(705,000		)
Proceeds from term loans	1,139,487			—			—			—			—				1,139,487
Payments on term loans	(1,153,502		)	—			—			(23,065		)	—				(1,176,567		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—				(4,392		)
Borrowings of other debt	21,572			—			3,232			2,767			—				27,571
Principal payments on other debt	(10,122		)	(306		)	(2,150		)	(2,534		)	—				(15,112		)
Dividends paid to Holdings	(3,603		)	—			—			—			—				(3,603		)
Equity investment by Holdings	1,634			—			—			—			—				1,634
Intercompany	(101,888		)	107,834			(5,946		)	—			—				—
Decrease in overdrafts	(20,439		)	—			—			—			—				(20,439		)
Proceeds from issuance of non-controlling interests	—			—			8,986			—			—				8,986
Distributions to non-controlling interests	—			(130		)	(4,776		)	(4,370		)	—				(9,276		)
Net cash provided by (used in) financing activities	(31,253		)	107,398			(654		)	(27,202		)	—				48,289
Net increase (decrease) in cash and cash equivalents	(10,998		)	(108		)	(508		)	19,885			—				8,271
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—				99,029
Cash and cash equivalents at end of period	$	73		$	6,359		$	4,548		$	96,320		$	—			$	107,300

_______________________________________________________________________________

(a) 

Elimination of equity in earnings of consolidated subsidiaries.

XML

Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Use of Estimates

Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent and Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements

Lease Accounting

Beginning in February 2016, the Financial Accounting Standards Board (the “FASB”) issued several Accounting Standards Updates (“ASU”) which established Topic 842, Leases (the “standard”). This standard includes a lessee accounting model that recognizes two types of leases: finance and operating. This standard requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in the standard will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. There are two transition approaches available under the standard: a modified retrospective approach for leases that exist, or are entered into, after the beginning of the earliest comparative period in the financial statements or a cumulative-effect approach with an adjustment to the opening balance of retained earnings in the period of adoption.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019, using the cumulative-effect approach, without adjusting the comparative periods. The Company has completed its inventory of leases and has begun to implement a new technology platform to account for leases under the new standard.  The Company has substantially completed validating its lease data to ensure it is complete and accurate. The Company’s remaining implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

Cloud Computing Arrangements

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective for interim and annual reporting periods beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the impacts that adoption of this ASU will have on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

Revenue from Contracts with Customers

Beginning in May 2014, the FASB issued several ASUs which established Topic 606, Revenue from Contracts with Customers (the “revenue recognition standard”). This revenue recognition standard supersedes existing revenue recognition requirements and seeks to eliminate most industry-specific guidance under current GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company adopted the new revenue recognition standard on January 1, 2018, using the full retrospective transition method. Adoption of the revenue recognition standard impacted the Company’s reported results as follows:

	Three Months Ended September 30, 2017
	As Reported		As Adjusted(1)		Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	1,097,166	$	1,077,014	$	(20,152	)
Bad debt expense	20,321		169		(20,152		)

	Nine Months Ended September 30, 2017
	As Reported			As Adjusted(1)			Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	3,329,202		$	3,270,996		$	(58,206	)
Bad debt expense	59,120			914			(58,206		)
Condensed Consolidated Statements of Cash Flows
Provision for bad debts	$	59,120		$	914		$	(58,206	)
Changes in accounts receivable	(201,514		)	(143,308		)	58,206

 _____________________________________________________________

(1) Bad debt expense is now included in cost of services on the condensed consolidated statements of operations.

	December 31, 2017
	As Reported		As Adjusted		Adoption Impact
	(in thousands)
Condensed Consolidated Balance Sheets
Accounts receivable	$	767,276	$	691,732	$	(75,544	)
Allowance for doubtful accounts	75,544		—		(75,544		)
Accounts receivable	$	691,732	$	691,732	$	—

The Company has presented the applicable disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers in Note 7.

Income Taxes

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), and Intra-Entity Transfers of Assets Other Than Inventory. Previous GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra‑entity transfer of an asset other than inventory when the transfer occurs. The Company adopted the guidance effective January 1, 2018. Adoption of the guidance did not have a material impact on the Company’s consolidated financial statements.

XML

Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of effects on financial statement lines for adoption of new standard

The Company adopted the new revenue recognition standard on January 1, 2018, using the full retrospective transition method. Adoption of the revenue recognition standard impacted the Company’s reported results as follows:

	Three Months Ended September 30, 2017
	As Reported		As Adjusted(1)		Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	1,097,166	$	1,077,014	$	(20,152	)
Bad debt expense	20,321		169		(20,152		)

	Nine Months Ended September 30, 2017
	As Reported			As Adjusted(1)			Adoption Impact
	(in thousands)
Condensed Consolidated Statements of Operations
Net operating revenues	$	3,329,202		$	3,270,996		$	(58,206	)
Bad debt expense	59,120			914			(58,206		)
Condensed Consolidated Statements of Cash Flows
Provision for bad debts	$	59,120		$	914		$	(58,206	)
Changes in accounts receivable	(201,514		)	(143,308		)	58,206

 _____________________________________________________________

(1) Bad debt expense is now included in cost of services on the condensed consolidated statements of operations.

	December 31, 2017
	As Reported		As Adjusted		Adoption Impact
	(in thousands)
Condensed Consolidated Balance Sheets
Accounts receivable	$	767,276	$	691,732	$	(75,544	)
Allowance for doubtful accounts	75,544		—		(75,544		)
Accounts receivable	$	691,732	$	691,732	$	—

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Schedule of reconciliation of preliminary allocation of fair value to identifiable net assets and goodwill acquired to the consideration given for the acquired business

The following table reconciles the preliminary allocation of estimated fair value to identifiable net assets and goodwill to the consideration given for the acquired business (in thousands):

Identifiable tangible assets	$	184,163
Identifiable intangible assets	140,406
Goodwill	533,124
Total assets	857,693
Total liabilities	104,693
Consideration given	$	753,000

Schedule of finite-lived intangible assets acquired as part of business combination

	Fair Value		Weighted Average Amortization Period
	(in thousands)		(in years)
Customer relationships	$	135,000	15.0 years
Trademarks	5,000		1.0 year
Favorable leasehold interests	406		2.9 years
Identifiable intangible assets	$	140,406

Schedule of pro forma unaudited results of operations

The following pro forma unaudited results of operations have been prepared assuming the acquisition of U.S. HealthWorks occurred on January 1, 2017. These results are not necessarily indicative of results of future operations nor of the results that would have occurred had the acquisition been consummated on the aforementioned date.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Net revenue	$	1,215,869	$	1,267,401	$	3,687,574	$	3,864,155
Net income	21,929		45,721		85,317		153,144
Net income attributable to the Company	17,011		34,441		69,237		116,135
Income per common share:
Basic	$	0.13	$	0.26	$	0.52	$	0.86
Diluted	$	0.13	$	0.26	$	0.52	$	0.86

XML

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of carrying amount of goodwill

The following table shows changes in the carrying amounts of goodwill by reporting unit for the nine months ended September 30, 2018:

	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation			Concentra			Total
	(in thousands)
Balance as of December 31, 2017	$	1,045,220	$	415,528	$	647,522		$	674,542		$	2,782,812
Acquired	—		1,118		2,465			536,945			540,528
Measurement period adjustment	—		—		—			(2,472		)	(2,472		)
Sold	—		—		(9,409		)	—			(9,409		)
Balance as of September 30, 2018	$	1,045,220	$	416,646	$	640,578		$	1,209,015		$	3,311,459

_______________________________________________________________________________

(1)

The critical illness recovery hospital reporting unit was previously referred to as the long term acute care reporting unit. The rehabilitation hospital reporting unit was previously referred to as the inpatient rehabilitation reporting unit.

Schedule of carrying value and amortization of identifiable intangible assets

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company’s identifiable intangible assets:

	December 31, 2017							September 30, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived intangible assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	19,155		—			19,155		19,118		—			19,118
Accreditations	1,895		—			1,895		1,857		—			1,857
Finite-lived intangible assets:
Trademarks	—		—			—		5,000		(3,333		)	1,667
Customer relationships	143,953		(38,281		)	105,672		279,967		(55,760		)	224,207
Favorable leasehold interests	13,295		(4,319		)	8,976		13,553		(5,653		)	7,900
Non-compete agreements	28,023		(3,900		)	24,123		28,953		(5,553		)	23,400
Total identifiable intangible assets	$	373,019	$	(46,500	)	$	326,519	$	515,146	$	(70,299	)	$	444,847

Schedule of amortization expense for customer relationships, non-compete agreements, and trademarks

Estimated amortization expense for the Company’s finite-lived customer relationships, non-compete agreements, and trademarks for the remaining period of 2018 and each of the four succeeding years is as follows:

	2018		2019		2020		2021		2022
	(in thousands)
Amortization expense	$	7,811	$	26,490	$	25,864	$	25,648	$	25,443

XML

Long-Term Debt and Notes Payable (Tables)

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Company's long-term debt and notes payable

As of December 31, 2017, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	778		$	(6,553	)	$	704,225	$	727,750
Credit facilities:
Revolving facility	230,000		—			—			230,000		211,600
Term loans	1,141,375		(12,445		)	(12,500		)	1,116,430		1,154,215
Other	36,877		—			(533		)	36,344		36,344
Total Select debt	2,118,252		(11,667		)	(19,586		)	2,086,999		2,129,909
Concentra:
Credit facilities:
Term loans	619,175		(2,257		)	(10,668		)	606,250		625,173
Other	6,653		—			—			6,653		6,653
Total Concentra debt	625,828		(2,257		)	(10,668		)	612,903		631,826
Total debt	$	2,744,080	$	(13,924	)	$	(30,254	)	$	2,699,902	$	2,761,735

As of September 30, 2018, the Company’s long-term debt and notes payable are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	607		$	(5,122	)	$	705,485	$	718,875
Credit facilities:
Revolving facility	65,000		—			—			65,000		59,800
Term loans	1,132,750		(11,000		)	(11,058		)	1,110,692		1,139,830
Other	49,004		—			(508		)	48,496		48,496
Total Select debt	1,956,754		(10,393		)	(16,688		)	1,929,673		1,967,001
Concentra:
Credit facilities:
Term loans	1,414,175		(3,078		)	(20,417		)	1,390,680		1,427,181
Other	9,355		—			—			9,355		9,355
Total Concentra debt	1,423,530		(3,078		)	(20,417		)	1,400,035		1,436,536
Total debt	$	3,380,284	$	(13,471	)	$	(37,105	)	$	3,329,708	$	3,403,537

Schedule of principal maturities of the Company's long-term debt and notes payable

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2018		2019		2020		2021		2022		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	710,000	$	—	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		65,000		—		65,000
Term loans	2,875		11,500		11,500		11,500		11,500		1,083,875		1,132,750
Other	3,992		5,391		24,285		221		—		15,115		49,004
Total Select debt	6,867		16,891		35,785		721,721		76,500		1,098,990		1,956,754
Concentra:
Credit facilities:
Term loans	—		—		5,719		12,365		1,156,091		240,000		1,414,175
Other	1,341		3,625		346		346		324		3,373		9,355
Total Concentra debt	1,341		3,625		6,065		12,711		1,156,415		243,373		1,423,530
Total debt	$	8,208	$	20,516	$	41,850	$	734,432	$	1,232,915	$	1,342,363	$	3,380,284

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Schedule of selected financial data for the Company's reportable segments

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2018			2017			2018
	(in thousands)
Net operating revenues:(1)
Critical illness recovery hospital(2)	$	416,934		$	420,108		$	1,301,251		$	1,327,236
Rehabilitation hospital(2)	157,499			176,885			453,702			525,428
Outpatient rehabilitation	246,644			265,927			751,999			790,491
Concentra	255,881			404,481			763,357			1,173,420
Other	56			—			687			—
Total Company	$	1,077,014		$	1,267,401		$	3,270,996		$	3,816,575
Adjusted EBITDA:
Critical illness recovery hospital(2)	$	46,873		$	53,292		$	194,253		$	186,989
Rehabilitation hospital(2)	22,581			25,343			62,038			80,314
Outpatient rehabilitation	29,298			34,531			102,575			107,003
Concentra	40,003			68,754			125,656			199,119
Other	(22,928		)	(25,292		)	(71,125		)	(75,337		)
Total Company	$	115,827		$	156,628		$	413,397		$	498,088
Total assets:
Critical illness recovery hospital(2)	$	2,008,485		$	1,785,336		$	2,008,485		$	1,785,336
Rehabilitation hospital(2)	740,276			888,342			740,276			888,342
Outpatient rehabilitation	945,765			991,105			945,765			991,105
Concentra	1,332,012			2,201,869			1,332,012			2,201,869
Other	97,269			113,529			97,269			113,529
Total Company	$	5,123,807		$	5,980,181		$	5,123,807		$	5,980,181
Purchases of property and equipment, net:
Critical illness recovery hospital(2)	$	8,003		$	8,134		$	28,717		$	31,455
Rehabilitation hospital(2)	29,373			8,769			77,707			29,766
Outpatient rehabilitation	6,496			7,209			19,370			22,565
Concentra	5,369			12,539			21,656			29,281
Other	19,257			2,740			26,350			7,972
Total Company	$	68,498		$	39,391		$	173,800		$	121,039

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	46,873		$	22,581		$	29,298		$	40,003		$	(22,928	)
Depreciation and amortization	(10,932		)	(4,505		)	(5,964		)	(15,014		)	(2,357		)
Stock compensation expense	—			—			—			(212		)	(4,745		)
Income (loss) from operations	$	35,941		$	18,076		$	23,334		$	24,777		$	(30,030	)	$	72,098
Equity in earnings of unconsolidated subsidiaries																4,431
Interest expense																(37,688		)
Income before income taxes																$	38,841

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	53,292		$	25,343		$	34,531		$	68,754		$	(25,292	)
Depreciation and amortization	(11,136		)	(6,079		)	(6,597		)	(24,488		)	(2,227		)
Stock compensation expense	—			—			—			(767		)	(5,497		)
Income (loss) from operations	$	42,156		$	19,264		$	27,934		$	43,499		$	(33,016	)	$	99,837
Equity in earnings of unconsolidated subsidiaries																5,432
Non-operating gain																2,139
Interest expense																(50,669		)
Income before income taxes																$	56,739

 

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	194,253		$	62,038		$	102,575		$	125,656		$	(71,125	)
Depreciation and amortization	(34,891		)	(14,500		)	(18,182		)	(46,566		)	(5,505		)
Stock compensation expense	—			—			—			(782		)	(13,445		)
Income (loss) from operations	$	159,362		$	47,538		$	84,393		$	78,308		$	(90,075	)	$	279,526
Loss on early retirement of debt																(19,719		)
Equity in earnings of unconsolidated subsidiaries																15,618
Non-operating loss																(49		)
Interest expense																(116,196		)
Income before income taxes																$	159,180

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(2)			Rehabilitation Hospital(2)			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,989		$	80,314		$	107,003		$	199,119		$	(75,337	)
Depreciation and amortization	(34,146		)	(17,816		)	(19,938		)	(70,332		)	(6,790		)
Stock compensation expense	—			—			—			(2,116		)	(15,059		)
U.S. HealthWorks acquisition costs	—			—			—			(2,895		)	—
Income (loss) from operations	$	152,843		$	62,498		$	87,065		$	123,776		$	(97,186	)	$	328,996
Loss on early retirement of debt																(10,255		)
Equity in earnings of unconsolidated subsidiaries																14,914
Non-operating gain																9,016
Interest expense																(147,991		)
Income before income taxes																$	194,680

_______________________________________________________________________________

(1) Net operating revenues were retrospectively conformed to reflect the adoption Topic 606, Revenue from Contracts with Customers.

(2)

The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

XML

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of net operating revenues by operating segment

The following tables disaggregate the Company’s net operating revenues by operating segment for the three and nine months ended September 30, 2017 and 2018:

	Three Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	217,116	$	64,227	$	36,821	$	472
Non-Medicare	195,872		53,054		179,171		253,437
Total patient services revenues	412,988		117,281		215,992		253,909
Other revenues	3,946		40,218		30,652		1,972
Total net operating revenues	$	416,934	$	157,499	$	246,644	$	255,881

	Three Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	210,101	$	71,564	$	40,563	$	455
Non-Medicare	206,629		64,322		185,787		401,537
Total patient services revenues	416,730		135,886		226,350		401,992
Other revenues	3,378		40,999		39,577		2,489
Total net operating revenues	$	420,108	$	176,885	$	265,927	$	404,481

	Nine Months Ended September 30, 2017
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	682,286	$	183,820	$	111,638	$	1,588
Non-Medicare	610,372		151,731		551,983		755,345
Total patient services revenues	1,292,658		335,551		663,621		756,933
Other revenues	8,593		118,151		88,378		6,424
Total net operating revenues	$	1,301,251	$	453,702	$	751,999	$	763,357

	Nine Months Ended September 30, 2018
	Critical Illness Recovery Hospital(1)		Rehabilitation Hospital(1)		Outpatient Rehabilitation		Concentra
	(in thousands)
Patient service revenues:
Medicare	$	676,950	$	217,459	$	120,228	$	1,600
Non-Medicare	639,718		188,611		569,298		1,164,711
Total patient services revenues	1,316,668		406,070		689,526		1,166,311
Other revenues	10,568		119,358		100,965		7,109
Total net operating revenues	$	1,327,236	$	525,428	$	790,491	$	1,173,420

_______________________________________________________________________________

(1)

The critical illness recovery hospital segment was previously referred to as the long term acute care segment. The rehabilitation hospital segment was previously referred to as the inpatient rehabilitation segment.

XML

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Schedule of reconciliations of the statutory federal income tax rate to the effective income tax rate

Reconciliations of the statutory federal income tax rate to the effective income tax rate are as follows:

	Three Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	4.0		5.0
Permanent differences	0.8		2.7
Valuation allowance	0.1		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.6	)	(1.0	)
Stock-based compensation	(2.3	)	(2.7	)
Other	(0.1	)	(0.3	)
Total effective income tax rate	36.1	%	24.8	%

	Nine Months Ended September 30,
	2017		2018
Federal income tax at statutory rate	35.0	%	21.0	%
State and local income taxes, less federal income tax benefit	3.8		4.7
Permanent differences	1.1		2.1
Valuation allowance	0.2		(0.1	)
Uncertain tax positions	0.2		0.2
Non-controlling interest	(1.8	)	(1.8	)
Stock-based compensation	(0.9	)	(2.6	)
Other	(0.2	)	0.9
Total effective income tax rate	37.4	%	24.4	%

XML

Income per Common Share (Tables)

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted earnings per share

The following table sets forth the calculation of income per share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2018		2017		2018
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	18,462	$	32,917	$	76,387	$	113,167
Less: Earnings allocated to unvested restricted stockholders	608		1,098		2,464		3,732
Net income available to common stockholders	$	17,854	$	31,819	$	73,923	$	109,435
Denominator:
Weighted average shares—basic	129,142		130,387		128,745		129,972
Effect of dilutive securities:
Stock options	180		60		171		94
Weighted average shares—diluted	129,322		130,447		128,916		130,066
Basic income per common share:	$	0.14	$	0.24	$	0.57	$	0.84
Diluted income per common share:	$	0.14	$	0.24	$	0.57	$	0.84

XML

Condensed Consolidating Financial Information (Tables) - Select Medical Corporation

9 Months Ended

Sep. 30, 2018

Condensed Financial Statements, Captions [Line Items]

Schedule of Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

December 31, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	73		$	4,856	$	4,561		$	113,059	$	—			$	122,549
Accounts receivable	—			449,493		122,728			119,511		—				691,732
Intercompany receivables	—			1,598,212		60,707			—		(1,658,919		)	(a)	—
Prepaid income taxes	22,704			5,703		31			2,949		—				31,387
Other current assets	13,021			30,209		13,031			18,897		—				75,158
Total Current Assets	35,798			2,088,473		201,058			254,416		(1,658,919		)		920,826
Property and equipment, net	39,836			623,085		79,013			170,657		—				912,591
Investment in affiliates	4,524,385			124,104		—			—		(4,648,489		)	(b)(c)	—
Goodwill	—			2,108,270		—			674,542		—				2,782,812
Identifiable intangible assets, net	—			104,067		5,046			217,406		—				326,519
Other assets	36,494			98,575		35,440			23,898		(9,989		)	(e)	184,418
Total Assets	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166
Liabilities and Equity
Current Liabilities:
Overdrafts	$	29,463		$	—	$	—		$	—	$	—			$	29,463
Current portion of long-term debt and notes payable	16,635			740		2,212			2,600		—				22,187
Accounts payable	12,504			85,489		17,475			12,726		—				128,194
Intercompany payables	1,598,212			60,707		—			—		(1,658,919		)	(a)	—
Accrued payroll	16,736			98,887		4,819			40,120		—				160,562
Accrued vacation	4,083			58,355		12,295			18,142		—				92,875
Accrued interest	17,479			7		6			2,393		—				19,885
Accrued other	39,219			57,378		12,599			33,970		—				143,166
Income taxes payable	—			1,302		30			7,739		—				9,071
Total Current Liabilities	1,734,331			362,865		49,436			117,690		(1,658,919		)		605,403
Long-term debt, net of current portion	2,042,555			127		24,730			610,303		—				2,677,715
Non-current deferred tax liability	—			88,376		780			45,750		(9,989		)	(e)	124,917
Other non-current liabilities	36,259			56,721		8,138			44,591		—				145,709
Total Liabilities	3,813,145			508,089		83,084			818,334		(1,668,908		)		3,553,744
Redeemable non-controlling interests	—			—		—			16,270		624,548			(d)	640,818
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	947,370			—		—			—		—				947,370
Retained earnings (accumulated deficit)	(124,002		)	1,416,857		(35,942		)	64,626		(1,445,541		)	(c)(d)	(124,002		)
Subsidiary investment	—			3,221,628		273,415			437,779		(3,932,822		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	823,368			4,638,485		237,473			502,405		(5,378,363		)		823,368
Non-controlling interests	—			—		—			3,910		105,326			(d)	109,236
Total Equity	823,368			4,638,485		237,473			506,315		(5,273,037		)		932,604
Total Liabilities and Equity	$	4,636,513		$	5,146,574	$	320,557		$	1,340,919	$	(6,317,397	)		$	5,127,166

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Condensed Consolidating Balance Sheet

September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	77		$	5,627	$	3,045		$	151,664	$	—			$	160,413
Accounts receivable	—			412,454		123,622			210,740		—				746,816
Intercompany receivables	—			1,722,475		75,391			—		(1,797,866		)	(a)	—
Prepaid income taxes	16,325			—		—			3,527		—				19,852
Other current assets	15,441			32,281		14,839			33,653		—				96,214
Total Current Assets	31,843			2,172,837		216,897			399,584		(1,797,866		)		1,023,295
Property and equipment, net	36,947			615,299		90,821			222,323		—				965,390
Investment in affiliates	4,448,449			123,809		—			—		(4,572,258		)	(b)(c)	—
Goodwill	—			2,102,444		—			1,209,015		—				3,311,459
Identifiable intangible assets, net	3			102,423		4,972			337,449		—				444,847
Other assets	38,861			137,897		33,902			33,498		(8,968		)	(e)	235,190
Total Assets	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181
Liabilities and Equity
Current Liabilities:
Overdrafts	$	23,291		$	—	$	—		$	—	$	—			$	23,291
Current portion of long-term debt and notes payable	15,508			268		3,631			4,768		—				24,175
Accounts payable	12,183			76,776		19,948			28,633		—				137,540
Intercompany payables	1,722,475			75,391		—			—		(1,797,866		)	(a)	—
Accrued payroll	12,061			95,717		4,935			63,508		—				176,221
Accrued vacation	4,394			58,590		13,584			29,458		—				106,026
Accrued interest	17,775			16		27			5,830		—				23,648
Accrued other	60,190			62,049		16,637			49,203		—				188,079
Income taxes payable	2,764			—		—			3,365		—				6,129
Total Current Liabilities	1,870,641			368,807		58,762			184,765		(1,797,866		)		685,109
Long-term debt, net of current portion	1,871,407			72		38,787			1,395,267		—				3,305,533
Non-current deferred tax liability	—			91,487		882			64,826		(8,968		)	(e)	148,227
Other non-current liabilities	39,463			62,354		8,730			63,623		—				174,170
Total Liabilities	3,781,511			522,720		107,161			1,708,481		(1,806,834		)		4,313,039
Redeemable non-controlling interests	—			—		—			19,402		760,172			(d)	779,574
Stockholders’ Equity:
Common stock	0			—		—			—		—				0
Capital in excess of par	964,683			—		—			—		—				964,683
Retained earnings (accumulated deficit)	(190,091		)	1,506,874		(33,181		)	11,504		(1,485,197		)	(c)(d)	(190,091		)
Subsidiary investment	—			3,225,115		272,612			456,854		(3,954,581		)	(b)(d)	—
Total Select Medical Corporation Stockholders’ Equity	774,592			4,731,989		239,431			468,358		(5,439,778		)		774,592
Non-controlling interests	—			—		—			5,628		107,348			(d)	112,976
Total Equity	774,592			4,731,989		239,431			473,986		(5,332,430		)		887,568
Total Liabilities and Equity	$	4,556,103		$	5,254,709	$	346,592		$	2,201,869	$	(6,379,092	)		$	5,980,181

_______________________________________________________________________________

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclassification of equity attributable to non-controlling interests.

(e)  Reclassification of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Schedule of Condensed Consolidating Statement of Operations

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	56		$	654,964		$	166,113		$	255,881		$	—			$	1,077,014
Costs and expenses:
Cost of services	667			574,250			148,072			216,090			—				939,079
General and administrative	27,028			37			—			—			—				27,065
Depreciation and amortization	2,355			18,015			3,388			15,014			—				38,772
Total costs and expenses	30,050			592,302			151,460			231,104			—				1,004,916
Income (loss) from operations	(29,994		)	62,662			14,653			24,777			—				72,098
Other income and expense:
Intercompany interest and royalty fees	7,865			(4,328		)	(3,537		)	—			—				—
Intercompany management fees	51,241			(41,031		)	(10,210		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			4,416			15			—			—				4,431
Interest income (expense)	(30,240		)	271			(20		)	(7,699		)	—				(37,688		)
Income before income taxes	(1,128		)	21,990			901			17,078			—				38,841
Income tax expense (benefit)	(1,032		)	8,562			145			6,342			—				14,017
Equity in earnings of consolidated subsidiaries	18,558			397			—			—			(18,955		)	(a)	—
Net income	18,462			13,825			756			10,736			(18,955		)		24,824
Less: Net income attributable to non-controlling interests	—			24			359			5,979			—				6,362
Net income attributable to Select Medical Corporation	$	18,462		$	13,801		$	397		$	4,757		$	(18,955	)		$	18,462

_______________________________________________________________________________

(a) 

Elimination of equity in earnings of consolidated subsidiaries.Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	687		$	2,019,581		$	487,371		$	763,357		$	—			$	3,270,996
Costs and expenses:
Cost of services	1,843			1,725,060			423,025			638,483			—				2,788,411
General and administrative	83,291			124			—			—			—				83,415
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Total costs and expenses	90,637			1,782,752			433,032			685,049			—				2,991,470
Income (loss) from operations	(89,950		)	236,829			54,339			78,308			—				279,526
Other income and expense:
Intercompany interest and royalty fees	24,760			(14,029		)	(10,731		)	—			—				—
Intercompany management fees	176,443			(147,042		)	(29,401		)	—			—				—
Loss on early retirement of debt	(19,719		)	—			—			—			—				(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			15,555			63			—			—				15,618
Non-operating loss	—			(49		)	—			—			—				(49		)
Interest income (expense)	(93,725		)	270			(105		)	(22,636		)	—				(116,196		)
Income (loss) before income taxes	(2,191		)	91,534			14,165			55,672			—				159,180
Income tax expense (benefit)	(3,230		)	42,135			428			20,260			—				59,593
Equity in earnings of consolidated subsidiaries	75,348			10,131			—			—			(85,479		)	(a)	—
Net income	76,387			59,530			13,737			35,412			(85,479		)		99,587
Less: Net income attributable to non-controlling interests	—			21			3,606			19,573			—				23,200
Net income attributable to Select Medical Corporation	$	76,387		$	59,509		$	10,131		$	15,839		$	(85,479	)		$	76,387

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	2,072,237		$	570,918		$	1,173,420		$	—			$	3,816,575
Costs and expenses:
Cost of services	2,340			1,782,843			486,006			976,417			—				3,247,606
General and administrative	87,806			250			—			2,895			—				90,951
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Total costs and expenses	96,923			1,842,801			498,211			1,049,644			—				3,487,579
Income (loss) from operations	(96,923		)	229,436			72,707			123,776			—				328,996
Other income and expense:
Intercompany interest and royalty fees	22,029			(10,502		)	(10,685		)	(842		)	—				—
Intercompany management fees	166,749			(132,733		)	(34,016		)	—			—				—
Loss on early retirement of debt	(2,229		)	—			—			(8,026		)	—				(10,255		)
Equity in earnings of unconsolidated subsidiaries	—			14,884			30			—			—				14,914
Non-operating gain	1,654			7,362			—			—			—				9,016
Interest income (expense)	(89,416		)	220			(544		)	(58,251		)	—				(147,991		)
Income before income taxes	1,864			108,667			27,492			56,657			—				194,680
Income tax expense (benefit)	(83		)	36,112			350			11,081			—				47,460
Equity in earnings of consolidated subsidiaries	111,220			17,984			—			—			(129,204		)	(a)	—
Net income	113,167			90,539			27,142			45,576			(129,204		)		147,220
Less: Net income attributable to non-controlling interests	—			97			9,158			24,798			—				34,053
Net income attributable to Select Medical Corporation	$	113,167		$	90,442		$	17,984		$	20,778		$	(129,204	)		$	113,167

 _______________________________________________________________________________

(a) 

Elimination of equity in earnings of consolidated subsidiaries.Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	—		$	675,059		$	187,861		$	404,481		$	—			$	1,267,401
Costs and expenses:
Cost of services	815			585,110			164,643			336,494			—				1,087,062
General and administrative	29,791			184			—			—			—				29,975
Depreciation and amortization	2,215			19,726			4,098			24,488			—				50,527
Total costs and expenses	32,821			605,020			168,741			360,982			—				1,167,564
Income (loss) from operations	(32,821		)	70,039			19,120			43,499			—				99,837
Other income and expense:
Intercompany interest and royalty fees	6,357			(2,578		)	(3,445		)	(334		)	—				—
Intercompany management fees	50,601			(39,262		)	(11,339		)	—			—				—
Equity in earnings of unconsolidated subsidiaries	—			5,424			8			—			—				5,432
Non-operating gain	—			2,139			—			—			—				2,139
Interest income (expense)	(28,933		)	99			(207		)	(21,628		)	—				(50,669		)
Income (loss) before income taxes	(4,796		)	35,861			4,137			21,537			—				56,739
Income tax expense (benefit)	(1,428		)	9,923			112			5,453			—				14,060
Equity in earnings of consolidated subsidiaries	36,285			2,861			—			—			(39,146		)	(a)	—
Net income	32,917			28,799			4,025			16,084			(39,146		)		42,679
Less: Net income attributable to non-controlling interests	—			—			1,164			8,598			—				9,762
Net income attributable to Select Medical Corporation	$	32,917		$	28,799		$	2,861		$	7,486		$	(39,146	)		$	32,917

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Schedule of Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2017

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	76,387		$	59,530		$	13,737		$	35,412		$	(85,479	)	(a)	$	99,587
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			14,493			49			—			—				14,542
Depreciation and amortization	5,503			57,568			10,007			46,566			—				119,644
Provision for bad debts	—			864			—			50			—				914
Equity in earnings of unconsolidated subsidiaries	—			(15,555		)	(63		)	—			—				(15,618		)
Equity in earnings of consolidated subsidiaries	(75,348		)	(10,131		)	—			—			85,479			(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—				6,527
Loss (gain) on sale of assets and businesses	(8		)	(4,824		)	(4,687		)	20			—				(9,499		)
Stock compensation expense	13,445			—			—			782			—				14,227
Amortization of debt discount, premium and issuance costs	6,113			—			—			2,433			—				8,546
Deferred income taxes	5,014			—			—			(11,140		)	—				(6,126		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(105,536		)	(22,820		)	(14,952		)	—				(143,308		)
Other current assets	1,016			3,857			(6,772		)	(778		)	—				(2,677		)
Other assets	1,633			(3,709		)	3,044			439			—				1,407
Accounts payable	2,375			(823		)	1,580			781			—				3,913
Accrued expenses	164			(1,175		)	10,281			9,482			—				18,752
Income taxes	3,776			—			—			15,365			—				19,141
Net cash provided by (used in) operating activities	46,597			(5,441		)	4,356			84,460			—				129,972
Investing activities
Business combinations, net of cash acquired	—			(3,356		)	(295		)	(15,720		)	—				(19,371		)
Purchases of property and equipment	(26,350		)	(102,342		)	(23,452		)	(21,656		)	—				(173,800		)
Investment in businesses	—			(11,374		)	—			—			—				(11,374		)
Proceeds from sale of assets and businesses	8			15,007			19,537			3			—				34,555
Net cash used in investing activities	(26,342		)	(102,065		)	(4,210		)	(37,373		)	—				(169,990		)
Financing activities
Borrowings on revolving facilities	805,000			—			—			—			—				805,000
Payments on revolving facilities	(705,000		)	—			—			—			—				(705,000		)
Proceeds from term loans	1,139,487			—			—			—			—				1,139,487
Payments on term loans	(1,153,502		)	—			—			(23,065		)	—				(1,176,567		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—				(4,392		)
Borrowings of other debt	21,572			—			3,232			2,767			—				27,571
Principal payments on other debt	(10,122		)	(306		)	(2,150		)	(2,534		)	—				(15,112		)
Dividends paid to Holdings	(3,603		)	—			—			—			—				(3,603		)
Equity investment by Holdings	1,634			—			—			—			—				1,634
Intercompany	(101,888		)	107,834			(5,946		)	—			—				—
Decrease in overdrafts	(20,439		)	—			—			—			—				(20,439		)
Proceeds from issuance of non-controlling interests	—			—			8,986			—			—				8,986
Distributions to non-controlling interests	—			(130		)	(4,776		)	(4,370		)	—				(9,276		)
Net cash provided by (used in) financing activities	(31,253		)	107,398			(654		)	(27,202		)	—				48,289
Net increase (decrease) in cash and cash equivalents	(10,998		)	(108		)	(508		)	19,885			—				8,271
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—				99,029
Cash and cash equivalents at end of period	$	73		$	6,359		$	4,548		$	96,320		$	—			$	107,300

_______________________________________________________________________________

(a) 

Elimination of equity in earnings of consolidated subsidiaries.Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2018

(unaudited)

	Select  (Parent Company  Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Consolidating and Eliminating Adjustments				Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	113,167		$	90,539		$	27,142		$	45,576		$	(129,204	)	(a)	$	147,220
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	—			10,700			34			—			—				10,734
Depreciation and amortization	6,777			59,708			12,205			70,332			—				149,022
Provision for bad debts	—			(451		)	—			78			—				(373		)
Equity in earnings of unconsolidated subsidiaries	—			(14,884		)	(30		)	—			—				(14,914		)
Equity in earnings of consolidated subsidiaries	(111,220		)	(17,984		)	—			—			129,204			(a)	—
Loss on extinguishment of debt	115			—			—			369			—				484
Loss (gain) on sale of assets and businesses	(1,641		)	(7,493		)	5			—			—				(9,129		)
Stock compensation expense	15,059			—			—			2,116			—				17,175
Amortization of debt discount, premium and issuance costs	4,435			—			—			5,410			—				9,845
Deferred income taxes	1,804			2,527			103			(6,526		)	—				(2,092		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			37,490			(894		)	(13,101		)	—				23,495
Other current assets	(2,420		)	(2,100		)	(1,807		)	(3,947		)	—				(10,274		)
Other assets	(4,381		)	(8,576		)	1,604			16,181			—				4,828
Accounts payable	(42		)	(5,155		)	3,059			(1,369		)	—				(3,507		)
Accrued expenses	20,379			13,620			6,412			8,980			—				49,391
Income taxes	9,622			4,401			1			(4,952		)	—				9,072
Net cash provided by operating activities	51,654			162,342			47,834			119,147			—				380,977
Investing activities
Business combinations, net of cash acquired	—			(2,666		)	(22		)	(516,570		)	—				(519,258		)
Purchases of property and equipment	(6,412		)	(60,669		)	(24,677		)	(29,281		)	—				(121,039		)
Investment in businesses	—			(12,931		)	—			(5		)	—				(12,936		)
Proceeds from sale of assets and businesses	1,654			5,029			8			—			—				6,691
Net cash used in investing activities	(4,758		)	(71,237		)	(24,691		)	(545,856		)	—				(646,542		)
Financing activities
Borrowings on revolving facilities	420,000			—			—			—			—				420,000
Payments on revolving facilities	(585,000		)	—			—			—			—				(585,000		)
Proceeds from term loans (financing costs)	(11		)	—			—			779,915			—				779,904
Payments on term loans	(8,625		)	—			—			—			—				(8,625		)
Revolving facility debt issuance costs	(837		)	—			—			(496		)	—				(1,333		)
Borrowings of other debt	5,542			—			19,935			4,657			—				30,134
Principal payments on other debt	(8,455		)	(540		)	(4,504		)	(4,472		)	—				(17,971		)
Dividends paid to Holdings	(5,640		)	—			—			—			—				(5,640		)
Equity investment by Holdings	1,633			—			—			—			—				1,633
Intercompany	140,673			(88,344		)	(34,184		)	(18,145		)	—				—
Decrease in overdrafts	(6,172		)	—			—			—			—				(6,172		)
Proceeds from issuance of non-controlling interests	—			—			957			1,969			—				2,926
Distributions to non-controlling interests	—			(1,450		)	(6,863		)	(298,114		)	—				(306,427		)
Net cash provided by (used in) financing activities	(46,892		)	(90,334		)	(24,659		)	465,314			—				303,429
Net increase (decrease) in cash and cash equivalents	4			771			(1,516		)	38,605			—				37,864
Cash and cash equivalents at beginning of period	73			4,856			4,561			113,059			—				122,549
Cash and cash equivalents at end of period	$	77		$	5,627		$	3,045		$	151,664		$	—			$	160,413

_______________________________________________________________________________

(a)  Elimination of equity in earnings of consolidated subsidiaries.

XML

Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net operating revenues	$ 1,267,401	$ 1,077,014	$ 3,816,575	$ 3,270,996
Provision for bad debts		169	(373)	914
Changes in accounts receivable			23,495	(143,308)
Accounts receivable					$ 691,732
Allowance for doubtful accounts					0
Accounts receivable	$ 746,816		$ 746,816		691,732
As Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net operating revenues		1,097,166		3,329,202
Provision for bad debts		20,321		59,120
Changes in accounts receivable				(201,514)
Accounts receivable					767,276
Allowance for doubtful accounts					75,544
Accounts receivable					691,732
Accounting Standards Update 2014-09 | Adoption Impact
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net operating revenues		(20,152)		(58,206)
Provision for bad debts		$ (20,152)		(58,206)
Changes in accounts receivable				$ 58,206
Accounts receivable					(75,544)
Allowance for doubtful accounts					(75,544)
Accounts receivable					$ 0

XML

Acquisitions - U.S. HealthWorks Acquisition (Details) - USD ($) $ in Thousands		3 Months Ended	8 Months Ended	9 Months Ended
	Feb. 01, 2018	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Acquisitions
Non-cash equity exchange for acquisition of U.S. HealthWorks		$ 238,000	$ 238,000	$ 238,000		$ 0
Consideration given for the acquired business
Goodwill		3,311,459	3,311,459	3,311,459	$ 2,782,812
U.S. HealthWorks
Acquisitions
U.S. HealthWorks acquisition costs				$ 2,900
Total consideration (net of cash acquired)	$ 753,000
Estimated value of goodwill, deductible for tax purposes	83,100
Net revenues of acquiree		$ 133,300	$ 362,700
Consideration given for the acquired business
Identifiable tangible assets	184,163
Identifiable intangible assets	140,406
Goodwill	533,124
Total assets	857,693
Total liabilities	104,693
Consideration given	753,000
U.S. HealthWorks | Customer relationships
Consideration given for the acquired business
Identifiable intangible assets	$ 135,000
Identifiable intangible assets
Weighted Average Amortization Period	15 years
U.S. HealthWorks | Trademarks
Consideration given for the acquired business
Identifiable intangible assets	$ 5,000
Identifiable intangible assets
Weighted Average Amortization Period	1 year
U.S. HealthWorks | Favorable leasehold interests
Consideration given for the acquired business
Identifiable intangible assets	$ 406
Identifiable intangible assets
Weighted Average Amortization Period	2 years 10 months 24 days
Concentra Group Holdings Parent, LLC | U.S. HealthWorks
Acquisitions
Equity interest issued (percent)	20.00%
Non-cash equity exchange for acquisition of U.S. HealthWorks	$ 238,000

XML

Acquisitions - Pro Forma Results (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Pro Forma
Pro forma results of operations
Net revenue	$ 1,267,401	$ 1,215,869	$ 3,864,155	$ 3,687,574
Net income	45,721	21,929	153,144	85,317
Net income attributable to the Company	$ 34,441	$ 17,011	$ 116,135	$ 69,237
Basic income per common share (in dollars per share)	$ 0.26	$ 0.13	$ 0.86	$ 0.52
Diluted income per common share (in dollars per share)	$ 0.26	$ 0.13	$ 0.86	$ 0.52
U.S. HealthWorks
Acquisition costs
U.S. HealthWorks acquisition costs			$ 2,900
U.S. HealthWorks | Pro Forma
Acquisition costs
U.S. HealthWorks acquisition costs			$ (2,900)	$ 5,700

XML

Intangible Assets - Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Goodwill
December 31, 2017	$ 2,782,812
Acquired	540,528
Measurement period adjustment	(2,472)
Sold	(9,409)
September 30, 2018	3,311,459
Critical Illness Recovery Hospital
Goodwill
December 31, 2017	1,045,220
Acquired	0
Measurement period adjustment	0
Sold	0
September 30, 2018	1,045,220
Rehabilitation Hospital
Goodwill
December 31, 2017	415,528
Acquired	1,118
Measurement period adjustment	0
Sold	0
September 30, 2018	416,646
Outpatient Rehabilitation
Goodwill
December 31, 2017	647,522
Acquired	2,465
Measurement period adjustment	0
Sold	(9,409)
September 30, 2018	640,578
Concentra
Goodwill
December 31, 2017	674,542
Acquired	536,945
Measurement period adjustment	(2,472)
Sold	0
September 30, 2018	$ 1,209,015

XML

Intangible Assets - Carrying Value and Amortization of Identifiable Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Total identifiable intangible assets, gross carrying amount	$ 515,146		$ 515,146		$ 373,019
Finite-lived intangible assets, accumulated amortization	(70,299)		(70,299)		(46,500)
Total identifiable intangible assets, net carrying amount	444,847		444,847		326,519
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Finite-lived intangible assets, gross carrying amount	5,000		5,000		0
Finite-lived intangible assets, accumulated amortization	(3,333)		(3,333)		0
Finite-lived intangible assets, net carrying amount	1,667		1,667		0
Customer relationships
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Finite-lived intangible assets, gross carrying amount	279,967		279,967		143,953
Finite-lived intangible assets, accumulated amortization	(55,760)		(55,760)		(38,281)
Finite-lived intangible assets, net carrying amount	224,207		224,207		105,672
Favorable leasehold interests
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Finite-lived intangible assets, gross carrying amount	13,553		13,553		13,295
Finite-lived intangible assets, accumulated amortization	(5,653)		(5,653)		(4,319)
Finite-lived intangible assets, net carrying amount	7,900		7,900		8,976
Non-compete agreements
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Finite-lived intangible assets, gross carrying amount	28,953		28,953		28,023
Finite-lived intangible assets, accumulated amortization	(5,553)		(5,553)		(3,900)
Finite-lived intangible assets, net carrying amount	23,400		23,400		24,123
Customer relationships, non-compete agreements, and trademarks
Amortized intangible assets:
Amortization expense	7,900	$ 4,400	22,100	$ 13,100
Estimated amortization expense
2018	7,811		7,811
2019	26,490		26,490
2020	25,864		25,864
2021	25,648		25,648
2022	25,443		25,443
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite-lived intangible assets, carrying amount	166,698		$ 166,698		166,698
Amortized intangible assets:
Weighted average time until next renewal			8 years 4 months 24 days
Certificates of need
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite-lived intangible assets, carrying amount	19,118		$ 19,118		19,155
Accreditations
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite-lived intangible assets, carrying amount	$ 1,857		$ 1,857		$ 1,895
Amortized intangible assets:
Weighted average time until next renewal			1 year 6 months

XML

Long-Term Debt and Notes Payable - Components of Long-Term Debt And Notes Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal Outstanding	$ 3,380,284	$ 2,744,080
Unamortized Premium (Discount)	(13,471)	(13,924)
Unamortized Issuance Costs	(37,105)	(30,254)
Carrying Value	3,329,708	2,699,902
Fair Value	3,403,537	2,761,735
Select Excluding Concentra
Debt Instrument [Line Items]
Principal Outstanding	1,956,754	2,118,252
Unamortized Premium (Discount)	(10,393)	(11,667)
Unamortized Issuance Costs	(16,688)	(19,586)
Carrying Value	1,929,673	2,086,999
Fair Value	$ 1,967,001	2,129,909
Select Excluding Concentra | Senior notes | 6.375% Senior Notes Due June 2021
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.375%
Principal Outstanding	$ 710,000	710,000
Unamortized Premium (Discount)	607	778
Unamortized Issuance Costs	(5,122)	(6,553)
Carrying Value	705,485	704,225
Fair Value	718,875	727,750
Select Excluding Concentra | Other
Debt Instrument [Line Items]
Principal Outstanding	49,004	36,877
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	(508)	(533)
Carrying Value	48,496	36,344
Fair Value	48,496	36,344
Select Excluding Concentra | Revolving facility | Credit facilities
Debt Instrument [Line Items]
Principal Outstanding	65,000	230,000
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	0	0
Carrying Value	65,000	230,000
Fair Value	59,800	211,600
Select Excluding Concentra | Term loans | Credit facilities
Debt Instrument [Line Items]
Principal Outstanding	1,132,750	1,141,375
Unamortized Premium (Discount)	(11,000)	(12,445)
Unamortized Issuance Costs	(11,058)	(12,500)
Carrying Value	1,110,692	1,116,430
Fair Value	1,139,830	1,154,215
Concentra Inc
Debt Instrument [Line Items]
Principal Outstanding	1,423,530	625,828
Unamortized Premium (Discount)	(3,078)	(2,257)
Unamortized Issuance Costs	(20,417)	(10,668)
Carrying Value	1,400,035	612,903
Fair Value	1,436,536	631,826
Concentra Inc | Other
Debt Instrument [Line Items]
Principal Outstanding	9,355	6,653
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	0	0
Carrying Value	9,355	6,653
Fair Value	9,355	6,653
Concentra Inc | Term loans | Credit facilities
Debt Instrument [Line Items]
Principal Outstanding	1,414,175	619,175
Unamortized Premium (Discount)	(3,078)	(2,257)
Unamortized Issuance Costs	(20,417)	(10,668)
Carrying Value	1,390,680	606,250
Fair Value	$ 1,427,181	$ 625,173

XML

Long-Term Debt and Notes Payable - Principal Maturities Of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
2018	$ 8,208
2019	20,516
2020	41,850
2021	734,432
2022	1,232,915
Thereafter	1,342,363
Total	3,380,284	$ 2,744,080
Select Excluding Concentra
Debt Instrument [Line Items]
2018	6,867
2019	16,891
2020	35,785
2021	721,721
2022	76,500
Thereafter	1,098,990
Total	$ 1,956,754	2,118,252
Select Excluding Concentra | Senior notes | 6.375% Senior Notes Due June 2021
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.375%
2018	$ 0
2019	0
2020	0
2021	710,000
2022	0
Thereafter	0
Total	710,000	710,000
Select Excluding Concentra | Credit facilities | Revolving facility
Debt Instrument [Line Items]
2018	0
2019	0
2020	0
2021	0
2022	65,000
Thereafter	0
Total	65,000	230,000
Select Excluding Concentra | Credit facilities | Term loans
Debt Instrument [Line Items]
2018	2,875
2019	11,500
2020	11,500
2021	11,500
2022	11,500
Thereafter	1,083,875
Total	1,132,750	1,141,375
Select Excluding Concentra | Other
Debt Instrument [Line Items]
2018	3,992
2019	5,391
2020	24,285
2021	221
2022	0
Thereafter	15,115
Total	49,004	36,877
Concentra Inc
Debt Instrument [Line Items]
2018	1,341
2019	3,625
2020	6,065
2021	12,711
2022	1,156,415
Thereafter	243,373
Total	1,423,530	625,828
Concentra Inc | Credit facilities | Term loans
Debt Instrument [Line Items]
2018	0
2019	0
2020	5,719
2021	12,365
2022	1,156,091
Thereafter	240,000
Total	1,414,175	619,175
Concentra Inc | Other
Debt Instrument [Line Items]
2018	1,341
2019	3,625
2020	346
2021	346
2022	324
Thereafter	3,373
Total	$ 9,355	$ 6,653

XML

Long-Term Debt and Notes Payable - Select Credit Facilities (Details) - Select Excluding Concentra - Credit facilities - USD ($)	Mar. 22, 2018	Mar. 06, 2017
2017 Select Credit Facilities
Debt Instrument [Line Items]
Current borrowing capacity		$ 1,600,000,000
Revolving facility | 2017 Select Credit Facilities
Debt Instrument [Line Items]
Current borrowing capacity		$ 450,000,000.0
Revolving facility | 2017 Select Credit Facilities | Adjusted LIBO | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		3.00%
Revolving facility | 2017 Select Credit Facilities | Adjusted LIBO | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		3.25%
Revolving facility | 2017 Select Credit Facilities | Alternate Base Rate | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.00%
Revolving facility | 2017 Select Credit Facilities | Alternate Base Rate | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.25%
Revolving facility | 2017 Select Credit Facilities Amendment | Adjusted LIBO | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.50%
Revolving facility | 2017 Select Credit Facilities Amendment | Adjusted LIBO | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.75%
Revolving facility | 2017 Select Credit Facilities Amendment | Alternate Base Rate | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.50%
Revolving facility | 2017 Select Credit Facilities Amendment | Alternate Base Rate | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.75%
Term loans | 2017 Select Credit Facilities
Debt Instrument [Line Items]
Aggregate principal amount		$ 1,150,000,000
Term loans | 2017 Select Credit Facilities | Adjusted LIBO Rate floor
Debt Instrument [Line Items]
Interest rate margin (as a percent)		1.00%
Term loans | 2017 Select Credit Facilities | Adjusted LIBO
Debt Instrument [Line Items]
Interest rate margin (as a percent)		3.50%
Term loans | 2017 Select Credit Facilities | Alternate Base Rate floor
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.00%
Term loans | 2017 Select Credit Facilities | Alternate Base Rate
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.50%
Term loans | 2017 Select Credit Facilities Amendment | Adjusted LIBO | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.50%
Term loans | 2017 Select Credit Facilities Amendment | Adjusted LIBO | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.75%
Term loans | 2017 Select Credit Facilities Amendment | Alternate Base Rate | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.50%
Term loans | 2017 Select Credit Facilities Amendment | Alternate Base Rate | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.75%
Letter of credit | 2017 Select Credit Facilities
Debt Instrument [Line Items]
Current borrowing capacity		$ 75,000,000.0

XML

Long-Term Debt and Notes Payable - Concentra Credit Facilities (Details) - Credit facilities - Concentra Inc - USD ($)	Feb. 01, 2018	Jun. 01, 2015
Revolving facility
Line of Credit Facility [Line Items]
Additional borrowing capacity	$ 25,000,000.0
Maximum borrowing capacity		$ 50,000,000.0
Debt instrument term (in years)		5 years
Term loans
Line of Credit Facility [Line Items]
Additional borrowing capacity	$ 555,000,000.0
Adjusted LIBO | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.75%
Adjusted LIBO Rate floor | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.00%
Alternate Base Rate | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.75%
Alternate Base Rate floor | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.00%
Maximum | Adjusted LIBO | Revolving facility
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		3.00%
Maximum | Alternate Base Rate | Revolving facility
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		2.00%
Minimum | Adjusted LIBO | Revolving facility
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		2.75%
Minimum | Alternate Base Rate | Revolving facility
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		1.75%
Concentra second lien term agreement
Line of Credit Facility [Line Items]
Percentage of net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation to be used for prepayment of debt	100.00%
Percentage of net proceeds received from the issuance of debt obligations other than certain permitted debt obligations to be used for prepayment of debt	100.00%
Voting capital stock of domestic subsidiaries pledged (as a percent)	65.00%
Non-voting capital stock of foreign subsidiaries pledged (as a percent)	100.00%
Concentra second lien term agreement | Term loans
Line of Credit Facility [Line Items]
Aggregate principal amount	$ 240,000,000.0
Concentra second lien term agreement | On or prior to February 1, 2019 | Term loans
Line of Credit Facility [Line Items]
Prepayment premium rate	2.00%
Concentra second lien term agreement | On or prior to February 1, 2020 | Term loans
Line of Credit Facility [Line Items]
Prepayment premium rate	1.00%
Concentra second lien term agreement | Adjusted LIBO | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	6.50%
Concentra second lien term agreement | Adjusted LIBO Rate floor | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.00%
Concentra second lien term agreement | Alternate Base Rate | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	5.50%
Concentra second lien term agreement | Alternate Base Rate floor | Term loans
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.00%
Concentra second lien term agreement | Leverage ratio greater than 4.25 to 1.00
Line of Credit Facility [Line Items]
Percentage of excess cash flow to be used for prepayment of debt	50.00%
Leverage ratio of financial maintenance covenant	4.25
Concentra second lien term agreement | Less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00
Line of Credit Facility [Line Items]
Percentage of excess cash flow to be used for prepayment of debt	25.00%
Concentra second lien term agreement | Leverage ratio less than or equal to 3.75 to 1.00
Line of Credit Facility [Line Items]
Leverage ratio of financial maintenance covenant	3.75
Concentra second lien term agreement | Maximum | Less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00
Line of Credit Facility [Line Items]
Leverage ratio of financial maintenance covenant	4.25
Concentra second lien term agreement | Minimum | Less than or equal to 4.25 to 1.00 and greater than 3.75 to 1.00
Line of Credit Facility [Line Items]
Leverage ratio of financial maintenance covenant	3.75

XML

Long-Term Debt and Notes Payable - Loss on Early Retirement of Debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Line of Credit Facility [Line Items]
Loss on early retirement of debt	$ 10,255	$ 19,719
Loss on extinguishment of debt	484	$ 6,527
Credit facilities
Line of Credit Facility [Line Items]
Loss on early retirement of debt	10,300
Loss on extinguishment of debt	500
Loss on early retirement of debt, debt modification losses	$ 9,800

XML

Long-Term Debt and Notes Payable - Fair Value (Details)	Sep. 30, 2018
Select Excluding Concentra | Senior notes | 6.375% Senior Notes Due June 2021
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.375%

XML

Segment Information - Selected Financial Data (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Segment information
Net operating revenues	$ 1,267,401	$ 1,077,014	$ 3,816,575	$ 3,270,996
Adjusted EBITDA	156,628	115,827	498,088	413,397
Total assets	5,980,181	5,123,807	5,980,181	5,123,807	$ 5,127,166
Purchases of property and equipment, net	39,391	68,498	121,039	173,800
Operating Segments | Critical Illness Recovery Hospital
Segment information
Net operating revenues	420,108	416,934	1,327,236	1,301,251
Adjusted EBITDA	53,292	46,873	186,989	194,253
Total assets	1,785,336	2,008,485	1,785,336	2,008,485
Purchases of property and equipment, net	8,134	8,003	31,455	28,717
Operating Segments | Rehabilitation Hospital
Segment information
Net operating revenues	176,885	157,499	525,428	453,702
Adjusted EBITDA	25,343	22,581	80,314	62,038
Total assets	888,342	740,276	888,342	740,276
Purchases of property and equipment, net	8,769	29,373	29,766	77,707
Operating Segments | Outpatient Rehabilitation
Segment information
Net operating revenues	265,927	246,644	790,491	751,999
Adjusted EBITDA	34,531	29,298	107,003	102,575
Total assets	991,105	945,765	991,105	945,765
Purchases of property and equipment, net	7,209	6,496	22,565	19,370
Operating Segments | Concentra
Segment information
Net operating revenues	404,481	255,881	1,173,420	763,357
Adjusted EBITDA	68,754	40,003	199,119	125,656
Total assets	2,201,869	1,332,012	2,201,869	1,332,012
Purchases of property and equipment, net	12,539	5,369	29,281	21,656
Other
Segment information
Net operating revenues	0	56	0	687
Adjusted EBITDA	(25,292)	(22,928)	(75,337)	(71,125)
Total assets	113,529	97,269	113,529	97,269
Purchases of property and equipment, net	$ 2,740	$ 19,257	$ 7,972	$ 26,350

XML

Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment information
Adjusted EBITDA	$ 156,628	$ 115,827	$ 498,088	$ 413,397
Depreciation and amortization	(50,527)	(38,772)	(149,022)	(119,644)
Income (loss) from operations	99,837	72,098	328,996	279,526
Loss on early retirement of debt			(10,255)	(19,719)
Equity in earnings of unconsolidated subsidiaries	5,432	4,431	14,914	15,618
Non-operating gain (loss)	2,139	0	9,016	(49)
Interest expense	(50,669)	(37,688)	(147,991)	(116,196)
Income (loss) before income taxes	56,739	38,841	194,680	159,180
Operating Segments | Critical Illness Recovery Hospital
Segment information
Adjusted EBITDA	53,292	46,873	186,989	194,253
Depreciation and amortization	(11,136)	(10,932)	(34,146)	(34,891)
Stock compensation expense	0	0	0	0
U.S. HealthWorks acquisition costs			0
Income (loss) from operations	42,156	35,941	152,843	159,362
Operating Segments | Rehabilitation Hospital
Segment information
Adjusted EBITDA	25,343	22,581	80,314	62,038
Depreciation and amortization	(6,079)	(4,505)	(17,816)	(14,500)
Stock compensation expense	0	0	0	0
U.S. HealthWorks acquisition costs			0
Income (loss) from operations	19,264	18,076	62,498	47,538
Operating Segments | Outpatient Rehabilitation
Segment information
Adjusted EBITDA	34,531	29,298	107,003	102,575
Depreciation and amortization	(6,597)	(5,964)	(19,938)	(18,182)
Stock compensation expense	0	0	0	0
U.S. HealthWorks acquisition costs			0
Income (loss) from operations	27,934	23,334	87,065	84,393
Operating Segments | Concentra
Segment information
Adjusted EBITDA	68,754	40,003	199,119	125,656
Depreciation and amortization	(24,488)	(15,014)	(70,332)	(46,566)
Stock compensation expense	(767)	(212)	(2,116)	(782)
U.S. HealthWorks acquisition costs			(2,895)
Income (loss) from operations	43,499	24,777	123,776	78,308
Other
Segment information
Adjusted EBITDA	(25,292)	(22,928)	(75,337)	(71,125)
Depreciation and amortization	(2,227)	(2,357)	(6,790)	(5,505)
Stock compensation expense	(5,497)	(4,745)	(15,059)	(13,445)
U.S. HealthWorks acquisition costs			0
Income (loss) from operations	$ (33,016)	$ (30,030)	$ (97,186)	$ (90,075)

XML

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Critical Illness Recovery Hospital
Disaggregation of Revenue [Line Items]
Total net operating revenues	$ 420,108	$ 416,934	$ 1,327,236	$ 1,301,251
Critical Illness Recovery Hospital | Patient services revenue
Disaggregation of Revenue [Line Items]
Total net operating revenues	416,730	412,988	1,316,668	1,292,658
Critical Illness Recovery Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	210,101	217,116	676,950	682,286
Critical Illness Recovery Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	206,629	195,872	639,718	610,372
Critical Illness Recovery Hospital | Other revenues
Disaggregation of Revenue [Line Items]
Total net operating revenues	3,378	3,946	10,568	8,593
Rehabilitation Hospital
Disaggregation of Revenue [Line Items]
Total net operating revenues	176,885	157,499	525,428	453,702
Rehabilitation Hospital | Patient services revenue
Disaggregation of Revenue [Line Items]
Total net operating revenues	135,886	117,281	406,070	335,551
Rehabilitation Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	71,564	64,227	217,459	183,820
Rehabilitation Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	64,322	53,054	188,611	151,731
Rehabilitation Hospital | Other revenues
Disaggregation of Revenue [Line Items]
Total net operating revenues	40,999	40,218	119,358	118,151
Outpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Total net operating revenues	265,927	246,644	790,491	751,999
Outpatient Rehabilitation | Patient services revenue
Disaggregation of Revenue [Line Items]
Total net operating revenues	226,350	215,992	689,526	663,621
Outpatient Rehabilitation | Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	40,563	36,821	120,228	111,638
Outpatient Rehabilitation | Non-Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	185,787	179,171	569,298	551,983
Outpatient Rehabilitation | Other revenues
Disaggregation of Revenue [Line Items]
Total net operating revenues	39,577	30,652	100,965	88,378
Concentra
Disaggregation of Revenue [Line Items]
Total net operating revenues	404,481	255,881	1,173,420	763,357
Concentra | Patient services revenue
Disaggregation of Revenue [Line Items]
Total net operating revenues	401,992	253,909	1,166,311	756,933
Concentra | Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	455	472	1,600	1,588
Concentra | Non-Medicare
Disaggregation of Revenue [Line Items]
Total net operating revenues	401,537	253,437	1,164,711	755,345
Concentra | Other revenues
Disaggregation of Revenue [Line Items]
Total net operating revenues	$ 2,489	$ 1,972	$ 7,109	$ 6,424

XML

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Federal income tax at statutory rate	21.00%	35.00%	21.00%	35.00%
State and local income taxes, less federal income tax benefit	5.00%	4.00%	4.70%	3.80%
Permanent differences	2.70%	0.80%	2.10%	1.10%
Valuation allowance	(0.10%)	0.10%	(0.10%)	0.20%
Uncertain tax positions	0.20%	0.20%	0.20%	0.20%
Non-controlling interest	(1.00%)	(1.60%)	(1.80%)	(1.80%)
Stock-based compensation	(2.70%)	(2.30%)	(2.60%)	(0.90%)
Other	(0.30%)	(0.10%)	0.90%	(0.20%)
Total effective income tax rate	24.80%	36.10%	24.40%	37.40%

XML

Income per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator:
Net income attributable to Select Medical Holdings Corporation	$ 32,917	$ 18,462	$ 113,167	$ 76,387
Less: Earnings allocated to unvested restricted stockholders	1,098	608	3,732	2,464
Net income available to common stockholders	$ 31,819	$ 17,854	$ 109,435	$ 73,923
Denominator:
Weighted average shares—basic (in shares)	130,387	129,142	129,972	128,745
Effect of dilutive securities:
Stock options (in shares)	60	180	94	171
Weighted average shares—diluted (in shares)	130,447	129,322	130,066	128,916
Income per common share
Basic income per common share: (in dollars per share)	$ 0.24	$ 0.14	$ 0.84	$ 0.57
Diluted income per common share: (in dollars per share)	$ 0.24	$ 0.14	$ 0.84	$ 0.57

XML

Commitments and Contingencies - Litigation (Details) $ in Millions		9 Months Ended
	Oct. 19, 2015 hospital	Sep. 30, 2018 USD ($)
Amended complaint | SSH-Evansville
Commitments and Contingencies
Number of case managers identified as plaintiff | hospital	2
Professional liability claims
Commitments and Contingencies
Self insurance retention limit		$ 35.0
Professional liability claims | Minimum | Joint Venture Operations
Commitments and Contingencies
Self insurance retention limit		5.0
Professional liability claims | Maximum | Joint Venture Operations
Commitments and Contingencies
Self insurance retention limit		$ 20.0

XML

Subsequent Events - Amendment to the Select Credit Facilities (Details) - Select Excluding Concentra - Credit facilities	Oct. 26, 2018	Mar. 22, 2018
2017 Select Credit Facilities Amendment | Adjusted LIBO | Term loans | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.50%
2017 Select Credit Facilities Amendment | Adjusted LIBO | Term loans | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.75%
2017 Select Credit Facilities Amendment | Adjusted LIBO | Revolving facility | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.50%
2017 Select Credit Facilities Amendment | Adjusted LIBO | Revolving facility | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		2.75%
2017 Select Credit Facilities Amendment | Alternate Base Rate | Term loans | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		1.50%
2017 Select Credit Facilities Amendment | Alternate Base Rate | Term loans | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		1.75%
2017 Select Credit Facilities Amendment | Alternate Base Rate | Revolving facility | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		1.50%
2017 Select Credit Facilities Amendment | Alternate Base Rate | Revolving facility | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)		1.75%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Adjusted LIBO | Term loans | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.25%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Adjusted LIBO | Term loans | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.50%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Adjusted LIBO | Revolving facility | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.25%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Adjusted LIBO | Revolving facility | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	2.50%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Alternate Base Rate | Term loans | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.25%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Alternate Base Rate | Term loans | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.50%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Alternate Base Rate | Revolving facility | Minimum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.25%
Subsequent Event | Amendment No. 2, Select Credit Facilities | Alternate Base Rate | Revolving facility | Maximum
Debt Instrument [Line Items]
Interest rate margin (as a percent)	1.50%

XML

Subsequent Events - Amendment to the Concentra Credit Facilities (Details) - Concentra Inc - Credit facilities	Oct. 26, 2018	Feb. 01, 2018	Jun. 01, 2015
Term loans | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		2.75%
Term loans | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)		1.75%
Minimum | Revolving facility | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)			2.75%
Minimum | Revolving facility | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)			1.75%
Maximum | Revolving facility | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)			3.00%
Maximum | Revolving facility | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)			2.00%
Subsequent Event | Term loans | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.75%
Subsequent Event | Term loans | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.75%
Subsequent Event | Minimum | Term loans | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.50%
Subsequent Event | Minimum | Term loans | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.50%
Subsequent Event | Minimum | Revolving facility | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.25%
Subsequent Event | Minimum | Revolving facility | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.25%
Subsequent Event | Maximum | Term loans | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.75%
Subsequent Event | Maximum | Term loans | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.75%
Subsequent Event | Maximum | Revolving facility | Adjusted LIBO
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	2.50%
Subsequent Event | Maximum | Revolving facility | Alternate Base Rate
Line of Credit Facility [Line Items]
Interest rate margin (as a percent)	1.50%

XML

Condensed Consolidating Financial Information - Narrative (Details)	Sep. 30, 2018
Senior notes | Select Medical Corporation
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.375%

XML

Condensed Consolidating Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 160,413	$ 122,549	$ 107,300	$ 99,029
Accounts receivable	746,816	691,732
Prepaid income taxes	19,852	31,387
Other current assets	96,214	75,158
Total Current Assets	1,023,295	920,826
Property and equipment, net	965,390	912,591
Goodwill	3,311,459	2,782,812
Identifiable intangible assets, net	444,847	326,519
Other assets	235,190	184,418
Total Assets	5,980,181	5,127,166	5,123,807
Current Liabilities:
Overdrafts	23,291	29,463
Current portion of long-term debt and notes payable	24,175	22,187
Accounts payable	137,540	128,194
Accrued payroll	176,221	160,562
Accrued vacation	106,026	92,875
Accrued interest	23,648	19,885
Accrued other	188,079	143,166
Income taxes payable	6,129	9,071
Total Current Liabilities	685,109	605,403
Long-term debt, net of current portion	3,305,533	2,677,715
Non-current deferred tax liability	148,227	124,917
Other non-current liabilities	174,170	145,709
Total Liabilities	4,313,039	3,553,744
Redeemable non-controlling interests	779,574	640,818
Stockholders’ Equity:
Common stock	135	134
Capital in excess of par	477,822	463,499
Retained earnings (accumulated deficit)	296,635	359,735
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	774,592	823,368
Non-controlling interests	112,976	109,236
Total Equity	887,568	932,604
Total Liabilities and Equity	5,980,181	5,127,166
Consolidating and Eliminating Adjustments
Current Assets:
Cash and cash equivalents	0	0	0	0
Accounts receivable	0	0
Intercompany receivables	(1,797,866)	(1,658,919)
Prepaid income taxes	0	0
Other current assets	0	0
Total Current Assets	(1,797,866)	(1,658,919)
Property and equipment, net	0	0
Investment in affiliates	(4,572,258)	(4,648,489)
Goodwill	0	0
Identifiable intangible assets, net	0	0
Other assets	(8,968)	(9,989)
Total Assets	(6,379,092)	(6,317,397)
Current Liabilities:
Overdrafts	0	0
Current portion of long-term debt and notes payable	0	0
Accounts payable	0	0
Intercompany payables	(1,797,866)	(1,658,919)
Accrued payroll	0	0
Accrued vacation	0	0
Accrued interest	0	0
Accrued other	0	0
Income taxes payable	0	0
Total Current Liabilities	(1,797,866)	(1,658,919)
Long-term debt, net of current portion	0	0
Non-current deferred tax liability	(8,968)	(9,989)
Other non-current liabilities	0	0
Total Liabilities	(1,806,834)	(1,668,908)
Redeemable non-controlling interests	760,172	624,548
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	0	0
Retained earnings (accumulated deficit)	(1,485,197)	(1,445,541)
Subsidiary investment	(3,954,581)	(3,932,822)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	(5,439,778)	(5,378,363)
Non-controlling interests	107,348	105,326
Total Equity	(5,332,430)	(5,273,037)
Total Liabilities and Equity	(6,379,092)	(6,317,397)
Select (Parent Company Only) | Reportable legal entities
Current Assets:
Cash and cash equivalents	77	73	73	11,071
Accounts receivable	0	0
Intercompany receivables	0	0
Prepaid income taxes	16,325	22,704
Other current assets	15,441	13,021
Total Current Assets	31,843	35,798
Property and equipment, net	36,947	39,836
Investment in affiliates	4,448,449	4,524,385
Goodwill	0	0
Identifiable intangible assets, net	3	0
Other assets	38,861	36,494
Total Assets	4,556,103	4,636,513
Current Liabilities:
Overdrafts	23,291	29,463
Current portion of long-term debt and notes payable	15,508	16,635
Accounts payable	12,183	12,504
Intercompany payables	1,722,475	1,598,212
Accrued payroll	12,061	16,736
Accrued vacation	4,394	4,083
Accrued interest	17,775	17,479
Accrued other	60,190	39,219
Income taxes payable	2,764	0
Total Current Liabilities	1,870,641	1,734,331
Long-term debt, net of current portion	1,871,407	2,042,555
Non-current deferred tax liability	0	0
Other non-current liabilities	39,463	36,259
Total Liabilities	3,781,511	3,813,145
Redeemable non-controlling interests	0	0
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	964,683	947,370
Retained earnings (accumulated deficit)	(190,091)	(124,002)
Subsidiary investment	0	0
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	774,592	823,368
Non-controlling interests	0	0
Total Equity	774,592	823,368
Total Liabilities and Equity	4,556,103	4,636,513
Subsidiary Guarantors | Reportable legal entities
Current Assets:
Cash and cash equivalents	5,627	4,856	6,359	6,467
Accounts receivable	412,454	449,493
Intercompany receivables	1,722,475	1,598,212
Prepaid income taxes	0	5,703
Other current assets	32,281	30,209
Total Current Assets	2,172,837	2,088,473
Property and equipment, net	615,299	623,085
Investment in affiliates	123,809	124,104
Goodwill	2,102,444	2,108,270
Identifiable intangible assets, net	102,423	104,067
Other assets	137,897	98,575
Total Assets	5,254,709	5,146,574
Current Liabilities:
Overdrafts	0	0
Current portion of long-term debt and notes payable	268	740
Accounts payable	76,776	85,489
Intercompany payables	75,391	60,707
Accrued payroll	95,717	98,887
Accrued vacation	58,590	58,355
Accrued interest	16	7
Accrued other	62,049	57,378
Income taxes payable	0	1,302
Total Current Liabilities	368,807	362,865
Long-term debt, net of current portion	72	127
Non-current deferred tax liability	91,487	88,376
Other non-current liabilities	62,354	56,721
Total Liabilities	522,720	508,089
Redeemable non-controlling interests	0	0
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	0	0
Retained earnings (accumulated deficit)	1,506,874	1,416,857
Subsidiary investment	3,225,115	3,221,628
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	4,731,989	4,638,485
Non-controlling interests	0	0
Total Equity	4,731,989	4,638,485
Total Liabilities and Equity	5,254,709	5,146,574
Non-Guarantor Subsidiaries | Reportable legal entities
Current Assets:
Cash and cash equivalents	3,045	4,561	4,548	5,056
Accounts receivable	123,622	122,728
Intercompany receivables	75,391	60,707
Prepaid income taxes	0	31
Other current assets	14,839	13,031
Total Current Assets	216,897	201,058
Property and equipment, net	90,821	79,013
Investment in affiliates	0	0
Goodwill	0	0
Identifiable intangible assets, net	4,972	5,046
Other assets	33,902	35,440
Total Assets	346,592	320,557
Current Liabilities:
Overdrafts	0	0
Current portion of long-term debt and notes payable	3,631	2,212
Accounts payable	19,948	17,475
Intercompany payables	0	0
Accrued payroll	4,935	4,819
Accrued vacation	13,584	12,295
Accrued interest	27	6
Accrued other	16,637	12,599
Income taxes payable	0	30
Total Current Liabilities	58,762	49,436
Long-term debt, net of current portion	38,787	24,730
Non-current deferred tax liability	882	780
Other non-current liabilities	8,730	8,138
Total Liabilities	107,161	83,084
Redeemable non-controlling interests	0	0
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	0	0
Retained earnings (accumulated deficit)	(33,181)	(35,942)
Subsidiary investment	272,612	273,415
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	239,431	237,473
Non-controlling interests	0	0
Total Equity	239,431	237,473
Total Liabilities and Equity	346,592	320,557
Non-Guarantor Concentra | Reportable legal entities
Current Assets:
Cash and cash equivalents	151,664	113,059	96,320	76,435
Accounts receivable	210,740	119,511
Intercompany receivables	0	0
Prepaid income taxes	3,527	2,949
Other current assets	33,653	18,897
Total Current Assets	399,584	254,416
Property and equipment, net	222,323	170,657
Investment in affiliates	0	0
Goodwill	1,209,015	674,542
Identifiable intangible assets, net	337,449	217,406
Other assets	33,498	23,898
Total Assets	2,201,869	1,340,919
Current Liabilities:
Overdrafts	0	0
Current portion of long-term debt and notes payable	4,768	2,600
Accounts payable	28,633	12,726
Intercompany payables	0	0
Accrued payroll	63,508	40,120
Accrued vacation	29,458	18,142
Accrued interest	5,830	2,393
Accrued other	49,203	33,970
Income taxes payable	3,365	7,739
Total Current Liabilities	184,765	117,690
Long-term debt, net of current portion	1,395,267	610,303
Non-current deferred tax liability	64,826	45,750
Other non-current liabilities	63,623	44,591
Total Liabilities	1,708,481	818,334
Redeemable non-controlling interests	19,402	16,270
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	0	0
Retained earnings (accumulated deficit)	11,504	64,626
Subsidiary investment	456,854	437,779
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	468,358	502,405
Non-controlling interests	5,628	3,910
Total Equity	473,986	506,315
Total Liabilities and Equity	2,201,869	1,340,919
Select Medical Corporation
Current Assets:
Cash and cash equivalents	160,413	122,549	$ 107,300	$ 99,029
Accounts receivable	746,816	691,732
Intercompany receivables	0	0
Prepaid income taxes	19,852	31,387
Other current assets	96,214	75,158
Total Current Assets	1,023,295	920,826
Property and equipment, net	965,390	912,591
Investment in affiliates	0	0
Goodwill	3,311,459	2,782,812
Identifiable intangible assets, net	444,847	326,519
Other assets	235,190	184,418
Total Assets	5,980,181	5,127,166
Current Liabilities:
Overdrafts	23,291	29,463
Current portion of long-term debt and notes payable	24,175	22,187
Accounts payable	137,540	128,194
Intercompany payables	0	0
Accrued payroll	176,221	160,562
Accrued vacation	106,026	92,875
Accrued interest	23,648	19,885
Accrued other	188,079	143,166
Income taxes payable	6,129	9,071
Total Current Liabilities	685,109	605,403
Long-term debt, net of current portion	3,305,533	2,677,715
Non-current deferred tax liability	148,227	124,917
Other non-current liabilities	174,170	145,709
Total Liabilities	4,313,039	3,553,744
Redeemable non-controlling interests	779,574	640,818
Stockholders’ Equity:
Common stock	0	0
Capital in excess of par	964,683	947,370
Retained earnings (accumulated deficit)	(190,091)	(124,002)
Subsidiary investment	0	0
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	774,592	823,368
Non-controlling interests	112,976	109,236
Total Equity	887,568	932,604
Total Liabilities and Equity	$ 5,980,181	$ 5,127,166

XML

Condensed Consolidating Financial Information - Condensed Consolidating Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	$ 1,267,401	$ 1,077,014	$ 3,816,575	$ 3,270,996
Costs and expenses:
Cost of services	1,087,062	939,079	3,247,606	2,788,411
General and administrative	29,975	27,065	90,951	83,415
Depreciation and amortization	50,527	38,772	149,022	119,644
Total costs and expenses	1,167,564	1,004,916	3,487,579	2,991,470
Income (loss) from operations	99,837	72,098	328,996	279,526
Other income and expense:
Loss on early retirement of debt			(10,255)	(19,719)
Equity in earnings of unconsolidated subsidiaries	5,432	4,431	14,914	15,618
Non-operating gain (loss)	2,139	0	9,016	(49)
Interest income (expense)	(50,669)	(37,688)	(147,991)	(116,196)
Income (loss) before income taxes	56,739	38,841	194,680	159,180
Income tax expense (benefit)	14,060	14,017	47,460	59,593
Net income	42,679	24,824	147,220	99,587
Less: Net income attributable to non-controlling interests	9,762	6,362	34,053	23,200
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	32,917	18,462	113,167	76,387
Consolidating and Eliminating Adjustments
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	0	0	0	0
Costs and expenses:
Cost of services	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total costs and expenses	0	0	0	0
Income (loss) from operations	0	0	0	0
Other income and expense:
Intercompany interest and royalty fees	0	0	0	0
Intercompany management fees	0	0	0	0
Loss on early retirement of debt			0	0
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Non-operating gain (loss)	0		0	0
Interest income (expense)	0	0	0	0
Income (loss) before income taxes	0	0	0	0
Income tax expense (benefit)	0	0	0	0
Equity in earnings of consolidated subsidiaries	(39,146)	(18,955)	(129,204)	(85,479)
Net income	(39,146)	(18,955)	(129,204)	(85,479)
Less: Net income attributable to non-controlling interests	0	0	0	0
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	(39,146)	(18,955)	(129,204)	(85,479)
Select (Parent Company Only) | Reportable legal entities
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	0	56	0	687
Costs and expenses:
Cost of services	815	667	2,340	1,843
General and administrative	29,791	27,028	87,806	83,291
Depreciation and amortization	2,215	2,355	6,777	5,503
Total costs and expenses	32,821	30,050	96,923	90,637
Income (loss) from operations	(32,821)	(29,994)	(96,923)	(89,950)
Other income and expense:
Intercompany interest and royalty fees	6,357	7,865	22,029	24,760
Intercompany management fees	50,601	51,241	166,749	176,443
Loss on early retirement of debt			(2,229)	(19,719)
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Non-operating gain (loss)	0		1,654	0
Interest income (expense)	(28,933)	(30,240)	(89,416)	(93,725)
Income (loss) before income taxes	(4,796)	(1,128)	1,864	(2,191)
Income tax expense (benefit)	(1,428)	(1,032)	(83)	(3,230)
Equity in earnings of consolidated subsidiaries	36,285	18,558	111,220	75,348
Net income	32,917	18,462	113,167	76,387
Less: Net income attributable to non-controlling interests	0	0	0	0
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	32,917	18,462	113,167	76,387
Subsidiary Guarantors | Reportable legal entities
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	675,059	654,964	2,072,237	2,019,581
Costs and expenses:
Cost of services	585,110	574,250	1,782,843	1,725,060
General and administrative	184	37	250	124
Depreciation and amortization	19,726	18,015	59,708	57,568
Total costs and expenses	605,020	592,302	1,842,801	1,782,752
Income (loss) from operations	70,039	62,662	229,436	236,829
Other income and expense:
Intercompany interest and royalty fees	(2,578)	(4,328)	(10,502)	(14,029)
Intercompany management fees	(39,262)	(41,031)	(132,733)	(147,042)
Loss on early retirement of debt			0	0
Equity in earnings of unconsolidated subsidiaries	5,424	4,416	14,884	15,555
Non-operating gain (loss)	2,139		7,362	(49)
Interest income (expense)	99	271	220	270
Income (loss) before income taxes	35,861	21,990	108,667	91,534
Income tax expense (benefit)	9,923	8,562	36,112	42,135
Equity in earnings of consolidated subsidiaries	2,861	397	17,984	10,131
Net income	28,799	13,825	90,539	59,530
Less: Net income attributable to non-controlling interests	0	24	97	21
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	28,799	13,801	90,442	59,509
Non-Guarantor Subsidiaries | Reportable legal entities
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	187,861	166,113	570,918	487,371
Costs and expenses:
Cost of services	164,643	148,072	486,006	423,025
General and administrative	0	0	0	0
Depreciation and amortization	4,098	3,388	12,205	10,007
Total costs and expenses	168,741	151,460	498,211	433,032
Income (loss) from operations	19,120	14,653	72,707	54,339
Other income and expense:
Intercompany interest and royalty fees	(3,445)	(3,537)	(10,685)	(10,731)
Intercompany management fees	(11,339)	(10,210)	(34,016)	(29,401)
Loss on early retirement of debt			0	0
Equity in earnings of unconsolidated subsidiaries	8	15	30	63
Non-operating gain (loss)	0		0	0
Interest income (expense)	(207)	(20)	(544)	(105)
Income (loss) before income taxes	4,137	901	27,492	14,165
Income tax expense (benefit)	112	145	350	428
Equity in earnings of consolidated subsidiaries	0	0	0	0
Net income	4,025	756	27,142	13,737
Less: Net income attributable to non-controlling interests	1,164	359	9,158	3,606
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	2,861	397	17,984	10,131
Non-Guarantor Concentra | Reportable legal entities
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	404,481	255,881	1,173,420	763,357
Costs and expenses:
Cost of services	336,494	216,090	976,417	638,483
General and administrative	0	0	2,895	0
Depreciation and amortization	24,488	15,014	70,332	46,566
Total costs and expenses	360,982	231,104	1,049,644	685,049
Income (loss) from operations	43,499	24,777	123,776	78,308
Other income and expense:
Intercompany interest and royalty fees	(334)	0	(842)	0
Intercompany management fees	0	0	0	0
Loss on early retirement of debt			(8,026)	0
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Non-operating gain (loss)	0		0	0
Interest income (expense)	(21,628)	(7,699)	(58,251)	(22,636)
Income (loss) before income taxes	21,537	17,078	56,657	55,672
Income tax expense (benefit)	5,453	6,342	11,081	20,260
Equity in earnings of consolidated subsidiaries	0	0	0	0
Net income	16,084	10,736	45,576	35,412
Less: Net income attributable to non-controlling interests	8,598	5,979	24,798	19,573
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	7,486	4,757	20,778	15,839
Select Medical Corporation
Condensed Financial Statements, Captions [Line Items]
Net operating revenues	1,267,401	1,077,014	3,816,575	3,270,996
Costs and expenses:
Cost of services	1,087,062	939,079	3,247,606	2,788,411
General and administrative	29,975	27,065	90,951	83,415
Depreciation and amortization	50,527	38,772	149,022	119,644
Total costs and expenses	1,167,564	1,004,916	3,487,579	2,991,470
Income (loss) from operations	99,837	72,098	328,996	279,526
Other income and expense:
Intercompany interest and royalty fees	0	0	0	0
Intercompany management fees	0	0	0	0
Loss on early retirement of debt			(10,255)	(19,719)
Equity in earnings of unconsolidated subsidiaries	5,432	4,431	14,914	15,618
Non-operating gain (loss)	2,139	0	9,016	(49)
Interest income (expense)	(50,669)	(37,688)	(147,991)	(116,196)
Income (loss) before income taxes	56,739	38,841	194,680	159,180
Income tax expense (benefit)	14,060	14,017	47,460	59,593
Equity in earnings of consolidated subsidiaries	0	0	0	0
Net income	42,679	24,824	147,220	99,587
Less: Net income attributable to non-controlling interests	9,762	6,362	34,053	23,200
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 32,917	$ 18,462	$ 113,167	$ 76,387

XML

Condensed Consolidating Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net income	$ 42,679	$ 24,824	$ 147,220	$ 99,587
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,734	14,542
Depreciation and amortization	50,527	38,772	149,022	119,644
Provision for bad debts		169	(373)	914
Equity in earnings of unconsolidated subsidiaries	(5,432)	(4,431)	(14,914)	(15,618)
Loss on extinguishment of debt			484	6,527
Loss (gain) on sale of assets and businesses			(9,129)	(9,499)
Stock compensation expense			17,175	14,227
Amortization of debt discount, premium and issuance costs			9,845	8,546
Deferred income taxes			(2,092)	(6,126)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			23,495	(143,308)
Other current assets			(10,274)	(2,677)
Other assets			4,828	1,407
Accounts payable			(3,507)	3,913
Accrued expenses			49,391	18,752
Income taxes			9,072	19,141
Net cash provided by (used in) operating activities			380,977	129,972
Investing activities
Business combinations, net of cash acquired			(519,258)	(19,371)
Purchases of property and equipment	(39,391)	(68,498)	(121,039)	(173,800)
Investment in businesses			(12,936)	(11,374)
Proceeds from sale of assets and businesses			6,691	34,555
Net cash used in investing activities			(646,542)	(169,990)
Financing activities
Borrowings on revolving facilities			420,000	805,000
Payments on revolving facilities			(585,000)	(705,000)
Proceeds from term loans (financing costs)			779,904	1,139,487
Payments on term loans			(8,625)	(1,176,567)
Revolving facility debt issuance costs			(1,333)	(4,392)
Borrowings of other debt			30,134	27,571
Principal payments on other debt			(17,971)	(15,112)
Dividends paid to Holdings			0	0
Equity investment by Holdings			0	0
Decrease in overdrafts			(6,172)	(20,439)
Proceeds from issuance of non-controlling interests			2,926	8,986
Distributions to non-controlling interests			(306,427)	(9,276)
Net cash provided by (used in) financing activities			303,429	48,289
Net increase (decrease) in cash and cash equivalents			37,864	8,271
Cash and cash equivalents at beginning of period			122,549	99,029
Cash and cash equivalents at end of period	160,413	107,300	160,413	107,300
Consolidating and Eliminating Adjustments
Operating activities
Net income	(39,146)	(18,955)	(129,204)	(85,479)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			0	0
Depreciation and amortization	0	0	0	0
Provision for bad debts			0	0
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Equity in earnings of consolidated subsidiaries	39,146	18,955	129,204	85,479
Loss on extinguishment of debt			0	0
Loss (gain) on sale of assets and businesses			0	0
Stock compensation expense			0	0
Amortization of debt discount, premium and issuance costs			0	0
Deferred income taxes			0	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			0	0
Other current assets			0	0
Other assets			0	0
Accounts payable			0	0
Accrued expenses			0	0
Income taxes			0	0
Net cash provided by (used in) operating activities			0	0
Investing activities
Business combinations, net of cash acquired			0	0
Purchases of property and equipment			0	0
Investment in businesses			0	0
Proceeds from sale of assets and businesses			0	0
Net cash used in investing activities			0	0
Financing activities
Borrowings on revolving facilities			0	0
Payments on revolving facilities			0	0
Proceeds from term loans (financing costs)			0	0
Payments on term loans			0	0
Revolving facility debt issuance costs			0	0
Borrowings of other debt			0	0
Principal payments on other debt			0	0
Dividends paid to Holdings			0	0
Equity investment by Holdings			0	0
Intercompany			0	0
Decrease in overdrafts			0	0
Proceeds from issuance of non-controlling interests			0	0
Distributions to non-controlling interests			0	0
Net cash provided by (used in) financing activities			0	0
Net increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents at beginning of period			0	0
Cash and cash equivalents at end of period	0	0	0	0
Select (Parent Company Only) | Reportable legal entities
Operating activities
Net income	32,917	18,462	113,167	76,387
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			0	0
Depreciation and amortization	2,215	2,355	6,777	5,503
Provision for bad debts			0	0
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Equity in earnings of consolidated subsidiaries	(36,285)	(18,558)	(111,220)	(75,348)
Loss on extinguishment of debt			115	6,527
Loss (gain) on sale of assets and businesses			(1,641)	(8)
Stock compensation expense			15,059	13,445
Amortization of debt discount, premium and issuance costs			4,435	6,113
Deferred income taxes			1,804	5,014
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			0	0
Other current assets			(2,420)	1,016
Other assets			(4,381)	1,633
Accounts payable			(42)	2,375
Accrued expenses			20,379	164
Income taxes			9,622	3,776
Net cash provided by (used in) operating activities			51,654	46,597
Investing activities
Business combinations, net of cash acquired			0	0
Purchases of property and equipment			(6,412)	(26,350)
Investment in businesses			0	0
Proceeds from sale of assets and businesses			1,654	8
Net cash used in investing activities			(4,758)	(26,342)
Financing activities
Borrowings on revolving facilities			420,000	805,000
Payments on revolving facilities			(585,000)	(705,000)
Proceeds from term loans (financing costs)			(11)	1,139,487
Payments on term loans			(8,625)	(1,153,502)
Revolving facility debt issuance costs			(837)	(4,392)
Borrowings of other debt			5,542	21,572
Principal payments on other debt			(8,455)	(10,122)
Dividends paid to Holdings			(5,640)	(3,603)
Equity investment by Holdings			1,633	1,634
Intercompany			140,673	(101,888)
Decrease in overdrafts			(6,172)	(20,439)
Proceeds from issuance of non-controlling interests			0	0
Distributions to non-controlling interests			0	0
Net cash provided by (used in) financing activities			(46,892)	(31,253)
Net increase (decrease) in cash and cash equivalents			4	(10,998)
Cash and cash equivalents at beginning of period			73	11,071
Cash and cash equivalents at end of period	77	73	77	73
Subsidiary Guarantors | Reportable legal entities
Operating activities
Net income	28,799	13,825	90,539	59,530
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,700	14,493
Depreciation and amortization	19,726	18,015	59,708	57,568
Provision for bad debts			(451)	864
Equity in earnings of unconsolidated subsidiaries	(5,424)	(4,416)	(14,884)	(15,555)
Equity in earnings of consolidated subsidiaries	(2,861)	(397)	(17,984)	(10,131)
Loss on extinguishment of debt			0	0
Loss (gain) on sale of assets and businesses			(7,493)	(4,824)
Stock compensation expense			0	0
Amortization of debt discount, premium and issuance costs			0	0
Deferred income taxes			2,527	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			37,490	(105,536)
Other current assets			(2,100)	3,857
Other assets			(8,576)	(3,709)
Accounts payable			(5,155)	(823)
Accrued expenses			13,620	(1,175)
Income taxes			4,401	0
Net cash provided by (used in) operating activities			162,342	(5,441)
Investing activities
Business combinations, net of cash acquired			(2,666)	(3,356)
Purchases of property and equipment			(60,669)	(102,342)
Investment in businesses			(12,931)	(11,374)
Proceeds from sale of assets and businesses			5,029	15,007
Net cash used in investing activities			(71,237)	(102,065)
Financing activities
Borrowings on revolving facilities			0	0
Payments on revolving facilities			0	0
Proceeds from term loans (financing costs)			0	0
Payments on term loans			0	0
Revolving facility debt issuance costs			0	0
Borrowings of other debt			0	0
Principal payments on other debt			(540)	(306)
Dividends paid to Holdings			0	0
Equity investment by Holdings			0	0
Intercompany			(88,344)	107,834
Decrease in overdrafts			0	0
Proceeds from issuance of non-controlling interests			0	0
Distributions to non-controlling interests			(1,450)	(130)
Net cash provided by (used in) financing activities			(90,334)	107,398
Net increase (decrease) in cash and cash equivalents			771	(108)
Cash and cash equivalents at beginning of period			4,856	6,467
Cash and cash equivalents at end of period	5,627	6,359	5,627	6,359
Non-Guarantor Subsidiaries | Reportable legal entities
Operating activities
Net income	4,025	756	27,142	13,737
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			34	49
Depreciation and amortization	4,098	3,388	12,205	10,007
Provision for bad debts			0	0
Equity in earnings of unconsolidated subsidiaries	(8)	(15)	(30)	(63)
Equity in earnings of consolidated subsidiaries	0	0	0	0
Loss on extinguishment of debt			0	0
Loss (gain) on sale of assets and businesses			5	(4,687)
Stock compensation expense			0	0
Amortization of debt discount, premium and issuance costs			0	0
Deferred income taxes			103	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(894)	(22,820)
Other current assets			(1,807)	(6,772)
Other assets			1,604	3,044
Accounts payable			3,059	1,580
Accrued expenses			6,412	10,281
Income taxes			1	0
Net cash provided by (used in) operating activities			47,834	4,356
Investing activities
Business combinations, net of cash acquired			(22)	(295)
Purchases of property and equipment			(24,677)	(23,452)
Investment in businesses			0	0
Proceeds from sale of assets and businesses			8	19,537
Net cash used in investing activities			(24,691)	(4,210)
Financing activities
Borrowings on revolving facilities			0	0
Payments on revolving facilities			0	0
Proceeds from term loans (financing costs)			0	0
Payments on term loans			0	0
Revolving facility debt issuance costs			0	0
Borrowings of other debt			19,935	3,232
Principal payments on other debt			(4,504)	(2,150)
Dividends paid to Holdings			0	0
Equity investment by Holdings			0	0
Intercompany			(34,184)	(5,946)
Decrease in overdrafts			0	0
Proceeds from issuance of non-controlling interests			957	8,986
Distributions to non-controlling interests			(6,863)	(4,776)
Net cash provided by (used in) financing activities			(24,659)	(654)
Net increase (decrease) in cash and cash equivalents			(1,516)	(508)
Cash and cash equivalents at beginning of period			4,561	5,056
Cash and cash equivalents at end of period	3,045	4,548	3,045	4,548
Non-Guarantor Concentra | Reportable legal entities
Operating activities
Net income	16,084	10,736	45,576	35,412
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			0	0
Depreciation and amortization	24,488	15,014	70,332	46,566
Provision for bad debts			78	50
Equity in earnings of unconsolidated subsidiaries	0	0	0	0
Equity in earnings of consolidated subsidiaries	0	0	0	0
Loss on extinguishment of debt			369	0
Loss (gain) on sale of assets and businesses			0	20
Stock compensation expense			2,116	782
Amortization of debt discount, premium and issuance costs			5,410	2,433
Deferred income taxes			(6,526)	(11,140)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(13,101)	(14,952)
Other current assets			(3,947)	(778)
Other assets			16,181	439
Accounts payable			(1,369)	781
Accrued expenses			8,980	9,482
Income taxes			(4,952)	15,365
Net cash provided by (used in) operating activities			119,147	84,460
Investing activities
Business combinations, net of cash acquired			(516,570)	(15,720)
Purchases of property and equipment			(29,281)	(21,656)
Investment in businesses			(5)	0
Proceeds from sale of assets and businesses			0	3
Net cash used in investing activities			(545,856)	(37,373)
Financing activities
Borrowings on revolving facilities			0	0
Payments on revolving facilities			0	0
Proceeds from term loans (financing costs)			779,915	0
Payments on term loans			0	(23,065)
Revolving facility debt issuance costs			(496)	0
Borrowings of other debt			4,657	2,767
Principal payments on other debt			(4,472)	(2,534)
Dividends paid to Holdings			0	0
Equity investment by Holdings			0	0
Intercompany			(18,145)	0
Decrease in overdrafts			0	0
Proceeds from issuance of non-controlling interests			1,969	0
Distributions to non-controlling interests			(298,114)	(4,370)
Net cash provided by (used in) financing activities			465,314	(27,202)
Net increase (decrease) in cash and cash equivalents			38,605	19,885
Cash and cash equivalents at beginning of period			113,059	76,435
Cash and cash equivalents at end of period	151,664	96,320	151,664	96,320
Select Medical Corporation
Operating activities
Net income	42,679	24,824	147,220	99,587
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,734	14,542
Depreciation and amortization	50,527	38,772	149,022	119,644
Provision for bad debts			(373)	914
Equity in earnings of unconsolidated subsidiaries	(5,432)	(4,431)	(14,914)	(15,618)
Equity in earnings of consolidated subsidiaries	0	0	0	0
Loss on extinguishment of debt			484	6,527
Loss (gain) on sale of assets and businesses			(9,129)	(9,499)
Stock compensation expense			17,175	14,227
Amortization of debt discount, premium and issuance costs			9,845	8,546
Deferred income taxes			(2,092)	(6,126)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			23,495	(143,308)
Other current assets			(10,274)	(2,677)
Other assets			4,828	1,407
Accounts payable			(3,507)	3,913
Accrued expenses			49,391	18,752
Income taxes			9,072	19,141
Net cash provided by (used in) operating activities			380,977	129,972
Investing activities
Business combinations, net of cash acquired			(519,258)	(19,371)
Purchases of property and equipment			(121,039)	(173,800)
Investment in businesses			(12,936)	(11,374)
Proceeds from sale of assets and businesses			6,691	34,555
Net cash used in investing activities			(646,542)	(169,990)
Financing activities
Borrowings on revolving facilities			420,000	805,000
Payments on revolving facilities			(585,000)	(705,000)
Proceeds from term loans (financing costs)			779,904	1,139,487
Payments on term loans			(8,625)	(1,176,567)
Revolving facility debt issuance costs			(1,333)	(4,392)
Borrowings of other debt			30,134	27,571
Principal payments on other debt			(17,971)	(15,112)
Dividends paid to Holdings			(5,640)	(3,603)
Equity investment by Holdings			1,633	1,634
Intercompany			0	0
Decrease in overdrafts			(6,172)	(20,439)
Proceeds from issuance of non-controlling interests			2,926	8,986
Distributions to non-controlling interests			(306,427)	(9,276)
Net cash provided by (used in) financing activities			303,429	48,289
Net increase (decrease) in cash and cash equivalents			37,864	8,271
Cash and cash equivalents at beginning of period			122,549	99,029
Cash and cash equivalents at end of period	$ 160,413	$ 107,300	$ 160,413	$ 107,300